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ABSTRACT
Breast cancer is the most commonly diagnosed cancer among women in the United States. It
is the most common cause of death in women ages 45-55. Optical techniques can potentially
play a diagnostic role in several aspects of breast cancer evaluation and treatment. This
thesis outlines progress on the use of Raman spectroscopy to diagnose breast cancer.
Laboratory studies on fresh-frozen tissues are used to demonstrate that the detailed
information provided by Raman spectroscopy yields accurate breast disease diagnosis. A
Raman spectroscopic-based diagnostic algorithm was developed which classifies samples
into four categories according to specific pathological diagnoses: normal, fibrocystic change,
fibroadenoma, and infiltrating carcinoma. Cancerous lesions were separated from non-
cancerous tissues with a sensitivity of 94% and a specificity of 95%. Further, use of a
spectral model based on the morphological structures that comprise breast tissue allows
increased understanding of the relationship between a Raman spectrum and tissue disease
state. Based on the excellent results of our laboratory work, two clinical studies were
undertaken. These studies translate Raman spectroscopy from a laboratory technique into a
clinically useful tool. The first study tests the diagnostic algorithm in a prospective manner
on freshly excised tissue. Preliminary results are promising. The second study is the first
demonstration of in vivo data acquisition of Raman spectra of breast tissue. The culmination
of this research is the demonstration of accurate intra-operative margin status assessment
during partial mastectomy surgeries. Application of our previously developed diagnostic
algorithm resulted in perfect sensitivity and specificity in this small in vivo data set. These
preliminary findings indicate that Raman spectroscopy has the potential to lessen the need for
re-excision surgeries resulting from positive margins and thereby reduce the recurrence rate
of breast cancer following partial mastectomy surgeries. The experiments and theory
presented throughout this thesis demonstrate that Raman spectroscopy is a viable clinical tool
that can be used to accurately diagnosis breast cancer and breast disease.
Thesis Supervisor: Michael S. Feld, Ph.D.
Title: Professor of Physics
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Chapter I. Introduction
The work in this thesis develops analytical Raman spectroscopy into a tool for the diagnosis
of breast cancer. Laboratory studies on fresh-frozen tissues are used to demonstrate that the
detailed information provided by Raman spectroscopy yields accurate breast disease
diagnosis. Further, use of a spectral model based on the morphological structures that
comprise breast tissue allows increased understanding of the relationship between a Raman
spectrum and tissue disease state. Based on the excellent results of our laboratory work, two
clinical studies were undertaken. These studies translate Raman spectroscopy from a
laboratory technique into a clinically useful tool. The first study tests the diagnostic
algorithm in a prospective manner on freshly excised tissue. Preliminary results are
promising. In the second study, data was acquired in vivo during partial mastectomy
surgeries. This is the first demonstration of in vivo collection of Raman spectra of breast
tissue. These advances culminated in an approach that was employed intra-operatively
during partial mastectomy surgeries to accurately assess margin status.
-14-
I. A. Objectives
Develop a Spectral Model for Diagnosing Breast Disease
Statistical interpretations of the Raman spectra acquired from biological tissue can diagnose
disease. Indeed, previous investigations using principal component analysis demonstrated
that Raman spectroscopy is capable of accurately diagnosing breast cancer. Although it is
possible to use statistical methods of analysis to provide diagnoses, there is a wealth of
information in Raman spectra that enables enhanced understanding of disease etiology. One
goal of this research is the development of a spectroscopic model based on tissue
morphology. We utilize confocal Raman microscopy to examine the various morphological
structures present in normal and diseased breast tissues. Our model identifies the
morphological components present in breast tissue through their unique Raman spectra and
uses them as basis spectra to describe the morphology of macroscopic data. Such a model
translates spectroscopic analysis into terminology commonly used by pathologists and can be
used to diagnose breast cancer.
Derive of an Analytical Method of Estimating Chemometric Prediction Error
Another aim of the research is the derivation and validation of an analytical formula that
estimates the uncertainty in concentrations predicted by our spectral model. In biological
samples, such as tissue, obtaining reference concentrations to assess measurement error is not
straightforward. The ability to make predictions concerning the concentration error is
valuable to the process of developing and refining analytical measurements.
Develop an Algorithm for Breast Cancer Diagnosis Using our Spectral Model
Development of an algorithm to diagnose breast cancer is a central objective of this thesis.
-15-
We employ our spectral model to diagnose normal, benign and malignant lesions in
specimens of fresh-frozen human breast tissue, based on their morphological compositions.
Assess the Diagnostic Importance of Microcalcifications
In our ex vivo studies, we see relatively little contribution from the two types of calcifications
found in breast tissue and included in our spectral model, calcium hydroxyapatite and
calcium oxalate dihydrate. Due to their diagnostic importance, microcalcifications in fresh
breast tissue are not typically made available for scientific research and thus our studies did
not include lesions containing microcalcifications. For this reason, we investigate the
diagnostic power of Raman microscopy of microcalcifications in thin sections of
deparaffinized fixed breast tissue. Results can be coupled with the diagnostic algorithm
developed using fresh-frozen tissues to create a powerful new tool for the diagnosis of benign
and malignant breast lesions.
Prospective Validation of the Diagnostic Algorithm
The main goal of this study is to validate our diagnostic algorithm developed on fresh-frozen
tissues with a large data set that closely mimics an in vivo environment. In this work, we
utilize freshly excised tissues. Further, we aim to elucidate differences between the Raman
spectra of fresh-frozen and fresh breast tissues. Additional goals include expanding our
diagnostic algorithm to include pathologies not seen in our ex vivo laboratory data and
incorporating microcalcifications into our diagnostic scheme.
Demonstrate In Vivo Application of Raman Spectroscopy to Breast Cancer Diagnosis
-16-
Ultimately, this thesis culminates in the translation of Raman spectroscopy from a laboratory
technique to a clinical tool. To collect the first in vivo Raman spectra of breast tissue, we
employ our Raman optical fiber probe to acquire data from patients undergoing partial
mastectomy procedures. This study serves to demonstrate the feasibility of in vivo Raman
spectroscopy for the diagnosis of breast cancer.
I. B. Accomplishments
The experiments and theory presented throughout this thesis demonstrate that Raman
spectroscopy can be used to accurately diagnosis breast cancer and breast disease.
Furthermore, we have demonstrated extension of the technique to in vivo clinical applications
with excellent results. We have developed a spectral model based on the major morphological
structures in breast tissue, including epithelial cell cytoplasm, the cell nucleus, fat, -carotene,
collagen, calcium hydroxyapatite, calcium oxalate dihydrate, cholesterol-like lipid deposits
and water. A diagnostic algorithm, which utilizes this spectral model, was developed in the
laboratory with samples of fresh-frozen breast tissue. This diagnostic algorithm, which
encompasses all data and classifies samples according to specific pathological diagnoses,
results in high sensitivity and specificity.
Based on the excellent results of these laboratory studies, we sought to employ
Raman spectroscopy clinically. Studies were undertaken to validate our algorithm on a large
data set of freshly excised tissue as well as demonstrate in vivo data acquisition. Preliminary
results in which the diagnostic algorithm is used in a prospective manner to examine fresh
tissue are encouraging, although further data analysis is necessary. This thesis culminates in
a demonstration of in vivo data acquisition during partial mastectomy surgeries. The study
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was the first in vivo acquisition of Raman spectra of breast tissue and thus extends the
technique from a laboratory to a clinical setting. Further, using our diagnostic algorithm
developed on ex vivo tissues, we were able to accurately provide intra-operative margin
assessment. The work demonstrates that Raman spectroscopy can be used for real-time
breast cancer diagnosis in a clinical setting.
I. C. Outline
The goals and accomplishments of this thesis are further elucidated as follows:
Chapter II. Breast Cancer
Raman spectroscopy can potentially play a diagnostic role in several aspects of breast cancer
evaluation and treatment. Research to develop new diagnostic modalities must be grounded
in knowledge of both the disease progression and current medical practices. Only with this
information as a basis can diagnostic schemes be created that provide relevant information
and are easily incorporated into clinical practice. This chapter details fundamentals of breast
cancer. Anatomy and pathology of the breast are discussed, along with a critique of the
current methods used for disease diagnosis.
Chapter III. Raman Spectroscopy
The Raman effect and its application to biomedical spectroscopy are presented along with the
previous work that has been accomplished in this field. Competing research technologies for
breast cancer diagnosis are also discussed. The experimental instrumentation used
throughout this research is presented.
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Chapter IV. Data Processing
This chapter presents approaches that we use to analyze Raman spectra. The motivation for
the development of a Raman spectroscopic morphological model is explained. Techniques
for the development of this model and its application to disease diagnosis are described. In
addition, an analytical formula that estimates the uncertainty in concentrations predicted by
our spectral model is derived and validated. By understanding the sources of prediction
error, efforts can be made to reduce it scientifically. Further analytic methods for calculating
the concentration error allow smart experimental design to detect moieties of interest with the
appropriate accuracy.
Chapter V. Raman Spectroscopic Breast Cancer Diagnosis: Ex Vivo Studies
We employ Raman spectroscopy to diagnose normal, benign and malignant lesions in
specimens of human breast tissue, based on their morphological compositions. The
morphologic makeup of the tissue is determined through the application of our spectral
model. A diagnostic algorithm is presented that was developed in the laboratory with
samples of fresh-frozen human breast tissue. The diagnostic algorithm, which encompasses
all data and classifies samples according to specific pathological diagnoses, is used to
identify those lesions that would need to be excised. This algorithm results in a positive
predictive value of 85% and a negative predictive value of 100%, indicating that no
malignant lesions in our data set are left unexcised. The excellent results of this study thus
supported moving the technique to a clinical setting for further testing of its efficacy in breast
cancer diagnosis. Preliminary results in which the diagnostic algorithm is used in a
prospective manner to examine fresh tissue are also presented.
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Chapter VI. Raman Microscopy of Microcalcifications
In our ex vivo studies, we see relatively little contribution from the two types of calcifications
found in breast tissue and included in our spectral model, calcium hydroxyapatite and
calcium oxalate dehydrate. Microcalcifications are a feature of particular diagnostic
significance on a mammogram. However, due to their diagnostic importance,
microcalcifications in fresh breast tissue are not typically made available for scientific
research and thus our studies did not include lesions containing them. For this reason, we
have investigated the diagnostic power of Raman microscopy of microcalcifications in thin
sections of deparaffinized fixed breast tissue. We were able to distinguish
microcalcifications occurring in benign and malignant ducts with a sensitivity of 88% and a
specificity of 93%. This is a significant improvement over current X-ray mammography
techniques which are unable to reliably differentiate microcalcifications in benign and
malignant lesions.
Chapter VII. Raman Spectroscopic Breast Cancer Diagnosis: In Vivo Studies
The final objective of this thesis, the in vivo application of Raman spectroscopy for
diagnosing breast cancer, is described in this chapter. The culmination of this work is the
demonstration of accurate intra-operative margin status assessment. Application of our
previously developed diagnostic algorithm resulted in perfect sensitivity and specificity in
this small data set. Significantly, we detected a grossly invisible cancer that, upon
pathological review, required the patient to undergo a second surgical procedure. Had
Raman spectroscopy been employed in a real-time fashion during the procedure, the
additional re-excision surgery would have been avoided. These preliminary findings indicate
that Raman spectroscopy has the potential to lessen the need for re-excision surgeries
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resulting from positive margins and thereby reduce the recurrence rate of breast cancer
following partial mastectomy surgeries.
Chapter VIII. Other Applications of Raman and Fluorescence Spectroscopies
Although there are many advantages to Raman spectroscopy, other optical techniques may
also play a role in breast cancer diagnosis. Preliminary investigations have examined the
diagnostic potential of fluorescence and reflectance spectroscopies. Studies have also been
conducted using spectroscopic techniques that have only recently been applied to tissue, such
as surface enhanced Raman spectroscopy and fluorescence lifetime measurements. Finally,
Raman and fluorescence spectroscopies are used in a synergistic manner to elucidate the
mechanism of ceroid formation in situ. Ceroid is an insoluble lipid-protein complex
characteristic of atherosclerotic plaques. The mechanism of ceroid formation has been
extensively studied but despite intensive research, ceroid is only defined empirically through
its fluorescence properties and its behavior during various staining processes. The synergy of
these two types of spectroscopy allows for the identification of ceroid via its fluorescence
signature and the subsequent elucidation of its chemical composition through the acquisition
of a Raman spectrum. A better understanding of the mechanism of ceroid formation may
suggest avenues to induce regression or prevent progression of atherosclerotic plaques with
medical therapy
Chapter IX. Future Directions
Future directions, comprised of both clinical and basic studies, are presented. With the
successful demonstration of in vivo Raman spectroscopy for breast cancer diagnosis, there
are many clinical applications that can be addressed. Clinical studies to further investigate
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the role of Raman spectroscopy for intra-operative margin assessment are discussed. Also,
development of a side-looking optical fiber Raman probe for transdermal needle
measurements is detailed. Basic research will focus on quantitative analysis and spectral
model refinement. Our current spectral model only provides relatively quantitative data and
does not utilize the intensity information contained within the spectra. Studies to incorporate
intensity information into our diagnostic schemes and to extract quantitative morphological
information are presented. These studies simultaneously provide a basis for model
refinement as well as insight into the lower detection limits of the approach. Finally,
approaches to combining Raman spectroscopy with fluorescence and reflectance data are
presented. The combination of these spectroscopic modalities may provide an even more
powerful tool for guiding patient care.
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Chapter II. Breast Cancer
Breast cancer is the most common female cancer in the United States, the second most
common cause of cancer death in women (after lung cancer), and the main cause of death in
women ages 45 to 55 [Jemal et al. 2004]. Optical techniques can potentially play a
diagnostic role in several aspects of breast cancer evaluation and treatment. Numerous
spectroscopic modalities are currently under investigation for this purpose. This thesis
outlines progress on the use of Raman spectroscopy to diagnose breast cancer. Research to
develop new diagnostic modalities must be grounded in knowledge of both the disease
progression and current medical practices. Only with this information as a basis, can
diagnostic schemes be created that provide relevant information and are easily incorporated
into a clinical setting. This chapter details fundamentals of breast cancer. Both breast
anatomy and pathology are described, thereby providing a framework for interpretation of
spectroscopic data. To astutely apply spectroscopy to breast cancer diagnosis, an extensive
understanding of breast pathology and the morphologic changes associated with each disease
is imperative. Also summarized in this chapter are current diagnostic strategies for breast
cancer as well as breast cancer staging, prognosis, and treatment. With knowledge of the
current biopsy and surgical approaches, areas where spectroscopic modalities can play
beneficial roles in breast cancer diagnosis and treatment are evident. As spectroscopic
techniques move into the clinic, a through understanding of surgical procedures also allows
smart study designs that utilize existing procedures. Further, tissue changes induced by
therapy and the effect this will have on spectroscopic data must be considered. Knowledge
of the strengths and limitations of breast cancer diagnosis and treatment is key for developing
new diagnostic modalities.
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II. A. Breast Anatomy
The mature breast serves as:a secretory, milk producing, gland [Cotran et al. 1999]. Breast
tissue extends from below the collarbone to the level of the sixth or seventh rib, and from the
breastbone to the axilla. In the center of the breast are the nipple and areola. Fibrous
connective tissue, called fascia, lies between the breast tissue and the skin, and separates
breast tissue from the chest muscles. Cooper's ligaments, made of elastin, run from the deep
fascia throughout the breast tissue and attach to the dennis providing a supportive network
schematic of the female breast. The
from the breasts. The surface veins of the
for the breast. Figure 11.1 shows a
andaxillary,mammary,
blood; and the internal mammary, axillary,
intercostal arteries supply the breasts with
internal
to the internal mammary, axillary, and
breast encircle the nipple and carry blood
and intercostal veins carry blood away
intercostal veins, and to the lungs. Breast
Figure 11.1. Schematic of the female breast.
@ Bristol-Myers Squibb
cancer cells can travel to the lungs via surface veins and form metastatic tumors. The
intercostal veins join a complex network of vertebral veins in and around the spine, providing
a path for breast cancer cells to spread to bone tissue. Most lYmphatic vessels in the breast
drain into a network of lymph nodes located around the breast's edges, in the underarm, and
near the coJ1arbone. Axillary lymph nodes are often the first site of breast cancer metastasis.
The skin of the upper breast is innervated by nerves that branch from a network of nerves in
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the neck. The long thoracic nerve innervates the muscle that helps move the upper arm.
Surgeons must be careful not to sever or injure this nerve when operating near underarm
lymph nodes. Chest muscles located under the breasts include the major and minor pectorals,
the serratus magnus and the rectus abdominus. Some mastectomy procedures, excision of
the entire breast, involve removing the fascia overlying the chest muscles, while others
involve removing the muscles themselves.
II. A. 1. Normal Breast Tissue
The breast itself is composed of three types of tissue; adipose, fibrous, and glandular. A
microscopic image of a thin section of normal breast tissue stained with hematoxylin and
eosin (H&E) is shown in Figure II.2a. The three tissue types comprising normal breast can
be visualized in this image. In the histopathological diagnosis routine, tissue is fixed,
sectioned, stained, visually examined by a pathologist and evaluated for abnormalities
[Burkitt et al. 1996]. H&E is applied to tissues fixed in formalin or alcohol and is the most
commonly used technique in routine pathology. The basic dye, hematoxylin, stains acidic
structures a purplish blue. Nuclei, ribosomes and the rough endoplasmic reticulum have a
strong affinity for this dye owing to their high DNA and RNA content, respectively. In
contrast, eosin is an acidic dye that stains basic structures red or pink. Most cytoplasmic
proteins are basic and hence the cytoplasm usually stains pink or pinkish red. Fibrous tissue
is also composed of basic proteins and thus stains pink, as can be seen in Figure II.2a. Also
seen in the image, are the purplish appearing ducts and lobules that are lined with glandular
epithelium. Epithelium is membranous tissue composed of one or more layers of cells
separated by very little intercellular substance. It forms the covering of most internal and
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external surfaces of the body and its organs. The epithelium appears purple due to the
abundance of cell nuclei. Adipose tissue can be visualized as clear spaces in Figure II.2a
because fat is washed away during the tissue processing.
The primary composition of normal breast is fatty tissue interspersed with fibrous or
connective tissue. Together, these two types of tissue make up the stroma, or tissue lying
between the glands. The fatty tissue contains cells, called adipocytes, which harbor copious
amounts of cytoplasmic fat. The fibrous tissue is mainly composed of collagen and small
amounts of glycosaminoglycans. The stroma also contains fibroblasts and blood vessels
[Sternberg, 1997]. Fibroblasts are stellate or spindle-shaped cells capable of producing
connective tissue by forming collagen fibers. The glandular tissue is comprised of several
lobes or milk glands connected to a conduit of ducts that carry milk to the nipples. Each lobe
is autonomous and empties into its own excretory duct. The lobes themselves are divided
into smaller units called lobules, which in turn are made up of acini. The lobules are the
functional, milk producing, units of the mammary parenchyma. The lobular units and the
ducts that connect them are separated from the stroma by a basement membrane, primarily
composed of collagen. Figure II.2b depicts the high magnification appearance of a normal
breast acinus. In the image, a low, flattened layer of contractile cells, some slightly
vacuolated, can be identified beneath the more prominent lining epithelium. Indeed, the
larger ducts in the breast consist of a double layer of cuboidal cells, an inner layer of
epithelial cells surrounded by a layer of myoepithelial cells. The myoepithelial cells are
smooth muscle like cells found in between the epithelium and the basement membrane.
They contain myofilaments, are flatter than epithelial cells and are oriented parallel to the
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long axis of the duct, enabling them to control the transport of milk. As the ducts become
smaller, they are reduced to a single layer of epithelial cells.
II. A. 2. Menstrual Cycle, Pregnancy and Menopause
The breast undergoes significant changes in response to hormonal influences, such as during
the menstrual cycle, pregnancy, and menopause [Cotran et aL 1999]. In the first half of the
menstrual cycle, the lobules are relatively quiescent. After ovulation, under the influence of
estrogen and rising progesterone levels, cell proliferation increases as does the number of
acin per lobule. When menstruation occurs, the fall in estrogen:and progsterone levels is
followel:byapoptosis, a form of programmed epithelial cell death. It-is only with the onset
. " .. , -:''. . .... . . . .
of plregnay:t hat the breast assumes its complete morphboloi :maturation and functional
activity. During pregnancy, the female breast underges lobar hyiertrophy, resulting in
dense; clusters of epithelial cells, so that following birthlatation can occur.- As such, there is
a reversal'of the usual stromal-epithelial relationship so- that by the end of the pregnancy the
breast is cmposed almost entirely of lobules. The breast, w h istologically is a modified
sweat giand, secretes milk by budding off portions of cell cytplasm. The epithelial cells
lining the lumen in Figure II.2b demonstrate apocrine secretion: with:snouting, or cytoplasmic
extrusions, into the lumen. About 15 to 20 ducts come togethernear the areola to form
reservoirs of milk to be drawn from the nipple. After cessation of lactation, the lobules
regress and atrophy, and the total breast size diminishes remarkably. Female breast also
undergoes substantial biochemical alterations at menopause. The ducts and lobules atrophy
with concurrent shrinkage of the stroma and a large amount of collagen is replaced by fat.
The lobular acini and stroma may almost disappear in the very aged, leaving only ducts to
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create a morphologic pattern that resembles that of the male breast. Males have a small
amount of breast tissue, but it consists of just a few ducts, without lobules, in a fibrous
stroma.-
II. B. Breast Pathology
II. B. 1. Benign Breast Lesions
Fibrocystic changes account for the majority of "breast lumps" that are found in women of
reproductive years, particularly between age 30 and menopause [Cotran et al., 1999]. Table
II.1 displays the typical distribution of findings in women seeking evaluation of breast lumps,
an important consideration when developing a
No Disease 30% diagnostic modality. Fibrocystic change is a benign
Benign 60% condition which can manifest itself as fibrosis
Fibrocystic Change 40%
Miscellaneous Benign 13% (formation of fibrous tissue), adenosis (increase in
Fibroadenoma 7%
Cancer 10% the number of ductules) or cyst formation (dilation
Table II.1. Distribution of the findings in of ducts and lobules with semi-transparent fluid).
women seeking evaluation of breast lumps.
Each of these changes can occur with or without the
presence of others. Figure II.2c depicts the histologic appearance of fibrocystic changes in
the breast. Cystically dilated ducts lined by a single layer of epithelial cells can be seen.
There are also areas of lobules that are laced with abundant fibrous connective tissue
(sclerosing adenosis), and stromal fibrosis. Additionally, there is a small area of
microcalcification, highlighted with an arrow. Microcalcifications form as a result of either
calcified secretory material or necrotic debris. No atypical changes are seen in Figure II.2c.
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Atypia refers to abnormality of a cell, which may or may not be associated with later
malignancy.
Fibroadenoma, illustrated in Figure II.2d, is the most common benign tumor of the
human female breast. Its growth is induced by estrogen and often stimulated by lactation and
pregnancy. Most cases of fibroadenoma arise in younger women. Because of the lack of
estrogen after menopause, regression occurs which can result in mucoid degeneration,
hyalinization, involution of the epithelial component and calcification. On physical
examination, the mass feels firm because of proliferative fibrous stroma and its glandular
composition. The tumor is relatively mobile because it does not induce peripheral fibroblast
proliferation, and is rarely tender and painful. To the right in Figure II.2d, compressed breast
connective tissue forming a "capsule" to the mass can be seen. The tumor itself is composed
of a fibroblastic stroma that contains elongated compressed ducts lined by benign appearing
epithelium. Lesions diagnosed as fibroadenoma show an accumulation of collagen due to
fibroblast proliferation which results in expansion of the stroma. Thus, although
fibroadenoma is a benign lesion, it often grows rapidly resulting in significant morbidity, and
thus is typically excised [Khan et al. 2001]. Fibroadenoma is most closely related to
phylloides tumors, the malignant counterpart of which is not carcinoma but cystosarcoma
phylloides, in which the stroma rather than the epithelium is malignant.
Intraductal papilloma, a benign epithelial tumor projecting from the ductal surface, is
often associated with a serous or bloody nipple discharge. In Figure II.2e, a small intraductal
papilloma appears in a breast duct. They are typically in one of the main lactiferous ducts
beneath the areola and thus may cause some nipple retraction. Figure II.2e demonstrates a
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fine pink collagenous stroma within the papilloma and epithelial cells that do not show
atypia.
Fat necrosis of the breast is a less prevalent benign pathology descriptive of focal
areas of fat destruction. The most common etiology is trauma but fat necrosis can also occur
with surgery and radiation therapy. It can be a localized, firm area with scarring that may
mimic a breast carcinoma. Microscopically, fat necrosis consists of irregular steatocytes with
no peripheral nuclei and intervening pink amorphous necrotic material. Steatosis refers to
abnormal accumulation of triglycerides within a parenchymal cell, in this case the adipocyte.
Inflammatory cells, including foreign body giant cells, responding to the necrotic fat cells are
also present. A foreign body giant cell is a very large cell, containing several nuclei and
formed by the fusion of multiple macrophages. Macrophages are large, phagocytic cells that
engulf dead and dying cells as well as antigens that enter the body. Figure II.2f shows fat
necrosis at high magnification. Some lipid-laden macrophages can be seen between the
necrotic adipose tissue cells.
Ductal epithelial hyperplasia (DEH), shown in Figure II.2g, is a pathology
characterized by intraductal proliferation of epithelial cells. In DEH, the epithelial cells
encroach into the duct lumen, producing solid masses, whereas in sclerosing adenosis, also
characterized by epithelial cell proliferation, the epithelial cells continue to form well-defined
glandular units despite somewhat distorted cells. Epithelial hyperplasia is defined by an
increase in the layers of cells and may be due to increased proliferation or, more likely,
failure of cells to undergo apoptosis. Here it is florid and occurs in the setting of fibrocystic
change. DEH confers a slightly increased risk, 1.5 to 2 times normal, for breast carcinoma
[Page et al. 1990]. Figure II.2h shows atypical DEH of the breast. Atypical DEH is
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recognized by its histologic resemblance to ductal carcinoma in situ. However, the lesions
are characteristically limited in extent, and the cells are not completely monomorphic in type
or fail to completely fill ductal spaces. Monomorphic refers to cells that have the same
phenotype. This occurs in tumors as the neoplastic cells often arise from a single progenitor
cancerous cell. In breasts with invasive cancer, multiple independent atypical clones may be
present, suggesting that this is a multicentric process and that only a minority of these lesions
progress to malignancy [Cotran et al. 19991. However, a significantly increased risk, 5 times
normal, for breast carcinoma occurs with cytologically atypical epithelial hyperplasia Page
et al. 19901.
Like the female breast, the male breast is subject to hormonal influences which can
cause gynecomastia, a benign condition characterized by enlargement of the male breast. It
is estimated that 15% of men have gynecomnastia ICotran et al. 19991. It can be characterized
by DEH or prominent periductular edema and may be unilateral or bilateral. Gynecomastia
results from an imbalance between estrogens, which stimulate breast tissue, and androgens,
which counteract these effects. It can occur at puberty or with aging. Gynecomastia may
also occur as a result of cirrhosis of liver, Leydig cell tumors of the testis, or drugs.
II. B. 2. Breast Cancer
The incidence of breast carcinoma increases with age, with 85% of cases arising in women
older than 30 years. The largest proportion of cases, 50% of breast carcinomas, occur in the
upper outer quadrant of the breast. Most breast cancer develops in glandular tissue,
epithelium, and is classified as adenocarcinoma. Cancer is characterized by abnormal cell
proliferation as well as abnormal maturation of cells. Genetic mutations often override the
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Figure 11.2. H&E images of a-b) normal and c-h) benign tissues.
normal cell signaling system allowing cellular proliferation and growth to occur in the
absence of any external stimulus. Thus, unlike normal cells, malignant cells do not stop
reproducing after they have doubled 50 or 60 times. They may also become more resistant to
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MaliQnant Breast PatholoQies
apoptosis than normal cells, thereby ultimately forming a monomorphic tumor that is made
up of billions of copies of the original cancerous cell. A schematic illustrating the start of
this process is shown in Figure 11.3. Differentiation, a feature of normal tissue growth, refers
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to the maturation of cells into a form
differentiated, whereas stem cells are
adapted to a specific function. Thus, a
highlyasdescribedISline
fully mature cell of any particular cell
Figure 11.3. Schematic illustrating uncontrolled
relatively undifferentiated. Cancerous neoplastic cell growth and monomorphic expansion.
cells exhibit variable states of differentiation and often fail to achieve a highly differentiated
state. Poorly differentiated cancers typically confer a worse prognosis. In general, the cells
Normal
~
Hyperplasia
(increase in number of cells)
~
Atypical Hyperplasia
(increase in number of cells, cells exhibit abnormalities)
~
Carcinoma in situ
(cancer exists but is confined to the ducts or lobules)
~
Invasive Cancer
(cancer exists and has spread beyond the breast ducts or lobules)
Figure 11.4. Rowchart describing the breast cancer 'continuum'.
of benign lesions are well differentiated. A simple flowchart detailing the breast cancer
"continuum" is shown in Figure 11.4.
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The earliest form of breast cancer, ductal carcinoma in situ (DCIS), develops solely in
the milk ducts. Figure II.2i is a high power microscopic view demonstrating DCIS.
Malignant cells are still within the ductules and have not broken through the basement
membrane and into the stroma. The two large lobules in the center contain
microcalcifications. The classic cribriform pattern of DCIS of the breast, shown in Figure
II.2j, is characterized by holes with sharp margins as though punched out by a cookie cutter.
The neoplastic epithelial cells within the duct show minimal hyperchromatism and
pleomorphism. Hyperchromatism is an increase in the chromatin content in the cell nucleus.
It can be visualized as an increased staining capacity of the cell nuclei for hematoxylin.
Pleomorphism refers to cells of the same species which occur in more than one
morphological form, in other words cells which have a variety of shapes and sizes.
Hyperchromatism, pleomophism, atypical mitoses, DNA aneuploidy and nuclear
enlargement are all hallmarks of cancer. However, they are not observed in this tissue
section because cribriform DCIS is typically a low grade lesion. Tumor grade is an
important indicator of prognosis, with low grade cancers behaving less aggressively than
high grade tumors. Comedocarcinoma, shown in Figure II.2k, is a less common type of
intraductal carcinoma characterized by the presence of rapidly proliferating, high grade
malignant cells. The cells in the center of ducts with comedocarcinoma are often necrotic
and calcify, as can be seen in Figure 1.2k. This central necrosis leads to the gross
characteristic of extrusion of cheesy material from the ducts with pressure, comedone-like.
Comedocarcinoma is much more likely to exhibit hyperchromatism, pleomorphism, atypical
mitoses, DNA aneuploidy and nuclear enlargement than cribriform DCIS due to its high
grade.
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The most common type of breast cancer, invasive ductal carcinoma (IDC), develops
from DCIS, spreads through the duct walls, and invades the breast tissue. Lesions diagnosed
as infiltrating carcinoma exhibit increases in cellularity and often increases in collagen due to
fibroblast proliferation in response to stromal invasion by the malignant epithelial cells. IDC
arises from breast ducts and accounts for 70-80% of cases of breast cancer [Cotran et al.
1999]. The IDC of the breast, shown in Figure II.21, is poorly differentiated with very
pleomorphic cells.
Lobular carcinoma in situ (LCIS) consists of neoplastic proliferation in the terminal
breast ducts and acini. The cells are small and round. LCIS is seen in Figure II.2m. Though
these lesions are low grade, they confer a 30% risk for development of invasive carcinoma in
the same or the opposite breast [Cotran et al. 1999]. Invasive lobular carcinoma (ILC)
accounts for 5-15% of invasive breast cancers. ILC of the breast is shown in Figure II.2n.
There is roughly a 20% chance that the opposite breast will also be involved, and many ILCs
arise multicentrically in the same breast. ILCs often have a diffusely invasive pattern
causing tumors to be difficult to detect by either physical examination or mammography.
There are several less common types of breast cancer. A phyllodes tumor of the
breast, the malignant counterpart to fibroadenoma, is shown in Figure II.2o. They arise from
interlobular stroma, but unlike fibroadenomas are not common and are much larger. They
are low-grade neoplasms which are more cellular than fibroadenomas but rarely metastasize.
From the Greek word phyllodes, meaning leaf-like, these tumors are characterized by
projections of stroma into the ducts which create a leaf-like pattern. Inflammatory
carcinoma, shown in Figure II.2p, tends to spread quickly. It is characterized by breast tissue
that is warm and appears red. The hallmark of inflammatory carcinoma can be seen in the
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skin overlying the breast which
has prominent lymphatic spaces
filled with small metastases from
breast carcinoma. Medullary
carcinoma originates in central
breast tissue. Interestingly, it has
a slightly better prognosis than
do most carcinomas, despite the
almost universal presence of poor
Histologic Type Total Cancers
In Situ Carcinoma 15°/o-30%
Ductal carcinoma in situ 80%
Lobular carcinoma in situ 20%
Invasive Carcinoma 70%85%
Ductal carcinoma 79%
Lobular carcinoma 10%
Tubular/cribriform carcinoma 6%
Mucinous carcinoma 2%
Medullary carcinoma 2%
Papillary carcinoma 1%
Table 1.2. Frequency of histologic types of breast cancer.
prognostic factors. Mucinous carcinoma, also called colloid carcinoma, is a rare type of
invasive cancer that usually occurs in postmenopausal women. It arises from mucin
producing cells and tends to grow slowly. Mucinous carcinoma is characterized by abundant
extracellular mucin surrounding nests of carcinoma cells. Paget's disease of the nipple
originates in the milk ducts and spreads to the skin of the nipples or areola. Table 11.2 shows
AtypicalDuctal
Epithelial tal
~Hyperplasia
Fibrocystic HyperplasiaNormal
Changes Lobular Atypical
Noma Lobular -
Hyperplasia HyperplasiaHyperplasia
Ductal Infiltrating
Carcinoma -~ Ductal
In Situ Carcinoma
Lobular Infiltrating
Carcinoma o- Lobular
In Situ Carcinoma
Normal Fibroadenoma
Normal <
Benign Phyllodies Tumor - Malignant Phyllodies Tumor
("Giant Fibroadenoma") (Cystosarcoma Phylloides)
Figure 11.5. Flowchart depicting the relationship between the breast lesions encountered in our studies.
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the distribution of the histologic types of breast cancer. Tubular carcinoma is a small tumor
that is often undetectable by palpation. It is a well differentiated form of invasive breast
carcinoma and is usually associated with foci of DCIS. Tubular carcinomas are almost
always less than 2 cm in greatest dimension. Sarcomas, cancer of the connective tissue, and
lymphomas, cancer of the lymph tissue, rarely develop in the breasts. Figure II.5 shows a
flowchart depicting the relationship of breast lesions encountered in our studies.
Although the majority of breast cancers are confined to women, carcinoma in the
male breast does arise. It is a rare occurrence, with a frequency ratio to breast cancer in the
female of less than 1:100. The dearth of glandular tissue in the male breast is a significant
reason for the rarity of male breast cancer. However, the scant amount of breast tissue in
men also results in malignant neoplasms that rapidly infiltrate to become attached to the
overlying skin and underlying thoracic wall. Metastasis follows the same pattern as in
women, and axillary lymph node involvement is present in about half of the cases of male
breast cancer at the time of lesion discovery. Although men present at higher stages, when
they are matched by stage, prognosis is similar in men and women [Cotran et al. 1999].
II. C. Breast Cancer Risk Factors
Most women who develop breast cancer have no identifiable risk factors other than their
gender. The growth of breast cancer tumors is often affected by the presence of estrogen and
progesterone. The following risk factors result from exposure to these hormones: age greater
than 50 years, first pregnancy after age 30 years, long-term hormone replacement therapy
(more than 5 years), menstruation before age 12 years, menopause after age 50 years, and
nulliparity (not bearing children). Other risk factors include a family history of the disease,
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which means a mother or sister has been affected with premenopausal breast cancer, a
genetic link, a history of breast biopsy or chest radiation, moderate alcohol use (2 to 5 drinks
daily), obesity, a personal history of disease (women with a history of breast cancer are 3 to 4
times more likely to have a recurrence), race (breast cancer is slightly more common in
Caucasians), and a sedentary lifestyle.
Approximately 5% of breast cancer cases have a genetic link that results from an
inherited mutation in genes identified as BRCA1 (BReast CAncer 1) and BRCA2 (BReast
CAncer 2) [Radford et al. 1996]. BRCA1, on chromosome 17, and BRCA2, on chromosome
13, are autosomal dominant tumor suppressor genes first identified in 1994 [Miki et al. 1994;
Wooster et al. 1995]. Until recently, the function of these genes was not known. However,
studies on a related protein in yeast revealed that the genes code for proteins which
participate in repairing radiation-induced breaks in deoxyribonucleic acid (DNA) [Zhang et
al. 1998]. It is thought that mutations in BRCA1 or BRCA2 disable this mechanism, leading
to more errors in DNA replication and ultimately to cancerous growth. Patients who inherit
an altered BRCAl or BRCA2 gene have an increased risk for developing premenopausal
breast cancer and are more likely to have family members with the condition. Studies have
shown that for women who inherit a BRCA1 or BRCA2 mutation, breast cancer risk could be
as high as 80% to 90% by the age of 70. These mutations are particularly prevalent in the
Ashkenazi Jewish population [Beller et al. 1997]. Both mutations also carry an increased
risk of developing ovarian cancer. Genetic testing can be performed to determine BRCA1
and BRCA2 status and patients carrying the genes may choose preventative measures such as
prophylactic mastectomy or prophylactic medication. Prophylactic mastectomy, which can
reduce the risk of breast cancer by 90%, is the removal of one or both breasts [Hartmann et
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al. 1999]. However, surgeons can never be certain that they have removed all of a patient's
breast tissue and in 10% of cases tissue that eventually develops cancer is left behind. In
1998, tamoxifen became the first drug approved by the U.S. Food and Drug Administration
(FDA) to prevent breast cancer. Research has shown that it reduces the chance of developing
breast cancer by 49% in women at high risk [Fletcher et al. 1998]. While tamoxifen reduces
the chance of breast cancer in women with the BRCA2 mutation, it doesn't appear to work
for women with the BRCA1 mutation [King et al. 2001]. Tamoxifen is discussed in more
detail in section II.F.5.
Genetic screening for breast cancer is complicated by the fact that both BRCA genes
are extremely large and may harbor hundreds of possible mutations. Therefore genetic
testing is often performed with affected and unaffected family members and comparison is
used to pinpoint the exact location of the mutation. For people of Ashkenazi Jewish descent
genetic testing is somewhat simplified. This is because in 90% of cases, an Ashkenazi Jewish
family with a pattern of hereditary breast and ovarian cancer will have one of three specific
mutations [Roa et al. 1996]. This has made it possible to develop a test that looks for the
presence or absence of these three specific mutations, rather than the hundreds that can be
associated with these types of cancer in other populations.
II. D. Breast Cancer Screening
The American Cancer Society recommends these guidelines for women who do not have
symptoms of breast cancer:
Women at age 20 should learn about the benefits and limitations of breast self-
examination (BSE). The American Cancer Society considers performing BSE to be
optional.
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* Women between the ages of 20 and 39 should have a clinical breast examination by a
physician or other health care practitioner every 3 years.
* Women age 40 and older should have a clinical breast examination and mammogram
annually.
* Older women with serious health problems should evaluate the benefit of screening
with their physician.
* Women with a family history of breast cancer should discuss early detection testing,
breast ultrasound, and MRI with their physician.
II. E. Breast Cancer Diagnosis
Cancers of the breast are usually first discovered by a woman or her physician as a solitary,
painless mass in the breast or because of mammographic abnormalities during screening. On
average, palpable invasive carcinomas are 2 to 3 cm in size when they are first found, and
approximately one third have already spread to axillary or other lymph nodes. In contrast,
mammographically detected invasive carcinomas average 1 cm in size and less than one fifth
will have axillary metastases. The older the patient at the time of discovery, the more likely
the lesion is to be cancer. Diagnosis of breast cancer is made through a process called triple
assessment, which includes:
· clinical examination,
· imaging procedures (mammogram, breast ultrasound), and
· biopsy of a mass detected by clinical examination or mammogram.
However, it is important to note that biopsy and pathological review are the final arbiters of
clinical condition.
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II. E. 1. Clinical Examination
During clinical breast examination (CBE), the health care provider examines the breasts
including the nipples and areola for retractions, skin changes, and discharge [Donegan and
Spratt, 1995]. Next, the breasts and underarms are palpated. If a mass is found, texture and
mobility are assessed. On physical examination, benign lesions are typically mobile while
cancers are often firm and immovable due to stromal invasion. If a lesion is identified during
CBE, the health care provider will likely order additional studies. Typically, health
professionals perform a CBE once every three years between the ages of 20 and 40 and once
a year for patients over 40 years of age.
II. E. 2. Imaging Techniques
Mammography and ultrasound are important counterparts to physical examination that allow
many cancers to be discovered at an early stage. Both are imaging techniques, which rely on
density changes in the breast to detect cancers.
II. E. 2. a) Mammography
Mammography is a non-invasive imaging procedure that uses x-rays to create images of
breast tissue [Dahnert 1999; Feig and Piccoli 1997]. During a mammogram, the breast is
compressed between a compression paddle and a film holder or digital detector that is used to
record the attenuation of x-rays as they traverse the tissue. Compression of the breast
reduces tissue thickness, thereby producing improved images. However, the compression
causes moderate discomfort. A mammogram is a screening test, not a diagnostic test. An
abnormal mammographic result cannot alone indicate cancer. In most cases further testing
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shows masses detected via mammography to be benign, and in 10% of cases, radiologists can
interpret normal tissue as abnormal [NCI 2002]. An abnormal screening mammogram
indicates that further testing should be done, such as a diagnostic mammogram, ultrasound,
or biopsy. There are two basic forms of mammography: screening and diagnostic.
A screening mammogram is used to look for cancer in women with no symptoms and
no history of breast surgery. The mammogram is first checked by the technologist and then
read by a diagnostic radiologist. The radiologist looks for unusual shadows, masses,
distortions, special patterns of tissue density, and differences between the two breasts.
Mammograms are used for comparative study, that is, the left breast is compared to the right
breast, and current films are compared to older films. The goal of regular mammographic
screening is to detect small breast cancers because they are easier to treat and present a better
prognosis for the patient. How often women under age 50 should have a screening
mammogram continues to be controversial. However, most prominent health organizations
(e.g., World Health Organization, National Cancer Institute, American Cancer Society) agree
that women between the ages of 40 and 69 can significantly reduce their risk for dying of
breast cancer by having a mammogram every 1 or 2 years. Women who have significant risk
factors for breast cancer should discuss whether to begin screening earlier, and how often,
with their physicians.
In standard mammography studies two images of each breast are obtained for
evaluation: a mediolateral oblique view, side, and a cranial-caudal view, from above.
Different tissues in the breast absorb different amounts of x-rays, producing varying shades
of black, gray, and white on the film. Fatty tissue absorbs a relatively small amount of x-rays
and thus appears black or dark gray. Normal fibrous and glandular tissues contain water that
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causes absorption of a moderate amount of x-rays and thus appear light gray. Dense breast
tissue, with more collagen, can make mammogram evaluation difficult because the tissue can
obscure small cancers. Younger women and those with fibrocystic change typically have a
more dense breast stroma, however there is significant variation. Many mammograms show
nontransparent white specks. These are calcium deposits known as calcifications and they are
a key component that radiologists look for in a mammogram. Although there is no reliable
way to distinguish between calcifications occurring in benign and malignant lesions in a
clinical mammogram, their presence does provide some insight into the underlying tissue
pathology.
calcifications.
Changing of mammographic views may cause disappearance of the
If there is a new mass, has been a change in the size or the shape of the edges of a
mass, or if a suspicious calcification within a mass is seen, the radiologist is likely to order
additional studies. An area in one breast that has a distinctly different appearance than the
same area in the other breast is referred to as asymmetric density. In Figure 11.6 an
asymmetric density can be seen in both the mediolateral oblique and cranial-caudal views.
Figure 11.6.Mammograms exhibiting asymmetric densities.
@ The MIAS Digital Mammography Database.
-44-
This finding necessitates additional studies. A new mass or a mass that has grown since the
last mammogram was taken is usually evaluated with ultrasound to assess cyst formation, as
cancers do not typically grow so rapidly. The shape of a mass detected by mammography is
important for differentiating benign and malignant lesions.
A growth that is benign, such as a cyst or fibroadenoma, generally looks smooth,
round and has a clearly defined edge. Figure 11.7
displays a mammogram of a cystic lesion.
Several masses may be seen in women who
harbor fibrocystic change and microcalcifications
may be present in foci of fibrocystic change
containing cysts. When the calcium sediments at Figure 11.7. Mammogram showing a cyst.
@ Mammography Specialists Medical Group, Inc.
the bottom of a cyst, crescent-shaped calcification
is produced. The calcification evident in Figure II.8a appears to rim the entire cyst. In a
breast lobule, epithelial hyperplasia may also appear as crescent-shaped calcification as it
Figure 11.8. Mammographic manifestations of microcalcifications, highlighted by arrows, occurring in
a) a cystic lesion, b) fibroadenoma, and c) Monkeburg's arteriosclerosis.
(!) The MIAS Digital Mammography Database.
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often causes dilatation of acini and formation of cysts. The mammogram in Figure 1I.9a
demonstrates a suspicious area with microcalcifications that could be a carcinoma or just an
area of fibrocystic changes. On biopsy, this lesion had areas of fibrocystic change with
epithelial hyperplasia. Sclerosing adenosis, another manifestation of fibrocystic change, is
often difficult to distinguish from cancer. Its gross and mammographic appearance may
mimic carcinoma, and the two can be difficult to distinguish on frozen section. The
mammogram in Figure H.9b demonstrates a suspicious lesion that could be a carcinoma or
just an area of pronounced sclerosis with fibrocystic changes. On biopsy it was found to be
benign. In older woman with fibroadenoma, atrophy may give rise to calcification. As a
result, the "pop-corn" calcification, seen in Figure 1I.8b, is considered a pathognomonic
feature of fibroadenoma. Benign calcifications are usually associated with clusters of
apocrine cysts, sclerosing adenosis, fat necrosis, or hyalinized fibroadenomas. Idiopathic
arterial calcification, Monkeburg' s arteriosclerosis, is common on mammograms and
attributed to the ageing process. On mammography, arterial calcifications are observed as
two parallel continuous or discontinuous calcific lines along the vessel wall, as seen in Figure
H.8c. These calcifications
are unrelated to breast lesion
formation.
In contrast to well
circumscribed lesions, breast
cancer often has an irregular
Figure 11.9. Mammograms demonstrating suspicious lesions.
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mammography, a spiculated carcinoma is seen as a star-shaped mass with irregular borders
due to a desmoplastic process in conjunction with a possibly infiltrating tumor. Postsurgical
scarring (from a previous biopsy), trauma, and infection may also produce a lesion with
spiculated margins. IDC and ILC exhibit irregular borders, as can be seen in Figure 11.10.
However, many breast cancers appear circumscribed and thus may resemble benign lesions.
Medullary carcinoma, papillary carcinoma and some of the ductal carcinomas show this
feature. Higher density, irregular and non-homogeneous opacities, disruption of nonnal
architecture, increased vascularity, and perifocal haziness
are features which assist in distinguishing them from a
benign lesion. Microcalcification due to necrotic debris
can often be seen within or outside a cancerous mass.
This type of calcification is much fmer than that of
fibroadenoma. Calcifications associated with malignancy
are more commonly small, irregular, numerous, and
clustered or linear and branching. About half of the
'cancers found by mammography are detected as clusters
of microcalcifications. Clusters of numerous
Figure 11.10. Mammogram
demonstrating a spiculated mass.
e USF Image Analysis Research Laboratory.
microcalcifications in one area are often a sign of DCIS. In fact, DCIS is most commonly
detected as mammographic calcifications and only rarely as a palpable or radiographic mass.
DCIS is important to detect because it is limited to the breast and most cases can be cured by
local treatment. Any mammographic abnormality suggestive of cancer indicates that further
testing should be done, such as a diagnostic mammogram, ultrasound, or biopsy.
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Diagnostic imaging refers to special mammographic views and ultrasound. It may be
necessary in patients with breast implants, severe fibrocystic disease, or surgery for early
breast cancer that did not remove the entire breast. Diagnostic imaging is required for an
abnormal finding on a screening mammogram and a new finding during CBE. If the findings
obtained from diagnostic imaging indicate that there is a solid lesion, a biopsy is
recommended for final diagnosis. Special mammographic views include magnification and
spot compression. Magnification produces an enlarged image of a portion of the breast that
contains small calcifications or small masses. Spot compression applies pressure to a small
region in the breast. This is used to thin out an area of dense tissue so that a clearer image is
produced. Sometimes, views of the breast from different angles are required to better
visualize a questionable area. Typical additional views include: cleavage view (both breasts
are compressed between a set of panels at the same time providing a top-to-bottom view),
rolled view (the breast is rolled to the right or left, compressed, and a top-to-bottom view is
taken), mediolateral view (from the center of the chest to the outer side of the breast),
lateromedial view (from the outer side of the breast to the center of the chest).
Because small cancers are difficult to distinguish from normal breast tissue on a
mammogram and may not be palpable, some go undetected. Cases that elude diagnosis are
referred to as false-negatives. Other conditions in the breast may look similar to cancer, such
as calcifications or cysts. In this situation, additional studies that focus on the area of the
breast where the suspicious lesion is located will be performed. If additional studies are
inconclusive, a biopsy is recommended. If the biopsy proves to be benign, the finding is
called a false-positive. The high rate of false-positive readings in mammography is why it is
not a diagnostic modality and must be followed by biopsy. Age of the patient as well as
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breast tissue characteristics are factors in the false-positive rate. Most women who have
received false-positive readings are younger women whose breasts tend to be dense, women
with a history of breast biopsies, women with a family history of breast cancer, and women
who are taking hormone replacement therapy. There is also the possibility of misreading of a
mammogram by an unskilled or inexperienced radiologist. Research reports a correlation
between a radiologist inaccurately reading a mammogram and his or her experience and
training [Elmore et al. 2002]. A recent ten year study found that when subjects underwent a
median of four mammograms and five CBEs, approximately 32% experienced at least one
false-positive from either test [Elmore et al. 1998]. Consequently, each year a large number
of unnecessary breast biopsies are performed.
II. E. 2. b) Digital Mammography
Digital mammography promises to be a significant improvement over conventional
mammography in the early detection of breast cancer. In digital mammography, the film
normally used for recording the image is replaced by an electronic x-ray detector [Wu et al.
1992]. Instead of acquiring an image on film, a digital image is generated. This image can be
displayed and adjusted by the radiologist to facilitate detection of small breast cancers. With
digital mammography, the magnification, orientation, brightness, and contrast of the image
may be altered after the exam is completed to help the radiologist more clearly see certain
areas without having to take an additional image. Further, digital mammography allows
correction for under or over exposure after the exam is completed. Advances in image
registration, allow doctors to view the entire breast in one image. Digital mammograms also
offer the potential for more efficient access to past mammograms as they can be
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electronically transmitted to another hospital. This is important as mammograms are most
effective when used for comparative study.
Several studies have demonstrated that digital mammography is at least as accurate as
standard mammography and the FDA has recently approved a digital mammography system
to screen for breast cancer. Small studies have shown that digital mammography may
provide additional benefits, such as lower radiation doses and higher sensitivity to
abnormalities. Also, research efforts are focusing on use of automated programs to search
the digital images for telltale patterns of cancer, enabling radiologists to make diagnoses
based on subtle patterns in tumor architecture. The largest U.S. federally-funded clinical trial
on medical imaging will soon be underway to determine whether digital mammography is
equal or superior to standard film mammography in helping to detect breast cancer.
While digital mammography is quite promising, it still has additional hurdles to
undergo before it replaces conventional mammography. Digital mammography lacks the
spatial resolution of standard mammography. High resolution is especially useful for
imaging microcalcifications and very small abnormalities that may indicate early breast
cancer. While digital mammography lacks the spatial resolution of film, clinical trials have
shown it to be at least equivalent to standard film screening mammography. This is thought
to be because digital mammography has the benefit of providing improved contrast, which
may make abnormalities easier to see. Efforts to develop digital mammography systems with
resolution equivalent to standard film mammography are underway. The high cost of digital
mammography is another obstacle in its implementation. Standard mammography systems
are currently installed in over 10,000 locations across the United States. It may take years for
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this current equipment to be updated or replaced and for digital mammography to become
widespread.
II. E. 2. c) Ultrasound
Ultrasound uses high-frequency sound waves to create an image of the breast. It is
performed with a smaIl, handheld device called a transducer. A gel is spread on the skin of
the breast and the radiologist passes the transducer over the breast, directing sound waves
through the skin and into the body. Thus, ultrasound allows significant freedom in obtaining
images of the breast from almost any orientation. It is typically used to determine if a mass
is a cyst or a solid lesion, possibly a cancer. Figure II.lla shows an ultrasound of a breast
cyst with sharp walls and internal septation while Figure 11.11b displays a large cyst with
layered debris and a solid component. The ultrasound image in Figure 11.11c shows ductal
invasion associated with a malignant breast mass. Ultrasound is also useful when evaluating
dense fibrous breasts where contrast is limited. Though breast ultrasound has excellent
contrast, it lacks the spatial resolution of mammography. As a consequence, it is unable to
reliably image microcalcifications. Therefore, ultrasound is not approved by the FDA as a
screening tool for breast cancer. Rather, ultrasound is used as an adjunct to further
investigate an abnormality detected by mammography or during a eBB [Gordon 2002].
Figure 11.11. tntrasound of a) a breast cyst, b) a large cyst with layered debris, and c) an infiltrating ductal
carcinoma.
<D Siemens Medical Systems.
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II. E. 3. Biopsy
II. E. 3. a) Excisional Biopsy
Biopsy refers to the process of removing tissue from patients for diagnostic examination.
Traditionally, suspicious lesions undergo open excisional biopsy under general anesthesia in
the operating room. This procedure is preformed by a surgeon. Excisional biopsy removes
the entire lesion, which can range from a spheroid several centimeters in diameter to the
entire breast. With the increasing use of mammographic screening, a growing number of
breast biopsies are performed because of an abnormality detected by mammography in the
absence of a palpable mass. Nonpalpable lesions are surgically identified by mammographic
placement of a localizing wire within the lesion [Schnitt and Connolly 1992; Bennginton and
Lagios 1992]. A radiologist perfonns needle localization prior to surgery and the wire is
used as a guide to precisely locate the mammographic abnormality for excision. The most
frequent mammographic abnormalities prompting biopsy are microcalcifications, a soft tissue
density or a combination of the two. Specimen radiography, acquiring an x-ray of the
excised lesion, is used to document the presence of the lesion or
microcalcifications detected by mammography in the excised
tissue. It is also used to localize the suspicious area for histologic
examination. An example of a specimen radiograph is shown in
Figure 11.12. The localizing wire can be seen in the upper right of
the image. Specimen radiographs are compared with the
Figure D.I2. A
specimen radiograph.
preoperative mammograms to be certain that the lesion of concern has been excised.
After radiography of the intact specimen has demonstrated that the lesion of interest
IS present within the specimen, this area must be identified by the pathologist. Some
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specimens will contain a grossly evident tumor, in which case further efforts to demonstrate
the lesion are not necessary. If, however, there is no grossly evident lesion, a number of
methods can be used to identify the location of the lesion within the specimen. One simple
method consists of comparing the gross specimen with the specimen radiograph and placing
a pin or needle into the specimen at the site of the mammographic lesion to permit the
identification of its location by the prosector. Another method consists of performing the
initial specimen radiograph after placing the tissue in a specimen holder that incorporates a
grid that is visible on the radiograph. The holder containing the specimen and the specimen
radiograph are then compared to precisely locate the target lesion using the X and Y
coordinates of the grid. Once the excised lesion is located, the suspicious tissue is placed in a
cassette to be sectioned, stained, and examined microscopically by a pathologist. Pathology
is the gold standard for disease diagnosis and diagnostic algorithm development.
II. E. 3. b) Needle Biopsy
In recent years, less invasive needle based biopsy techniques have been developed and are
being used more frequently. Needle biopsies are performed in a radiologist's office on an
outpatient basis under local anesthesia. Needle procedures are less intrusive and less
disfiguring than excisional biopsy and yield equal diagnostic accuracy [Parker et al. 1994].
In light of the fact that up to 80% of breast biopsies are found to be benign upon tissue
excision, needle biopsy is an attractive alternative to excisional biopsy [Johnson et al. 1999].
If the lump to be biopsied cannot be felt, stereotactic mammography or ultrasound may be
utilized to help the physician guide the biopsy needle. Patient positioning depends on the
imaging method employed. If the procedure uses ultrasound, a doctor will obtain images of
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the breast tissue while the patient lies on her back.
In stereotactic procedures, patients lie facedown on
a special table, shown in Figure 11.13. The woman's
breast protrudes through a hole in the table's
surface, where it is compressed and immobilized
while mammograms are taken from two angles and
a computer maps the precise location of the lesion
me_~
Figure D.13. Instrumentation used in
stereotactic biopsy procedures.
C Ethicon Endo-Surgery, Inc.
to be biopsied. The sensitivity of the needle biopsy procedure is in large part related to the
size of the needle. In one study, for example, the sensitivity for malignancy was 65%, 92%,
and 100% for 18, 16, and 14-gauge needles, respectively [Nath et ale 1995]. Spectroscopic
modalities have the ability to provide minimal invasiveness, similar to fine needle aspiration,
with sensitivity to a larger tissue volume. Several types of needle biopsy will now be
described.
II. E. 3. c) Fine Needle Aspiration
In fine needle aspiration the doctor uses a hollow needle that is attached to a syringe to
extract fluid from a cyst or cells from a solid lesion. The needle used in this Proced~ is very
small, 20-25 gauge (0.89-0.51 mm). The procedure is performed under local anesthesia and
requires a small incision. The procedure takes a few minutes and typically leaves no scarring
and does not require stitches. Fine needle aspiration is the easiest and fastest method of
obtaining a breast biopsy, and is very effective for women who have fluid filled cysts.
However, the pathological evaluation can be incomplete because the tissue sample is
extremely small. As with many procedures, the effectiveness of fine needle aspiration
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depends on the skill of the surgeon or radiologist who performs it. Needle placement can be
guided by stereotactic mammography or ultrasound, but even with this guidance, insufficient
sampling is a problem. A study of fme needle aspiration found that 34% of patients were
insufficiently sampled, requiring further biopsy [Pisano et al. 1998].
II. E. 3. d) Core Needle Biopsy
Core needle biopsy is similar to fine needle aspiration, but the needle is larger, 14-18 gauge
(2.11-1.25 mm), enabling a larger sample to be obtained. It removes a cylinder of tissue
typically 1 mm in diameter and several centimeters long. Although less invasive than
excisional biopsy, core needle biopsy requires the collection of at least five specimens to
ensure proper sampling [Liberman et al. 1994]. The needle, shown in Figure 11.14, is
deployed by a spring-loaded device. Also shown in Figure 11.14 is a schematic of tissue
removal procedure. Repeated needle insertions are necessary to obtain each biopsy sample.
Figure 11.14. Biopsy needle and schematic of the
tissue removal procedure.
Core needle biopsy is also perfonned under
local anesthesia and ultrasound or
stereotactic mammography is used if the
lump cannot be felt. The procedure takes a
few minutes and no stitches are required.
Core needle biopsy may provide a more accurate analysis and diagnosis than fine needle
aspiration because tissue is removed, rather than just cells. However, this procedure is not
accurate in patients with very small or hard lumps. Specimen radiography is also used to
document the presence of the lesion or microcalcifications in tissue excised via core needle
biopsy. In biopsies performed for microcalcifications, the likelihood that the pathologist will
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be able to render a specific diagnosis is significantly greater when calcifications are
identified on the specimen radiograph than when they are not [Mainiero et al. 1996]. In one
study, a specific diagnosis was rendered in 81% of core biopsies in which calcifications were
present on the specimen radiograph compared with only 38% of cases in which calcifications
were not radiographically identified in the core biopsy specimens [Liberman et al. 1994].
II. E. 3. e) Vacuum-Assisted Biopsy
This method utilizes a vacuum-like device to remove breast tissue. Under local anesthesia,
following manual incision of the skin, a canula between 0.5 to 2 cm in diameter containing a
circular blade is advanced to the lesion position as identified by digital spot view
mammography. The needle is inserted only once to obtain multiple samples. As depicted in
Figure II1.15, when suction is applied, the
Position- WaCuiUmv i imb' Re
breast tissue is drawn into the needle and a : 
blade sections the trapped tissue. The Figure II.15. Schematic of vacuum-assisted biopsy.
© Ethicon Endo-Surgery, Inc.
suction also draws out the breast tissue and
the samples are passed through the hollow chamber of the probe and into a collection
chamber. Successive biopsies can be performed over 360 ° around the axis of the needle
without any need to withdraw the needle between biopsies. Typically twelve cores of tissue
are removed and in some cases, the entire lesion may be excised. 11 or 14 gauge needles are
used. At the completion of the procedure, a small metallic clip may be deployed through the
needle to mark the biopsy site in case therapeutic lumpectomy and/or radiation therapy, both
described in section II.F, need to be performed for invasive cancer. Vacuum-assisted biopsy
is safe, reliable, and valuable for patients who wish to avoid excisional biopsy.
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II. E. 3. f) Large Core Biopsy
Presently, large core biopsy, also called advanced breast biopsy instrumentation (ABBI), has
been FDA approved for diagnostic biopsy only. However, in the future ABBI may provide
an alternative for patients who prefer a less invasive procedure than surgery. This technique
can completely excise small lesions from the breast with clear histologic margin. ABBI
assemblies are available which can provide core tissues of 5, 10, 15, or 20 mm in diameter.
In this procedure, the radiologist localizes the lesion with a needle in the center of the device.
A surgeon then removes a core of tissue from the breast using a circular oscillating blade
which is advanced concentrically over the initial localization needle. The procedure is
performed through a skin incision, large enough to accommodate the blade, made under local
anesthesia and sutured closed by the surgeon at the completion of the procedure.
II. E. 3. g) Sentinal Node Biopsy and Axillary Node Dissection
Sentinal node biopsy and axillary node dissection are performed following a positive biopsy
to determine if cancer has spread beyond the breast. The axillary lymph nodes are located
under the arm. The sentinel node is the first axillary lymph node that filters fluid from the
breast. Cancer cells found in the lymph nodes suggest that the cancer has metastasized and
the patient may need more aggressive treatment. Many cancer experts believe that malignant
cells reach the sentinel node first and that this lymph node is more likely to contain cancer
cells. If the sentinel node is free of cancer cells, then it is highly unlikely that the other nodes
are positive. The results of this test are important for the patient and physician to plan the
best course of therapy.
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Sentinal node biopsy, combined with lumpectomy, is easily performed as an
outpatient procedure and causes less pain and deformity than an axillary node dissection.
After the patient is given general anesthesia in the operating room, a radioactive tracer or
blue dye is injected into and around the tumor. The material passes naturally through the
nearby lymphatics to the sentinal node for that area of the breast. With a small, hand-held
Geiger counter or by eye, the surgeon tracks the path the tracer takes as it travels away from
the breast and under the arm to the sentinal lymph node. Once located, the sentinel node is
removed and sent for histopathology and diagnosis. If the results are negative, it is assumed
that the cancer has not spread and there is no need for further surgery. If the sentinel node is
positive, the surgeon may perform an axillary node dissection to assess how many other
lymph nodes are affected. Because sentinel node biopsy removes fewer lymph nodes than
axillary lymph node dissection, many patients have no side effects. Pain, nerve damage, and
lymphedema (swelling of the arm caused by scarring of the lymph vessels) are more common
when additional lymph nodes are removed with the sentinel node.
After the sentinel node has been removed, it is examined by a pathologist. There are
two stains typically employed, H&E and an immunohistochemical stain for cytokeratin. The
standard test has always been the H&E stain, and prognostic estimates have been based on
seeing cancer cells in a lymph node through this method of staining. However, the
cytokeratin IHC stain is more sensitive than the H&E stain, and thus it picks up nodes that
are negative by H&E. Initially, it was thought this would allow more accurate diagnosis.
However, there are often a few cells dislodged during surgery that make it to the lymph
nodes, called micrometastases. Micrometastases do not appear to be the same as cancer cells
that find their own way to the lymph nodes, called macrometastases, and do not appear to
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affect overall survival [Ollila et al. 2001]. There are two clinical trials currently underway to
determine whether cytokeratin IHC staining should become a routine part of the sentinel
node analysis. Researchers experience with IHC staining has taught us that increases in
sensitivity do not necessarily translate into increases in a technique's efficacy. This lesson is
important to keep in mind when developing a new diagnostic modality.
An axillary node dissection removes all of the axillary lymph nodes and may be done
at the same time as a lumpectomy or a mastectomy. The surgeon makes an incision under
the arm and removes a pad of fat in which 10 to 20 lymph nodes are embedded. The incision
is sutured and a drain may be put in to remove excess fluid. The procedure takes between 1
and 2 hours. Complications include, permanent numbness under the arm, lymphedema and
infection of the incision site. An axillary dissection removes many of the lymph nodes that
protect against infection, and the hand and arm on the affected side may become more
susceptible. Blood should not be drawn from this arm, and minor injuries should be reported
to a physician. The hand and arm should be checked regularly for inflammation or cuts.
II. F. Breast Cancer Treatment
II. F. 1. Staging and Prognosis
The prognosis and therapeutic course for patients with breast cancer depends on the stage of
the disease at diagnosis as well as a number of other factors. If a diagnosis of breast cancer is
made, the cancer is staged. The American Joint Committee on Cancer Staging divides the
clinical stages as follows:
Stage 0. DCIS or LCIS, 5-year survival rate 92%.
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Stage I. Invasive carcinoma 2 cm or less in size without nodal involvement and no distant
metastases, 5-year survival rate 87%.
Stage II. Invasive carcinoma 5 cm or less in size with involved but movable axillary nodes
and no distant metastases, or a tumor greater than 5 cm without nodal involvement or distant
metastases, 5-year survival rate 75%.
Stage III. Breast cancers greater than 5 cm in size with nodal involvement; or any breast
cancer with fixed axillary nodes; or any breast cancer with involvement of the ipsilateral
internal mammary lymph nodes; or any breast cancer with skin involvement, pectoral and
chest wall fixation, edema, or clinical inflammatory carcinoma, if distant metastases are
absent, 5-year survival rate 46%.
Stage IV. Any form of breast cancer with distant metastases, 5-year survival rate 13%.
Axillary lymph node status is a key prognostic factor used in stage determination.
Lymphovascular invasion, in which tumor cells are seen within vascular spaces surrounding
the lesion, is strongly associated with the presence of lymph node metastases. The presence
of tumor cells in lymphatics of the dermis is strongly associated with the clinical appearance
of inflammatory cancer and bodes a very poor prognosis, with 3-year survival only 3% to
10%. Also, tumors invading skin or skeletal muscle are frequently associated with
concurrent or subsequent distant disease. Tumor size is another important prognostic factor
also used in staging a lesion, as a larger tumor increases the risk of axillary and systemic
metastasis. However, although rare, very small tumors are capable of distant metastasis.
There are a number of additional factors that influence the prognosis and clinical
course of women with breast cancer [Cotrain et al. 1999]. Histologic subtype plays a role in
prognosis. The 30-year survival of women with special types of invasive carcinomas
(tubular, colloid, medullary, lobular, and papillary) is more than 60%, compared with less
than 20% for women with cancers of no special type (ductal carcinomas).
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Tumor grade as well as receptor status are also important indicators of prognosis. A
low grade cancer is likely to be less aggressive in its behavior than a high grade tumor. The
most commonly used grading system, the modified Bloom and Richardson grading system
shown in Table II.3, combines nuclear grade, tubule formation (percentage of cancer
Grade Descrintion Score 5 vr. survival 7 vr. survival
Grade 1 Well-differentiated breast cells; 3,4,5 95% 90%
cells generally appear normal
and are not growing rapidly;
cancer arranged in small tubules.
Grade 2 Moderately-differentiated breast cells; 6,7 75% 63%
have characteristics between
Grade I and Grade 3 tumors.
Grade 3 Poorly differentiated breast cells; 8,9 50% 45%
Cells do not appear normal and tend to
grow and spread more aggressively.
Table II.3. Bloom-Richardson grade system.
composed of tubular structures), and mitotic rate (rate of cell division). In general, each
element is given a score of 1 to 3 (1 being the best prognosis and 3 the worst) and the score
of all three components are added together to give the "grade" [Bloom and Richardson 1957;
Scarff et al. 1968; Elston and Ellis 1991]. The lowest possible score (1+1+1=3) is given to
well differentiated tumors that all form tubules and have a low mitotic rate. The highest
possible score is 9 (3+3+3=9). However, several large-scale studies suggest that mitotic rate
alone can be as predictive as the grading system [Clayton 1991]. Cancers with high levels of
hormone receptors, such as estrogen and progesterone, have a slightly better prognosis than
those without receptors.
DNA ploidy (amount of DNA) is another important prognostic factor. Cancers with
the same amount of DNA as normal cells are called diploid and those cancers with either
more or less than that amount are called aneuploid. About two-thirds of breast cancers are
aneuploid. Several studies have shown that aneuploid cancers tend to be more aggressive
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than normal cancers. Expression of oncogenes (Her2/neu, c-myc, ras p21) or loss of
expression of tumor-suppressor genes (INT2, p53, NM23), angiogenesis (blood vessel
formation), and proteases (stromal proteases are thought to be involved in tumor invasion by
degrading extracellular matrix) also influence prognosis. All biopsies are tested for Her2
over-expression since results of the test may help determine a course of treatment.
The course of treatment depends on both the stage of the disease and the patient's
preference. Treatment options include, surgery, radiation therapy, chemotherapy, hormone
therapy, and immunotherapy. If no axillary metastases are present, some patients may not
receive systemic therapy, depending on the characteristics of the tumor. Almost all women
with one to three positive axillary nodes receive some form of standard systemic treatment,
either hormonal therapy or chemotherapy. Women with four to nine positive axillary nodes
are eligible for clinical trials using high-dose chemotherapy. If ten or more nodes are
positive, women are eligible for other experimental treatments, such as autologous bone
marrow transplantation.
II. F. 2. Surgery
Surgery combined with radiation and/or chemotherapy is the most common treatment for
breast cancer. The type of surgical procedure recommended to the patient depends on the
stage of the disease. Lumpectomy and mastectomy are both commonly performed surgical
procedures.
A lumpectomy, also known as a partial mastectomy or breast conserving surgery, is
the surgical removal of a tumor. Lymph nodes may also be removed during this procedure,
depicted in Figure II.16a. When excising the tumor, the surgeon strives to encase the lesion
in normal tissue to ensure that all of the cancerous tissue has been removed. In routine
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practice, the evaluation of breast lumpectomy specimens to ensure complete excision is
assisted by the use of various tissue marking inks to delineate surgical margins and preserve
tissue orientation. If cancer cells are found touching or near (2 to 5 mm although definitions
11.16a 1.16b - 11.16 11.16d
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Figure 1.16. Schematic representations of breast cancer surgeries: a) lumpectomy or partial mastectomy, b)
simple mastectomy, c) modified radical mastectomy, and d) radical mastectomy.
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vary) the inked regions, it is assumed that malignant cells are likely still present in the
patient. The color of ink harboring the malignant cells identifies their location in the patient.
Many surgeons also remove several small samples of tissue, called margins, from different
areas of the surgical cavity. Following surgery, the margins are examined by a pathologist to
see if any cancer cells are present in the presumed normal tissue. If no cancer cells are found
in the margins they are called "clean margins". If cancer cells are found in the margin tissue
or near the inked region of the excised tumor, the surgeon will recommend additional steps,
which typically include another surgical procedure, called a re-excision, in which remaining
cancerous tissue is removed. The area to be excised is identified by which margin or which
face of the tumor the cancerous cells are found in. In general, lumpectomy procedures take
60 to 90 minutes. After a lumpectomy with clean margins, most women receive six to seven
weeks of radiation therapy, in order to eliminate any cancer cells that may remain after
surgery.
There are three types of mastectomies: simple, modified radical and radical
mastectomies, depicted in Figure II.16b-d. A simple mastectomy includes removal of the
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breast tissue, skin and nipple but rarely lymph nodes. This procedure is often performed for
prophylactic reasons when a strong probability of developing breast cancer exists, for
instance in patients who harbor a BRCA mutation. A modified radical mastectomy is the
most common form of mastectomy performed. This procedure includes removal of the entire
breast, nipple and areola and varying amounts of lymph nodes in the underarm region. The
procedure can also be performed through a much smaller incision near the areola to create a
skin sparing mastectomy. Skin sparing mastectomies work well if immediate reconstruction
is planned. A radical mastectomy includes the removal of the breast tissue, skin, nipple,
areola, underlying chest muscles and varying numbers of lymph nodes in the underarm
region. Prior to 1970 this was a common surgery used for breast cancer but is now reserved
for treatment of advanced disease as studies have shown survival rates are equal with that of
the less invasive modified radical mastectomy [Papatestas and Lesnick 1975]. Radical
mastectomy typically creates more difficulty with range of motion in the arm and shoulder on
the operative side. All mastectomies require general anesthesia and a hospital stay. Drains
are often placed in the breast and underarm area and are removed two weeks after the
surgery. A woman may opt for breast reconstruction or choose to wear a breast prosthesis
following a mastectomy. Patients often receive breast reconstruction immediately following
the mastectomy and as part of the same surgical procedure. Breast reconstruction falls into
two general categories: implant type restorations and those using the patient's own tissues.
For procedures using the patient's own tissues, the most common donor site is the abdomen,
the Transverse Rectus Abdominus skin-Muscle, or TRAM.
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II. F. 3. Radiation Therapy
Radiation therapy uses high-energy x-rays to destroy cancer cells. Treatment is delivered
externally or by radioactive "seeds" that are placed directly into the tumor, called
brachytherapy. Breast cancer is usually treated using highly focused and targeted external
radiation [Fletcher 1972]. Radiation may be used to shrink the tumor before surgery, called
neoadjuvant therapy, or may be used after surgery to destroy cancer cells that remain in the
breast, chest wall, or underarm, called adjuvant therapy [Ragaz et al. 1997; Overgaard et al.
1997; Overgaard et al. 1999]. Radiation therapy is performed in a hospital or outpatient
center. Each treatment lasts a few minutes and treatment is usually given 5 days per week,
for 6 weeks. Side effects include fatigue, reddening of the skin, and swelling.
II. F. 4. Chemotherapy
Chemotherapy is a systemic treatment that travels throughout the body via the bloodstream.
It often relies on a combination of drugs to slow tumor growth and destroy cancer cells.
Drugs may be administered orally or intravenously. Chemotherapy is also used as both
neoadjuvant and adjuvant therapy [Eifel et al. 2001; Goldhirsch et al. 2001]. One of the
main advantages of neoadjuvant chemotherapy is that it allows for assessment of pathologic
response to treatment. There are several pathologic changes associated with response to neo-
adjuvant chemotherapy. Tumor replacement by loose fibrosis is the most common pathologic
event. In most cases, the intensity of fibrotic change is proportional to the degree of clinical-
mammographic reduction of the tumor mass. Studies have also observed a decrease in tumor
cellularity, from 40% in core needle biopsy to 10% in resection specimens [Rajan et al.
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2004]. These changes in tissue morphology must be considered when collecting spectra from
patients who have undergone neo-adjuvant chemotherarpy.
The combination most commonly prescribed to treat breast cancer is doxorubicin and
cyclophosphamide. Paclitaxel (Taxol®) is often prescribed after this combination treatment,
when breast cancer has metastasized to the lymph nodes. It is also often prescribed following
breast cancer surgery. Other chemotherapy drugs include docetaxel and gemcitabine. Side
effects are typically severe and include fatigue, fever, alopecia (hair loss), infection, anemia
(low red blood cell count), neutropenia (low neutrophil count), thrombocytopenia (low
platelet count), and nausea.
II. F. 5. Hormone Therapy
Endocrine manipulations are among the most effective, and least toxic, of the systemic
therapies currently available for the management of hormone-responsive breast cancers.
Estrogen, a hormone produced by women's ovaries, promotes the growth of some breast
cancers, particularly those with detectable amounts of estrogen receptor protein. Estrogen
and progesterone receptors are intracellular steroid-hormone receptor proteins. 50% to 85%
of tumors exhibit estrogen receptors. Such tumors are more commonly found in
postmenopausal women. Hormone therapy involves blocking the effect of estrogen or
lowering estrogen levels. It can be used to treat breast cancer as both a neoadjuvant and
adjuvant therapy and to treat cancer that has spread or come back after it was first treated.
75% of tumors with estrogen receptors regress after hormonal manipulation, whereas only
5% of those that are negative respond [Early Breast Cancer Trialists' Collaborative Group
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2004]. The highest response rates are in patients with tumors exhibiting both estrogen and
progesterone receptors.
Several drugs, classified as anti-estrogen therapy, have been developed to treat breast
cancer that is responsive to estrogen. Selective estrogen-receptor agonists, such as tamoxifen
and raloxifene, inhibit the effects of estrogen on breast cancer cells [Early Breast Cancer
Trialists' Collaborative Group 1998]. Tamoxifen works by competing with estrogen to bind
to estrogen receptors in breast cancer cells. Tamoxifen is formally known as a selective
estrogen receptor modulator (SERM). By blocking estrogen in the breast, it helps slow the
growth and reproduction of breast cancer cells. Tamoxifen is taken in pill form, usually for 5
years after breast cancer surgery to prevent recurrence. After 5 years medication must be
discontinued because patients taking tamoxifen have an increased risk for uterine cancer.
The most common side effect of this medication is hot flashes. Other side effects include
depression, dizziness, alopecia, headache, and swelling. Fulvestrant destroys estrogen
receptors. It is used to treat metastatic breast cancer in postmenopausal women who have
been treated unsuccessfully with tamoxifen. This treatment is administered once a month by
intramuscular injection. Side effects include nausea, hot flashes, and weight gain.
Aromatase inhibitors, such as anastozole, letrozole and exemestane, are also prescribed for
postmenopausal women with advanced breast cancer that has been unsuccessfully treated
with tamoxifen [Goss et al. 2003]. They inhibit the action of the enzyme aromatase,
involved in small amounts of estrogen production in postmenopausal women. Side effects
include cough, depression, diarrhea, dizziness, fatigue, headache, hot flashes, increase
appetite, nausea, and pain. Goserelin is a synthetic form of luteinizing hormone-releasing
hormone that is prescribed to treat metastatic breast cancer in premenopausal women. This
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medication is a pituitary downregulator, signaling the body to stop producing estrogen,
thereby depriving the tumor of the estrogen it needs to grow. This therapy is not appropriate
for postmenopausal women because their ovaries no longer produce estrogen. Several weeks
of treatment are needed before tumor growth slows. Side effects include hot flashes, sexual
dysfunction, increased pain, and rash.
II. F. 6. Immunotherapy
Immunotherapy involves using trastuzumab (Herceptin®) to inhibit tumor growth and
enhance the immune system's ability to fight cancer. The Her2/neu oncogene encodes for a
185 KD transmembrane glycoprotein with intracellular tyrosine kinase activity [King et al.
1985]. The Her2 receptor belongs to the epidermal growth factor receptor family of
receptors, which are critical in the activation of subcellular signal transduction pathways
controlling epithelial cell growth and differentiation [Karunagaran et al. 1996; Klapper et al.
1999]. Amplification of Her2 or overexpression of its protein product is observed in 20% to
40% of human breast cancers [Slamon et al. 1987; Slamon et al. 1989]. All biopsies are
tested for Her2 over-expression since results of the test may help determine a course of
treatment. Her2 receptor protein overexpression correlates with several negative prognostic
variables in breast cancer, including estrogen receptor-negative status and high nuclear grade
[Sjogren et al. 1998]. Breast cancers that overexpress the Her2 receptor protein can be
therapeutically targeted with trastuzumab anti-Her2 monoclonal antibody therapy [Burstein
et al. 2003]. It also may be combined with chemotherapy as a first line treatment for
metastatic breast cancer and may be used after chemotherapy or anti-estrogen therapy to
improve the effectiveness of the treatment. When used alone or in combination, side effects
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include cardiac dysfunction resulting in headache, fever and chills, weakness, nausea and
vomiting, and anemia and neutropenia.
I1. G. Summary
The incidence of breast cancer has been increasing steadily from an incidence of 1:20 in
1960 to 1:8 women today. It is three times more common than all gynecologic malignancies
put together. As such, breast cancer is truly an epidemic among women. Breast cancer is
considered a heterogeneous disease, meaning that it is a different disease in different women,
a different disease in different age groups and has different cell populations within the tumor
itself. Due to its heterogeneity, complexity and numerous manifestations, an understanding
of breast pathology is necessary for intelligent diagnostic algorithm development. Further,
through knowledge of current approaches to breast cancer diagnosis and treatment,
spectroscopic modalities can be developed to aid in numerous aspects of breast cancer
management.
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Chapter III. Raman Spectroscopy
In this thesis we employ Raman spectroscopy to diagnose breast cancer. This chapter
outlines the general theory of Raman spectroscopy as well as its strengths and weaknesses.
Biomedical considerations of Raman spectroscopy are also presented. Previous work
applying Raman spectroscopy to breast cancer diagnosis is summarized and competing
research technologies for breast cancer diagnosis are discussed. Finally, the experimental
instrumentation used throughout this work is presented.
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III. A. General Theory
III. A. 1. Raman Spectroscopy
Raman scattering, discovered by the Indian physicist C.V. Raman in 1928, is a relatively new
effect [Raman and Krishnana 1928]. It arises when a photon incident on a molecule interacts
with the electron cloud of that molecule. In classical terms, the interaction can be viewed as
a perturbation of the molecule's electric field. In quantum mechanics, the Raman effect
describes a scattering interaction between light and matter. When light is scattered from a
molecule the majority of photons are elastically scattered. In elastic scattering, the scattered
photons have the same energy and, therefore, wavelength, as the incident photons. In Raman
spectroscopy, the wavelength and intensity of light inelastically scattered from a sample is
measured. Inelastic scattering refers to the process in which the energies of the incident and
scattered photons are different. In Raman spectroscopy an incident photon, with energy hvL
where h is Planck's constant (J s) and vL is the frequency of the excitation laser (s-l), excites a
molecule into a virtual state that is lower in energy than an electronic transition. A new
photon is created and scattered from this virtual level [Diem 1993; McCreery 2000]. The
scattering event occurs almost instantaneously, typically in 10-14 s. or less. If a molecule
begins in the vibrational ground state, then the final state can be either the vibrational ground
state (elastic scattering), called Rayleigh scattering, or an excited vibrational state, called
Stokes-Raman scattering. In Stokes-Raman scattering photons lose energy by exciting a
vibration within the sample molecule and thus the scattered light appears at a lower
frequency than the incident photon. In this case, the Raman scattered light will have an
energy of h(vL-VR), where VR is the frequency of the Raman scattered light (s'l). The
molecule can also begin in an excited vibrational state and proceed, via the virtual state, to
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the vibrational ground state. This process is called anti-Stokes-Raman scattering and in this
case photons gain energy from the molecular vibrations and the scattered signal appears at a
higher frequency. In anti-Stokes-Raman scattering the Raman scattered light will have an
energy of h(vL+vR). At room temperature the thermal population of vibrational excited states
is low, although not zero. The number of scattering molecules in a given state, N, is
governed by the Boltzmann distribution, ehv/kT, in which hv is the energy of the state, k is the
Boltzmann factor (J K'), and T (K) is the temperature. Therefore, at room temperature anti-
Stokes-Raman scattering is only strong enough to be useful for vibrational frequencies less
than about 1500 cm- , defined in Eq. III.1. The Stokes and anti-Stokes Raman spectra
contain identical frequency information. Thus, the ratio of anti-Stokes to Stokes intensity at
any vibrational frequency can be used as a measure of temperature.
Individual bands in the Raman spectrum are characteristic of specific molecular
motions. By measuring the energy of the emitted photon after the scattering event, and
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Figure I.1. Molecular energy level diagram depicting several light-matter interactions.
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knowing the energy of the incident photon, one can assess the structure of the molecule being
probed. Because the Raman effect is weak and comprises a very small fraction, about 1 in
107, of the incident photons, the intense Rayleigh background must be suppressed so that it
does not overwhelm the Raman scattered light. The processes of Rayleigh, Stokes-Raman,
and anti-Stokes Raman scattering are depicted schematically in Figure III.1. Also shown for
comparison are the processes of absorption and fluorescence. The lower energy levels in
Figure III.1 represent the ground electronic state, So, while the upper levels represent the first
excited electronic state, S'. Within the ground and excited electronic states are vibrational
and rotational energy levels. The open arrows represent the incident light, VL, and the solid
arrows the re-emitted light.
Numerically, the energy difference between the initial and final vibrational levels, ,
or Raman shift in wavenumbers (cm71), is calculated through Eq.III.1:
= (VLC1 ) - (VRC) (III.1)
in which c is the speed of light (cm s'). Raman frequency shifts are always the same,
regardless of the frequency of the incident light. The vibrational energy is ultimately
dissipated as heat. Because of the low probability of Raman scattering, the heat dissipation
does not cause a measurable temperature rise in the material, allowing safe biomedical
application. In clinical implementation, the largest source of heating is absorption of the
excitation light by the surrounding tissue. The energy of a particular vibrational mode
depends on molecular structure and environment. Atomic mass, bond order, molecular
substituents, molecular geometry and inter-molecular interactions, such as hydrogen bonding,
all effect the vibrational force constant which, in turn dictates the vibrational energy.
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Vibrational Raman spectroscopy is not limited to intra-molecular vibrations. Crystal
lattice vibrations and other motions of extended solids are also Raman active. Their spectra
are important in such fields as polymers and semiconductors. In the gas phase, rotational
structure is resolvable on vibrational transitions. The resulting vibration/rotation spectra are
widely used to study combustion and gas phase reactions. Vibrational Raman spectroscopy
in this broad sense is an extraordinarily versatile probe into a wide range of phenomena
ranging across disciplines from materials science to medicine.
mi. A. 2. Raman Selection Rules and Intensities
A simple classical electromagnetic field description of Raman spectroscopy can be used to
explain many of the important features of Raman band intensities. The dipole moment, P,
induced in a molecule by an external electric field, E, is proportional to the field as shown in
Eq. 111.2.
P=aE (111.2)
The proportionality constant a is the polarizability of the molecule. The polarizability
measures the ease with which the electron cloud around a molecule can be distorted. The
induced dipole emits or scatters light at the optical frequency of the incident light wave.
Raman scattering occurs because a molecular vibration can change the polarizability of the
molecule. The selection rule for a Raman-active vibration, that there be a change in
polarizability during the vibration, is given in Eq. 111.3, where Q is the normal coordinate of
the vibration.
a/iDQO0 (II1.3)
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The Raman selection rule is analogous to the more familiar selection rule for an infrared-
active vibration, which states that there must be a net change in permanent dipole moment
during the vibration. From group theory it is straightforward to show that if a molecule has a
center of symmetry, vibrations which are Raman-active will be silent in infrared
spectroscopy, and vice versa.
The Raman effect is weak, comprising a very small fraction, about 1 in 107, of the
incident photons. Typical non-resonant Raman cross-sections are on the order of 10-30 cm2
per molecule. The Raman scattering cross-section indicates the strength of the Raman signal
of a particular moiety at unit concentration. The Raman scattered intensity is given by
I=vL4IoNf(o2 ) (111.4)
where lo is the intensity and VL is the frequency of the excitation light, N is the number of
scattering molecules in a given state, and a is the polarizability of the sample. f(a2 )
describes a function in which scattering intensity is proportional to the square of the induced
dipole moment, that is to the square of the polarizability derivative, Eq. III.3. If a vibration
does not greatly change the polarizability, then the polarizability derivative will be close to
zero, and the intensity of the Raman band will be low. The vibrations of a highly polar
moiety, such as the O-H bond, are usually weak because an external electric field cannot
induce a large change in the dipole moment. This is advantageous for biomedical Raman
spectroscopy, as water signals do not overwhelm the spectrum. Typical strong Raman
scatterers are molecules with distributed electron clouds, such as those containing double
bonds. The pi-electron cloud of the double bond is easily distorted in an external electric
field.
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Raman scatter is partially polarized, even for molecules in a gas or liquid, where the
individual molecules are randomly oriented. The effect is most easily seen with an exciting
source that is plane polarized. In isotropic media, polarization arises because the induced
electric dipole has components that vary spatially with respect to the coordinates of the
molecule. Raman scatter from totally symmetric vibrations will be strongly polarized
parallel to the plane of polarization of the incident light. The scattered intensity from non-
totally symmetric vibrations is 3/4 as strong in the plane perpendicular to the plane of
polarization of the incident light as in the plane parallel to it.
III. A. 3. Resonance Enhanced Raman Scattering
Raman spectroscopy is conventionally performed with green, red or near-infrared (NIR)
lasers. These excitation wavelengths are below the first electronic transitions of most
molecules. However, if the wavelength of the exciting laser is within the electronic spectrum
of a molecule, the intensity of some Raman active vibrations increases by a factor of 102-104.
This is known as resonance enhanced Raman scattering.
Vibrations whose Raman bands are resonance enhanced fall into two general classes.
The most common case is Franck-Condon enhancement, in which a component of the normal
coordinate of the vibration is in a direction in which the molecule expands during an
electronic excitation. The more the molecule expands along this axis when it absorbs light,
the larger the enhancement factor. The in-plane ring breathing expansion modes of
porphyrins fall into this class. Vibrations which couple two electronic excited states are also
resonance enhanced. This mechanism is called vibronic enhancement. In both cases
enhancement factors roughly follow the intensities of the absorption spectrum [Myers and
Mathies 1987]. Resonance enhancement does not begin at a sharply defined wavelength. In
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fact, enhancements of 5x to 10x are commonly observed if the exciting laser is even a few
hundred wavenumbers below the electronic transition of a molecule. -carotene exhibits this
type of pre-resonance enhancement in our experimental data. Resonance enhancement can
also be implemented in the deep UV.
The resonance Raman effect can be quite useful. Because the spectrum of a
particular molecule is resonance enhanced and that of the surrounding sample is not,
selective monitoring of that moiety, without spectral interference from other components, is
easily attainable. This allows biological molecules to be examined in their natural
environments. Metalloporphyrins, carotenoids and several other classes of biologically
important molecules have strongly allowed electronic transitions in the visible. These
molecules often make up the active site of enzymes. Resonance Raman spectroscopy has
been successfully employed in vivo to quantitatively measure macular carotenoids. Levels
were compared in patients with age-related macular degeneration and normal subjects to
assess the role of dietary carotenoids in protecting against age-related visual loss [Bernstein
et al. 2002].
III. A. 4. Surface Enhanced Raman Spectroscopy
The Raman scattering from a compound adsorbed on or within a few Angstroms of a
structured metal surface can be 103 to 1010 times greater than in solution. This technique,
called surface enhanced Raman scattering (SERS), arises from two mechanisms. The first is
an enhanced electromagnetic field produced at the surface of the metal [Otto 1984; Campion
and Kambhampati 1998; Kneipp et. al 1999]. When the wavelength of the incident light is
close to the plasma wavelength of the metal, conduction electrons in the metal surface are
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excited into an extended surface electronic excited state called a surface plasmon resonance.
Thus, molecules adsorbed or in close proximity to the surface experience an exceptionally
large electromagnetic field. Vibrational modes normal to the surface are most strongly
enhanced. In addition to this "electromagnetic field enhancement," the electronic interaction
between the molecule and the metal can result in an increase of the Raman scattering cross-
section itself, called "chemical or electronic enhancement." Several mechanisms are
discussed to account for this chemical SERS enhancement, such as a resonance Raman
effect, which becomes operative due to possibly shifted and broadened electronic levels in
the adsorbed molecule compared to the free molecule or due to a new electronic transition in
the metal-molecule system [Otto 1984; Campion and Kambhampati 1998]. In many
experiments, the "chemical effect" provides a very small contribution and the total SERS
enhancement is determined by electromagnetic field enhancement [Kniepp et al. 1997].
SERS is strongest on silver, but is observable on gold and copper as well. The
intensity of the surface plasmon resonance is dependent on many factors including the
wavelength of the incident light and the morphology of the metal surface. The wavelength
should match the plasma wavelength of the metal. This is about 382 nm for a 5 gm silver
particle [Kerker et al. 1982], but can be as high as 600 nm for larger ellipsoidal silver
particles. The plasma wavelength is to the red of 650 nm for copper and gold [Morris 1992],
the other two metals which exhibit SERS at wavelengths in the 350-1000 nm region. The
best morphology for surface plasmon resonance excitation is a small (<100 nm) particle or an
atomically rough surface. Molecules with lone pair electrons or pi-electron clouds show the
strongest SERS.
SERS was first used to study monolayers of materials adsorbed on metals, including
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electrodes, however, many other formats can be used. The most popular include colloids,
metal films on dielectric substrates and, recently, arrays of metal particles bound to metal or
dielectric colloids through short linkages. The effect was first discovered with pyridine
[Jeanmaire and Van Duyne 1977]. Other aromatic nitrogen or oxygen containing
compounds, such as aromatic amines or phenols, are strongly SERS active. The effect can
also been seen with other electron-rich functionalities such as carboxylic acids. Recently,
SERS has been applied to the detection of glucose [Shafer-Peltier et al. 2003]. Although
SERS allows easy observation of Raman spectra from solution concentrations in the
micromolar range, slow adsorption kinetics and competitive adsorption have limited its
application in analytical chemistry.
III. B. Biomedical Considerations
Raman shifts are independent of excitation wavelength. This gives an important degree of
flexibility in generating a Raman spectrum; ultraviolet (UV), visible or infrared excitation
light can all be used, and in each case the Raman fingerprints will be the same. Thus, in
contrast to many spectroscopic techniques, the excitation frequency can be chosen such that
it is tailored to the specific application. For biological samples, NIR radiation is typically
employed, 770 nm to 1500 nm. The use of NIR excitation light confers three advantages to
biomedical Raman spectroscopy: a reduction of background fluorescence, deeper sampling
depths (>1 mm), and less laser-induced photothermal degradation. Reduced fluorescence
occurs because the lowest lying excited electronic state of biological molecules, responsible
for fluorescence, correspond to visible wavelengths and therefore cannot be excited by lower
energy NIR light. Background fluorescence is a competing process that can often obscure
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the Raman bands. It adds shot noise to the data, thereby degrading the signal-to-noise ratio
(SNR). Because Raman scattering is a weak process and clinical implementation
necessitates rapid data acquisition, attention must be paid to maintaining adequate SNR.
Further, the background must be removed prior to data analysis, which inherently results in
distortion of the Raman spectrum. We have found that excitation with 785 nm, employed by
several laboratories for biological Raman spectroscopic studies, results in at least a four-fold
increase in tissue fluorescence when compared with 830 nm excitation. Although excitation
wavelengths longer than 830 nm further reduce tissue fluorescence, the Raman scattering
cross-sections are simultaneously reduced because they depend on the excitation frequency
to the fourth power. Also, longer excitation wavelengths prohibit the use of CCD detectors.
Large penetration depths, the second advantage of using NIR excitation light, are obtained by
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working in a spectral region with minimal absorption. Figure III.2 shows spectra of the
predominant tissue absorbers. A group of minima can be seen in the NIR region below 1000
nm. The large penetration depth conferred by working in this wavelength region, often
referred to as the diagnostic window, provides the opportunity to observe subsurface
structures, regions which cannot be examined using conventional white light techniques.
Also, thermal and photochemical damage are minimized by the use of low energy NIR light.
NIR wavelengths are not mutagenic and absorption is relatively low so tissue heating is
minimized. Finally, when employing 830 nm frequency excitation, the resultant fingerprint
region of Raman shifts falls in a wavelength range that is efficiently transmitted by fused
silica optical fibers. Such fibers can be readily incorporated into optical fiber probes thereby
allowing remote sensing for in vivo clinical applications.
Because each molecule possesses a unique pattern of Raman shifts, the chemical
composition of the tissue can be determined via Raman spectroscopy. Raman spectra
provide direct chemical information and are capable of characterizing a sample both
qualitatively and quantitatively without the use of fluorescent tags or stains. Unlike
fluorescence, reflectance, and NIR absorption spectroscopies, Raman spectroscopy provides
narrow spectral bands, with high information content, that can be assigned to specific
molecular vibrations. To illustrate this, Figure 111.3 displays a fluorescence spectrum of
NADH and a Raman spectrum taken from cholesterol. Raman spectral band widths for
biological molecules are on the order of 10 cm -1 . Whereas there are relatively few
endogenous biological fluorophores, many of whose spectra significantly overlap, there exist
a multitude of Raman active chemicals in tissue that have unique spectra and which can be
specifically related to healthy and diseased conditions. Table III.1 displays the Raman band
-85-
assignments for a number of biological moieties [Sadtler 1974; Manoharan et al. 1992;
Baraga et al. 1992; Diem 1993; Manoharan et al. 1993; Manoharan et al. 1996]. Given the
heterogeneity and complexity of breast disease, presented in Chapter II, the ability to
measure several different chemicals is of particular importance in studying breast cancer.
Although Raman spectra provide high information content, the signals are orders of
magnitude weaker than fluorescence. However, with careful system design collection of
clinical data in relevant times with safe levels of laser power can be accomplished. For these
reasons, we have investigated the use of Raman spectroscopy as a clinical tool for the
examination of a variety of breast pathologies.
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Raman Molecule/Molecular Class Group/Vibration
Shift (cm '1)
702 Cholesterol/Cholesterol esters Sterol ring breathing
719 Phospholipids Symmetric choline stretch
762 Phospholipids Symmetric O-P-O stretch
801-805 CholesteroVCholesterol esters Sterol ring breathing
841-850 Cholesterol/Cholesterol esters Sterol ring breathing
853 Proteins C-C tyrosine ring breathing
855 (Hydroxy)Proline (collagen) C-C stretch
878 Cholesterol/Cholesterol esters Sterol ring breathing
878 Phospholipids Asymmetric O-P-O stretch
871-882 Cholesterol/Cholesterol esters Sterol ring breathing
923 Cholesterol/Cholesterol esters Sterol ring breathing
933 Proline (collagen) C-C stretch
940 Proteins C-C or C-H stretch
957 Cholesterol/Cholesterol esters Sterol ring breathing
959-962 Calcium hydroxyapatite Symmetric P043'
1004 Phenylalanine Phenyl ring breathing
1034 Proteins C-C or C-H stretch
1071 Calcium carbonate Symmetric C0 3'-, asymmetric P043-
1085 Cholesterol C-C stretch
1104 Desmosine/Isodesmosine (elastin) Ring breathing
1160 _-carotenoids C=C stretch
1176 Cholesterol C-C stretch
1245 Proteins Amide III, random coil
1264 Proteins Amide III (C-N stretch), a-helix
1268 Proteins Amide III, a-helix
1270 Cholesterol/Cholesterol esters -CH2, -CH3 bending
1274 Cholesterol 
-CH2, -CH3 bending
1299 Cholesterol/Cholesterol esters -CH2, -CH3 bending/twist
1301 Triglycerides 
-CH2, -CH3 bending/twist
1328 Cholesterol 
-CH2, -CH3 bending
1336 Proteins Amide III and -CH2, -CH3 wag
1336 Desmosine/Isodesmosine (elastin) -CH bending
1439 Cholesterol/Cholesterol esters -CH2, -CH3 bending
1440 Triglycerides 
-CH2, -CH3 bending
1443 Lipids -CH2, -CH3 bending
1449 Proteins 
-CH2, -CH3 bending
1451-1455 Proteins CH2 deformation, C-H bend
1523 -carotenoids C-C stretch
1660 Proteins Amide I
1654 Triglycerides, Proteins C=C stretch, Amide I, a-helix
1664 Proteins Amide I (C=0, C-N), a-helix
1668 Lipids C=C stretch
1671 Cholesterol/Cholesterol esters C=C stretch
1735 Cholesterol esters C=O stretch (ester)
1747 Triglycerides C=O stretch (ester)
Table III.1. Raman band assignments for morphological structures.
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111. C. Raman Spectroscopy for Breast Cancer Diagnosis: Previous Studies
III. C. 1. Raman Spectroscopy of Breast: Other Laboratories
The first Raman spectroscopy measurements of human breast tissue used 1064 nm excitation
and a Fourier transform Raman system [Alfano et al. 1991]. Collection times were 4 to 5
min. and employed a power density of less than 10 watt/cm2 . The area probed was 6x6 mm.
No depth information was provided. Histology of the tissue samples was performed before
the measurements and spectra were acquired from formalin-fixed tissue. Fourteen breast
tissue specimens were examined, 3 normal specimens, 4 benign tumors, and 7 malignant
tumors. No more detailed pathology information was provided. Four to 15 spectra were
collected per sample. Surprisingly, no significant changes in the Raman spectra were
observed between different locations on a single sample. This may be a function of relatively
noisy data provided by this now outdated experimental system. All specimens were found to
have peaks at 1445 cm 1l and 1651 cm 1l, while normal tissue also had peaks at 1078 cm l1 and
1330 cm 'l and benign at 1240 cm l. The 1445 cm 1 peak results from the -CH2 and -CH 3
bending modes and is indicative of lipids. The 1651 cm 1 peak was assigned to the C=O
stretching Amide I vibration, indicative of proteins. The 1240 cm1 band results from the
Amide mI vibration and the 1300 cm'I and
1078 cm l1 bands were assigned to C-C and Pathology I1651 cm')I(1445 cm)
C-N stretching vibration modes. The Normal 0.80±0.09
relative intensities of the 1445 cm'1 and Benign 1.08+0.03
1651 cm l1 bands were reported to correlate
Malignant 1.15±0.05
with disease classification although no
Table III.2. Summary of the results of Alfano and co-
diagnostic algorithm was presented. Table workers from their initial investigation of breast tissue
using Raman spectroscopy.
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III.2 summarizes these initial results.
In 1993, Redd et al. examined the application of Raman spectroscopy to 35 samples
of breast tissue using visible excitation [Redd et al. 1993]. They employed <50 mW or 0.4 to
1.0 watt/cm2 incident power and integration time was varied to optimize SNR, 2.5 to 50 s.
Differences between normal, benign and malignant samples were examined, as well as the
effects of excitation wavelength and formalin fixation on the Raman spectrum. Several
Raman bands, which were not observed in the Alfano study, were reported. Further, unlike
Alfano, Redd and coworkers observed variability of the Raman spectrum between different
locations on a single sample. This is not surprising considering the anatomic heterogeneity
of breast tissue. The additional peaks as well as the increased spectral variability observed in
this study may be attributable to a higher SNR, evident through comparison of the spectra
presented in each manuscript. Interestingly, Redd and coworkers debate several of the band
assignments made in the study of Alfano et al. Among other discrepancies, they attribute the
1651 cm- l peak to lipids, C=C stretching from the hydrocarbon region, rather than to
proteins. Due to the biochemical complexity of tissue, several chemicals often contribute
intensity to a particular Raman band. Clearly, spectral analysis based on peak heights is not
sufficient to elucidate the moieties responsible for the Raman signal.
The Raman spectra in Redd's study predominately contained features attributed to
various amounts of carotenoids and lipids. A small contribution from a heme-type signal, at
1358 cm', was detected in some samples of benign breast tissue, while a much stronger
heme-type signal was detected in most of the breast cancers. Thus far, we have not observed
contribution from heme containing species in our studies. The reason for this has not been
investigated, but is likely explained by resonant enhancement of the heme signal at visible
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excitation frequencies. Raman spectra of diseased breast tissue, both benign (fibrocystic
change) and malignant (mammary carcinoma), also showed markedly diminished to absent
contributions from lipids and reduced contributions from carotenoids. The concentration of
carotenoids often mirrors that of lipids as they are typically extremely lipophilic moieties.
This study also examined the effects of excitation wavelength on the Raman spectrum of
normal breast tissue, varied from 406.7 to 647.8 nm. The contribution of lipids was best
observed with 406.7 nm excitation while the contributions of carotenoids were found to be
enhanced at longer excitation wavelengths. In accordance with theory, they observed a
reduction in the fluorescence background with increasing excitation wavelength. Last, in an
effort to document possible changes in breast tissue following formalin fixation, a specimen
of normal breast tissue was studied in the fresh state, and then again after 24 hours of
formalin fixation. No new spectral lines were noted and the formalin fixation showed no
evidence of significant Raman features. However, the primary effect of fixation is cross-
linking the collagen proteins, a component not present in significant quantities in normal
breast tissue. Thus it is difficult to draw conclusions about the effect of formalin fixation
from this study. All other tissues examined in this study were formalin-fixed.
Frank and coworkers also examined the optimal excitation wavelength, ranging from
406 nm to 830 nm, to employ for Raman spectroscopy of breast tissue. Their objective was
to produce a detailed characterization of the Raman spectrum of normal human breast tissue
samples with visible and NIR excitation. Consistent with the studies of Redd et al., spectra
of formalin-fixed breast tissue revealed features of lipids and carotenoids. However, in
contrast to the results of Redd and coworkers, the best defined lipid features were observed
for 782 nm and 830 nm excitation, while carotenoid features were strongest in the 488 nm to
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515 nm range due to resonant enhancement. As expected, the fluorescence background was
reduced when working at longer wavelengths, and thus 691 nm to 832 nm excitation was
suggested for future breast studies. Lastly, a compact, portable, diode laser based system
with fiber optic sampling was used to demonstrate the clinical potential of Raman
spectroscopy. Using 7 mW of 782 nm light and a 60 s. integration time, they were able to
collect a Raman spectrum of normal tissue. However, normal breast tissue is mainly
composed of fat, which has a relatively strong Raman scattering cross-section. Again,
normal breast tissue is naively used as a representative sample for all types of breast
pathologies. The silica fiber background was clearly visible in the probe acquired spectra.
Frank et al. followed their preliminary investigations with a diagnostic study. In this
work, Raman spectra of histologically normal human breast biopsy samples were compared
to those exhibiting IDC and fibrocystic change. The study employed 784 nm excitation, 10-
200 mW laser power, 300 to 600 sec. integration times and formalin-fixed tissue. A total of
123 spectra from 12 patients were examined. The Raman spectra changed dramatically in
diseased specimens, with much weaker lipid bands being evident. This is consistent with our
studies and the findings of Redd and coworkers. A shift of the prominent 1439 c' feature
in normal tissue to 1450 cm' in IDC was noted and attributed to different CH2 deformation
frequencies in fatty acids and proteins. The spectrum of IDC samples was similar to that of
human collagen. Differences between fibrocystic and malignant lesions were smaller than
those between normal and IDC specimens, but were still reproducible. The fibrocystic
spectra had smaller amide I, 1656 cm'1, and amide III, 1259 cm7 , intensities relative to the
1449 cml CH 2 deformation band and the CH 2 deformation was shifted to a lower frequency
(1446 cmq1 vs. 1449 cm-'). In addition, structure in the 850 cm ' to 950 cm' region differed,
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with only two resolvable peaks in the fibrocystic specimens and four in the case of IDC.
However, the authors report that too few samples were evaluated to determine the statistical
significance of their findings. Again, fiber optic sampling through a hypodermic needle and
with a remote probe was demonstrated.
Treado and coworkers employed Raman imaging of breast tissue. Initially, they used
the technique to identify foreign polymer inclusions anchored in fibrous breast tissue
surrounding silicone implants [Schaeberle et al. 1996]. Their imaging system employed an
acousto-optical tunable filter for wavelength selection. In this implementation, the Raman
spectra obtained from breast tissue itself were extremely noisy. However, Dacron polyester,
the foreign polymer inclusion, has a strong Raman signal and thus it was possible to image
the polymer material within the breast tissue matrix. Using an improved device, outfitted
with a liquid crystal tunable filter, they were able to image characteristic bands of lipid and
protein in chicken breast, a poor model for human breast tissue [Kline and Treado 1997].
Although previous studies indicate the promise of Raman spectroscopy for breast
cancer diagnosis, they are exploratory in nature, and none contain a diagnostic algorithm.
These studies have consistently shown differentiation of normal and malignant breast
specimens, however, none have demonstrated statistically meaningful differences between
malignant and benign samples. Given the intended application, in which there is an a priori
expectation of non-normal tissue, accurate differentiation of benign and malignant lesions is
a crucial and significant step in the field. Both Alfano and Frank were able to distinguish
malignant and normal tissue based on the 1654 cm7' and 1439 cm71 bands. This difference
was attributed to increased protein concentrations in malignant samples and is consistent with
the results presented in this thesis. Further, previous studies relied on simple peak height
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ratios for analysis. The wealth of information available from Raman spectroscopy coupled
with the biochemical complexity of tissue necessitates a method of analysis that utilizes the
entire spectrum. Lastly, all of the previous work used formalin-fixed breast tissue. The
fixation process chemically alters the tissue and thus the Raman spectrum. The primary effect
of fixation is cross-linking the collagen proteins, a component which our studies show to be a
key diagnostic feature. To address these concerns and to fully assess the ability of Raman
spectroscopy to improve breast cancer diagnosis, especially the ability to distinguish benign
lesions from malignant lesions, we have undertaken further studies.
III. C. 2. Raman Spectroscopy of Breast: Our Laboratory
Our initial data set included 61 spectra obtained from 13 patients: 15 normal, 15 benign, and
31 malignant [Manoharan 1998]. Specifically, 11 normal, 4 normal glandular, 11 fibrocystic
change, 4 adenosis, 2 carcinoma in situ and 29 IDC. Fat and glandular samples were
grouped to form the normal category, fibrocystic change and adenosis into benign and
carcinoma in situ and infiltrating ductal carcinoma comprised malignant. Spectra were
acquired from fresh-frozen, but unfixed, samples of human breast tissue with 80 mW of 830
nm excitation and 100 sec. integration time. Absolute intensities were preserved by using
ethanol as an intensity standard and keeping the light delivery/collection geometry fixed for
all measurements. A third-order polynomial was fit to the spectra by least-square
minimization to remove the fluorescence background. To assess the degree of agreement
between our data and previous studies, we plotted the shift of the 1442 cmn' peak against the
ratio of the 1445 cm' and 1650 cn 1 bands, shown in Figure III.4. Trends in our data were
consistent with previous results. Specifically, I(1650/I(1445) generally increased from normal to
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benign to malignant samples. Further, the CH 2 deformation band appeared at lower
frequencies for normal and benign specimens. This algorithm, based on previous studies,
used features of the Raman spectra that are sensitive to differenced in lipid and protein
'aCO)
I
0
0
.
U)
a-
1435 1440 1445
Raman shift of CH2 bend (cm-')
1450
Figure III.4. Elementary breast cancer diagnostic plot.
modes. Because lipids dominate in normal tissue and proteins dominate in abnormal tissues,
this simple empirical diagnostic algorithm can differentiate normal and malignant samples.
However, it is clear that a more sophisticated approach in necessary to identify benign
lesions. As discussed above, accurate differentiation of benign and malignant lesions is
crucial for reducing the percentages of false positives and false negatives through Raman
assisted diagnosis.
In order to capitalize on the wealth of information available from Raman
spectroscopy, we employed principal component analysis (PCA). PCA is a multivariate
statistical method of analysis, discussed in detail in Chapter IV. It does not assume any
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knowledge about the chemical composition of the tissue. Rather, it resolves the spectra of
the entire data set into a small number of principal components (PC) that accurately
characterize the entire range of spectral variations. All 61 spectra in this study could be
accurately modeled, above the noise level, using 12 principal components. The scores were
then used to develop a diagnostic algorithm to classify the tissue into normal, benign and
malignant categories. Logistic regression was used to correlate the fit coefficients with the
pathological categories. This study did not employ cross-validation.
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Figure 111.5. Comparison of pathology and the PCA based Raman diagnosis.
Four PCs were found to be statistically significant classification indicators at the
P=0.05 level. They account for 98.70% of the variance in the data. PC 1, accounting for
96.770/0 of the data variance, closely resembles the Raman spectrum of fat while PC 4, 0.600/0
of the variance, exhibits features indicative of carotenoids. PC 2, which accounts for 1.24%
of the data variance, is somewhat reminiscent of cholesterol and PC 6, 0.09% of the variance,
has features of both collagen and epithelial cell cytoplasm. The 4 PCs were used to estimate
the probability for each sample that it belongs to one of the above three diagnostic categories.
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Figure 111.5 shows the resulting predicted classifications, determined using the algorithm,
versus the pathologic diagnosis. This decision algorithm enabled us to diagnose correctly 14
out of 15 normal samples, 13 out of 15 benign samples and 31 out of 31 malignant samples.
This initial success indicated there are consistent spectral differences among normal, benign
and malignant breast tissue samples and opened the possibility that NIR Raman spectroscopy
can be used for clinical diagnosis. Although PCA does not provide information about the
chemical basis responsible for diagnosis, this initial success demonstrated that there are
consistent spectral differences among normal, benign and malignant breast tissue samples
and motivated the development of our Raman spectral model of breast tissue, discussed in
Chapter IV.
III. D. Research Technologies for Breast Cancer Diagnosis
New technologies for breast cancer detection fall primarily into two categories: adapted
technologies and novel technologies. Adapted technologies are those that involve the
adaptation of devices used elsewhere in the clinic to the breast, such as ductal lavage,
ductoscopy, MRI and PET. Novel technologies refer to those that have not been employed
clinically outside of the research setting. Currently, a variety of optical imaging and
spectroscopic techniques are being explored to improve breast cancer diagnosis. They
employ visible or near-infrared light, have the potential to provide chemical information and
are less invasive than current diagnostic procedures. Optical techniques are only now being
introduced clinically and represent relatively new lines of research.
-96-
III. D. 1. Ductal Lavage
The majority of breast cancers begin in the epithelium lining the breast ducts. It can take
many years for these cells to grow into a tumor large enough to be detected by
mammography, -1 cm in diameter, or felt during a physical breast exam. Ductal lavage is a
minimally invasive procedure that involves collecting samples of cells washed out from the
breast ducts and pathological examination to determine whether they are normal, atypical, or
malignant. The idea of testing fluid from the nipple was first suggested in the 1950s by Dr.
Papanicolaou, the physician who developed the pap smear to test for cervical cancer.
In the procedure, gentle suction is applied to identify which
milk ducts produce droplets of fluid on the nipple surface. Next, a
microcatheter is inserted into the milk duct and sterile saline is
slowly infused to rinse the duct and collect cells. The collected
ductal fluid is then stained and microscopically analyzed by a
pathologist. A schematic detailing the ductal lavage procedure is
shown in Figure 111.6. Ductal lavage is not a replacement for
standard breast cancer detection tools such as mammography or
physical exam.
A multi-center clinical study of over 500 high-risk women
in the United States and Europe examined ductal lavage. All of the
women enrolled had normal mammograms and physical exams
Figure DL6. Ductal
lavage schematic.
to ~Duct Health.
within 12 months prior to their participation in the study. Preliminary results showed that
ductal lavage detected atypical cells in 23.5% of the breasts studied and malignant cells in
0.5% of the breasts studied. However, the presence of atypical cells does not necessarily
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signify subsequent breast cancer. In fact, it is believed that, in most cases, these cells don't
progress to cancer.
III. D. 2. Ductoscopy
Fiberoptic ductoscopy adapts endoscopes developed to detect cancer in organs such as the
colon, cervix, and esophagus to the study of breast ducts [Berna et al. 1991]. It is used to
directly visualize the epithelial lining of the breast ducts as well as provide access for
retrieval of epithelial cells, by lavage. Because the majority of both benign and malignant
breast disease originates in the epithelium, development of a minimally invasive procedure
which can directly assess early epithelial changes has important applications to the detection
and treatment of these conditions. In the ductoscopy procedure, the breast is first massaged
to promote nipple-aspirate fluid, serving to visually identify a ductal orifice. The duct is then
dilated and the ductoscope advanced under direct visualization. The ductoscope is typically
0.9 mm in diameter and contains an outer sheath, through which insufflation can occur
during the procedure and aspiration can be performed to retrieve epithelial cells for cytologic
analysis. The interior of the duct is illuminated, viewed via fiberoptics, and catalogued by
videotape [Shen et al., 2000]. If an intraluminal pathology is identified, it can be surgically
removed or marked with a small metallic clip for image-guided core biopsy. The limitations
of this approach stem from the fact that early cancers are difficult to identify visually, even in
organs where clinicians have significant experience using endoscopic devices.
Ductoscopy is primarily used in patients with pathologic nipple discharge [Yamamoto
et al. 2001]. This population is ideally suited for the ductoscopy procedure, as they generally
demonstrate single-duct discharge, making identification of the ductal orifice harboring the
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pathology straightforward. Additionally, many of these patients have ductal dilation or
ectasia, which makes maneuvering of the scope easier. Over 70% of patients undergoing
ductoscopy for nipple discharge are found to have an intraductal papilloma. The papilloma
can be localized and excised with the ductoscope. An example of typical fmdings during
mammary ductoscopy in a patient with pathologic nipple discharge are shown in Figure 111.7.
Ductoscopy is also being evaluated for intra-operative surgical margin assessment and in
patients who are at high-risk for developing cancer but have a normal breast exam and
imaging studies. There is an isolated report of a series of patients with known breast cancer
who underwent intra-operative ductoscopy to assess surgical margins with promising results
[Dooley 2000]. The use of ductal lavage for risk assessment has generated a population of
high-risk patients who have no imaged evidence of breast malignancy yet are found to have
atypical cells within one or more ductal systems. There are a small number of reports of
patients who have had mammary ductoscopy of the same ductal system that yielded atypical
cytology from ductal lavage, and a variety of pathologic lesions have been identified which
range from intraductal papillomas to DCIS and atypical DEH [Dooley et al. 2001].
Figure 111.7. Ductoscopy images: a) a normal bifurcation and b) an intraductal papilloma obstructing the
ductallumen.
CDCleveland Clinic Foundation.
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However, the clinical significance of these findings has not yet been elucidated. Ductoscopy
may provide a means for spectroscopic access to the breast and identification of pre-
cancerous changes.
III. D. 3. Magnetic Resonance Imaging
Magnetic Resonance Imaging (MRI) non-invasively monitors the distribution of water in the
body. MRI machines operate through high powered magnets in two groups, a stable field,
produced by a main magnet, and a variable field, produced by three gradient magnets. These
magnets manipulate the spin properties of hydrogen contained in the water comprising the
majority of the human body. A hydrogen atom without an external field will spin on its own
in random alignment. In an external magnetic field, the atoms spin will align parallel to the
applied field. In an MRI, the main magnet produces an applied magnetic field that aligns the
hydrogen atoms in the patient's body parallel to the field. When the magnetic field is turned
off, the hydrogen atoms return to regular alignment. In making this spin alignment shift, a
change in magnetization results and is detected.
MRI has been considered the imaging procedure of choice in the evaluation of breast
implant rupture. Some investigators have found that MRI increased sensitivity for the
detection of breast cancer as compared with conventional imaging techniques [Orel 2000].
MRI has been successful in detecting cancers that are mammographically and clinically
occult. The ability to detect cancer by MRI relies almost exclusively on the fact that tumors
exhibit angiogenesis to support their growth. In order to effectively distinguish small cancers
from fatty tissue, contrast material must be administered intravenously. Detection of
invasive breast cancer by MRI has sensitivity approaching 100%, but some breast lesions,
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such as DCIS, may have much lower rates of detection, 40% sensitivity, due to variable
angiogenesis [Morris et al. 1997]. MRI is emerging as a valuable diagnostic test for young
women in whom the sensitivity of mammography is reduced and appears more accurate than
mammography in annual breast cancer surveillance in women with a hereditary risk of breast
cancer. In a cohort of 179 women at high risk for developing cancer, mammography
detected 7 cancers while MRI detected 13 cancers [Stoutjesdijk et al. 2001]. In addition,
MRI appears equally sensitive, 99.2%, to the triple diagnostic technique in detecting breast
cancer [Drew et al. 1999].
Several problems with MRI imaging will require future resolution. Signals from
many benign lesions and even normal breast tissue may be enhanced following contrast
administration, thereby degrading specificity. Further, there is no universally accepted
standard or optimal technique for MRI imaging of the breast and there are no commercial
needle localization systems for use with MRI. Lastly, MRI is more expensive than other
currently used imaging techniques.
The history of MRI provides a relevant framework for the development of new
medical technologies. MRI has become the primary technique throughout the body in the
routine diagnosis of many disease processes. Similar to Raman spectroscopy, MRI developed
out of a laboratory technique, nuclear magnetic resonance (NMR). During the 1950's and
1960's NMR spectroscopy became a widely used technique for the non-destructive analysis
of small samples. Like Raman spectroscopy, many of its applications were at the
microscopic level. Initially, MR images were noisy and it took close to five hours to produce
a single image. Today, it is possible to image in seconds what used to take hours. The term
MRI was adopted soon after imaging of the human body became possible as the public could
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more easily adopt a term for an imaging modality without the word "nuclear" in it.
III. D. 4. Positron Emission Tomography
Positron Emission Tomography (PET) is already in clinical use to image the brain, but its
application to other organs is only now being explored. PET involves labeling biochemicals,
such as sugars, with positron emitting isotopes, and imaging their uptake in the organ of
interest [Phelps 2000]. Once a positron, an antielectron, is emitted, it combines with an
electron and annihilation occurs producing two photons traveling in opposite directions.
Detectors placed in a ring around the patient record the arrival of the photons. By monitoring
the arrival time and positions, the origin of the photon can be calculated and three
dimensional images constructed. In contrast to standard methods of anatomical imaging,
such as mammography and MRI, PET represents a form of functional imaging of the breast.
PET scanning exploits the metabolic difference between benign and malignant cells [Morris
et al. 2001]. Tumor cells demonstrate increased glucose metabolism, and thus the labeled
sugar molecules are proposed to preferentially accumulate in malignant tumors.
F-fluorodeoxyglucose (FDG)-PET imaging allows accurate diagnosis of breast
carcinoma, with sensitivity and specificity for both ranging from 80% to 100% [Delbeke and
Martin 2001]. By designing better molecular probes, improved diagnostic accuracy may be
possible and significant research is focused on this area. However, PET scanning can
produce false negative results with small lesions (< 1 cm in size) and well differentiated
tumors, such as tubular carcinoma and carcinoma in situ. False positive results may occur
with inflammatory breast conditions or in breast tissue soon after surgery. FDG-PET
scanning may have its greatest value in the local and regional staging of newly diagnosed
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breast cancer. Most women with primary invasive breast cancer undergo axillary lymph
node dissection, a costly procedure that can be associated with complications. However, now
many primary cancers are diagnosed as small invasive cancer without axillary node
involvement. PET scanning may help evaluate the status of the axilla and stage patients with
locally advanced disease.
III. D. 5. Diffuse Optical Tomography
Diffuse Optical Tomography (DOT), a promising optical imaging technique, studies the
propagation of amplitude modulated pulses of light through the breast. Similar in approach
to traditional x-ray mammography, it is non-invasive and can detect lesions deep within the
tissue [Tromberg et al. 1997; Fantini et al. 1998; Quaresima et al. 1998; Hebden et al. 2001].
An arrangement of sources and detectors in a measurement cup enables three-dimensional
images to be constructed. By using light of several different wavelengths, information about
the scattering and absorption can be extracted to measure oxy- and deoxy-hemoglobin
concentrations and the presence of lipids. However, DOT can only detect a limited number
of chemicals and is generally of low resolution, causing small lesions to go undetected.
Resolutions of 4 to 13 mm, depending on measurement geometry and a number of other
factors, have been reported [Culver et al. 2001]. Furthermore, in order to obtain the
sensitivity and specificity required for lesion detection in vivo, exogenous agents to improve
contrast are often employed [Ntziachristos et al. 2000]. Based on this approach, ViOptix,
Inc., has developed an instrument which provides two-dimensional maps of hemoglobin
distribution and oxygen saturation. The device was employed to 50 mammogram-positive
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patients. As an adjunct to mammography, the approach resulted in 92% sensitivity and 67%
specificity for detecting ductal carcinoma [Cheng et al. 2003].
II. D. 6. Fluorescence and Diffuse Reflectance Spectroscopies
Optical spectroscopic techniques are also under investigation for breast cancer diagnosis.
Unlike DOT, these techniques sample the tissue locally. Light delivery and collection can be
accomplished by means of optical fibers that could readily be incorporated into a biopsy
needle. As the needle was inserted or withdrawn, depth information would be obtained. As
opposed to standard biopsy, a spectroscopic transdermal needle measurement has the
advantage of providing immediate diagnosis. As a result, spectroscopy has the potential to
reduce both the likelihood of a non-diagnostic biopsy that would require repeat needle or
surgical biopsy, and patient anxiety by eliminating the currently unavoidable wait for a
traditional histopathology diagnosis. Furthermore, with the development of minimally
invasive breast cancer therapies, such as radiofrequency ablation which relies on insertion of
a thin metal probe into the breast, there is the potential that diagnosis and treatment could be
performed in a single procedure [Fornage et al. 2004]. Optical spectral techniques that have
been applied to breast tissue analysis include fluorescence, diffuse reflectance, and Raman
spectroscopies.
Fluorescence is emission of light from a singlet excited state, in which the electron in
the excited orbital has the same spin orientation as the ground state electron. The fluorescing
molecule stays in the excited state for a finite time, usually 1-10 nanoseconds. Fluorescence
spectra can be used to identify fluorophores and their concentrations in the tissue. Various
endogenous tissue flourophores include metabolic substances such as the reduced form of
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nicotinamide adenine dinucleotide (phosphate) NAD(P)H and flavins, aromatic amino acids
such as tryptophan, tyrosine and phenylalanine, structural proteins such as collagen and
elastin, several porphyrins, and some lipids such as ceroid and lipofuscin. Each of these
fluorophores is excited and emits at a specific wavelength in the near UV/visible range of
light. Fluorescence spectroscopy has been applied to ex vivo breast tissue for disease
diagnosis and trends which correlate with disease have been observed [Gupta and Majumder
1997; Yang et al. 1996; Majumder et al. 1998]. Fluorescence produces relatively large
signals. However, the small number of endogenous fluorophores present in breast tissue
coupled with their broad spectral lineshapes are limiting factors. Fluorescence spectroscopy
of breast has the potential to provide information not available from Raman data and is
discussed in greater detail in Chapter VIII. However, fluorescence spectra can be distorted
by the interplay of tissue scattering and absorption.
Preliminary studies have examined the efficacy of diffuse reflectance spectroscopy in
the diagnosis of breast lesions, as well as in the assessment of tumor margins and sentinel
lymph node metastasis [Bigio et al. 2000]. These studies monitor changes in the absorption
and reduced scattering coefficients among tissues with different pathologies. Combining
fluorescence and diffuse reflectance spectroscopies has shown promise in the breast [Yang et
al. 1996]. Studies are currently underway in our laboratory to assess the power of
fluorescence and diffuse reflectance spectroscopies for breast cancer diagnosis. The
preliminary data analysis is presented in Chapter VIII.
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III. E. Raman Instrumentation
III. E. 1. General Considerations
Despite its rich information content, Raman spectroscopy has not experienced extensive
clinical investigation because the Raman effect is weak, comprising a very small fraction,
about 1 in 107, of the incident photons. However, within the past few decades a variety of
instrumental developments, primarily new lasers, detectors and methods for rejecting
elastically scattered light, have expanded the utility of Raman spectroscopy for biomedical
applications. Compact diode lasers can provide stable narrow-line excitation over a range of
wavelengths in the NIR region. Silicon deep-depletion charge coupled device (CCD)
detectors are best suited for tissue Raman spectroscopy, because of their relatively high
sensitivity and lack of fixed-pattern noise [Murray and Dierker 1986].
Advances in thermoelectrically cooled detectors may soon allow them to replace
liquid nitrogen cooled cameras, allowing easier clinical implementation. The application of
holographic filter technology to Raman spectroscopy has also led to increased utilization of
the technique in medical settings [Carabba et al. 1990]. Because the Raman effect is weak,
the intense elastically scattered light must be removed so that it does not overwhelm the
Raman signal. Holographic notch filters are devices for rejecting scattered light and are
specific for the excitation wavelength employed. These new technologies make rapid data
acquisition as well as the design of compact, robust Raman instruments, needed for clinical
applicability, a reality.
III. E. 2. Laboratory Raman System: Confocal Microscope and Macroscopic System
The experimental system, shown in Figure 11.8, utilized for our in vitro Raman spectroscopy
-106-
studies, is designed for versatility. It is capable of collecting spectra from both macroscopic
size biopsies and thin microscopic sections of tissue. It is also capable of collecting data at a
wide range of wavelengths given the appropriate beamsplitters and notch filters. The
versatility of this system is ideal for exploring new approaches to studying Raman
spectroscopy of human tissue. Raman excitation is provided by an argon ion laser-pumped
Ti:sapphire laser (Coherent Innova 90C/Spectra Physics 3900S, Coherent Inc., Santa Clara,
CA). The Ti:sapphire laser is tunable from 720 nm to 1000 ~ however for biological
Raman studies we employ 830 nm excitation. Laser power is continuously monitored by a
PDA55 photodiode (ThorLabs, Newton, NJ). The excitation laser beam traverses a bandpass
830 nm
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Figure 111.8. Schematic of the laboratory Raman system.
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filter (Kaiser Optical Systems, Ann Arbor MI) and is collimated by two lenses to improve the
spatial resolution of the confocal Raman microscope. The excitation laser beam can either be
focused onto a macroscopic sample or launched into the microscope via a prism that can be
translated in and out of position.
III. E. 2. a) Confocal Raman Microscope
When the prism is out of position, the collimated laser is coupled into a microscope (Zeiss
Axioscope 50, Zeiss, Thornwood, NY) and deflected towards the sample via a dichroic
beamsplitter. A CCD camera atop the microscope allows for registration of the focused laser
spot with a white light image to verify the morphologic structures from which the spectra
were collected. The microscope is fitted with two phase contrast objectives (10x and 63x)
which are used for visual inspection of the samples. By adjusting the flip-mirror so that the
light is directed towards the CCD camera, a VCR and frame-grabber can be used to record
image.
The microscope itself is equipped with a range of objectives, both normal and phase
contrast. For the studies presented here we used a 63x infinity-corrected water immersion
objective (Zeiss Achroplan, NA 0.9). This microscope objective both focuses the excitation
and collects the Raman scattered light in a backscattering geometry. Lateral resolution of
this lens is -2 gm. The Raman microscope is equipped with a mapping stage enabling
Raman micro-imaging. As both the detector and the microscope stage are computer
controlled. spectral maps of the tissue can be created by moving the translation stage in a
raster-scan pattern under the microscope objective. The minimum step size of the motorized
translation stage (Prior Scientific) is 1 m in the x direction and 1.1 gm in the y direction. A
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dichroic beamsplitter and mirror combination redirect the Raman-scattered light to the
spectrograph system. The light is passed through a confocal pinhole to increase axial
resolution, filtered by a holographic Raman notch filter (Kaiser Optical Systems, Ann Arbor
MI) for laser line removal, and coupled into an f/4 0.25 m Czerny-Turner spectrograph
(Chromex 250IS/SM spectrograph monochromator, Albuquerque, NM) with an f/4
achromatic lens. At the smallest confocal aperture diameter, -300 gm, the spatial resolution
of the microscope is -(2 gm)3 .
The spectrograph itself has an adjustable slit and a turret, which holds three gratings
for a range of measurements. For the Raman studies a 600 grooves/mm grating blazed at 1
gum, linear dispersion of 4.3 nm/mm, was used along with the 140 ugm spectrograph entrance
slit setting, providing - 8.5 cm' resolution. The grating disperses the light onto a back-
illuminated, deep depletion, liquid nitrogen cooled CCD detector (Princeton Instruments,
Princeton, NJ). The CCD is composed of a 256x1024 array of 27 glm x 27 gm pixels and is
controlled by WinSpec software (Roper Scientific). A spectral range of -200-2000 cm is
typically collected.
Simply by changing the excitation source, the filters/beamsplitters, and spectrograph
grating, the system can be adapted for fluorescence spectroscopy. Fluorescence
measurements can be obtained at a variety of excitation wavelengths. In particular 352 nm,
476 nm, and 647 nm excitation light can be delivered to the system via fiber optics from an
argon ion laser (Coherent Innova 700, Coherent Inc., Santa Clara, CA) in an adjacent
laboratory. The switch between Raman and fluorescence can be made in less than one
minute.
-109-
III. E. 2. b) Raman Macroscopic System
The excitation laser light can also be diverted from the microscope via a prism to study
macroscopic samples. In this case, the light is focused and directed to the sample via a
mirror at a 60° angle. The excitation spot is ....100 Jlm in diameter. Diffusion in the tissue
results in a sampling volume of -1 mm3, depending on the sample properties. The Raman
scattered light is collected with an fJ 1.2 camera lens, notch filtered and then focused onto the
spectrograph. The switch between the Raman macroscopic and microscopic systems
involves considerably more system realignment than the switch between Raman and
fluorescence.
ID. E. 3. Clinical Raman System: Raman Optical Fiber Probe
For clinical studies, we have developed portable compact instrumentation including a Raman
Figure 111.9. Clinical Raman system and Raman optical fiber probe.
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optical fiber probe for remote sampling during surgical procedures. Photographs of the
instrumentation and Raman probe are shown in Figure III.9. A schematic of the
Figure III.10. Schematic of the clinical Raman system.
experimental system used in the clinical studies, Chapters V and VII, is shown in Figure
III.10. Light from an InGaAS diode laser (Process Instruments, Salt Lake City, UT), tuned to
830 nm, is collimated by two cylindrical lenses, directed through a bandpass filter (Kaiser
Optical Systems, Inc., Ann Arbor, MI), redirected by a gold coated mirror and focused into
the Raman probe excitation fiber by a 10x microscope objective (Newport, Irvine, CA). The
laser output is under computer control. A shutter (Uniblitz, Rochester, NY) is employed
prior to the microscope objective to prevent laser light from emerging from the probe except
when collecting data. The shutter is also under computer control and is triggered by the
onset of data collection. The proximal linear array of collection fibers from the Raman probe
are input to the f/1.8 spectrograph (Kaiser) which collimates the light before it passes through
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an RG850 long wavelength-pass filter (Schott, Elmsford, NY), to reduce an intense portion
of the silica fiber background, and the Rayleigh line removed with a notch filter. The light is
then focused onto a slit and re-collimated for dispersion by the holographic grating. Finally,
the dispersed light is focused onto a liquid nitrogen cooled, back-illuminated, deep depletion
CCD detector. The CCD is interfaced with a computer and controlled with code written in
LabVIEW (v. 6.1, National Instruments, Inc., Austin, TX). The grating dispersion of 0.04
cmfl/mm yields a two pixel spectral resolution of 9.4 cm 1 for the 200 gm collection fiber/ slit
diameter.
III. E. 3. a) Raman Optical Fiber Probe
Minimally invasive clinical applications of Raman spectroscopy require remote sampling via
optical fiber probes. These probes must be able to collect high SNR spectra in clinically
relevant timeframes with safe levels of laser exposure. This requires maximizing signal
collection and efficiency while minimizing all sources of noise. Our Raman optical fiber
probe implements an optical design strategy to fully utilize system throughput by
characterizing the Raman distribution from tissue [Motz et al. 2004]. The approach
optimizes collection efficiency, minimizes noise and has resulted in a small diameter, highly
efficient Raman probe capable of collecting high-quality data in 1 s.
The design of Raman fiber optic probes is quiet challenging. Efficient transmission
of NIR light for remote detection requires the use of fused silica optical fibers [Shim and
Wilson 1997]. However, even with low laser excitation powers, below 10 mW, the fused
silica fiber background is intense and saturates the detector for collection times under 0.1 s.
The fiber background is comprised of Raman light from the fused silica core, fluorescence
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from impurities and dopants used to produce fibers of a particular numerical aperture (NA),
and signal from various jacket materials. This fiber background, generated from 2 to 3 feet
traversed in the fibers, masks the tissue Raman signal which is generated from only a 1 mm
depth of tissue. In addition to obscuring and distorting the spectrum of interest, the intense
fiber background adds shot-noise to the signal.
To remove much of this background, we employ dielectric filters at the distal end of
the probe. The delivery fiber is terminated with a short wavelength-pass, or band-pass, filter
that transmits the laser excitation light while blocking the longer wavelength spectral
background generated in the delivery fiber. Also, the distal end of the collection fibers are
preceded by a long wavelength-pass, or notch, filter, which transmits the tissue Raman
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Figure 111.11. Schematic of the Raman optical fiber probe.
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spectrum, while blocking backscattered laser light. The filters must perform these functions
over the range of angles corresponding to the NA of the fibers they serve.
The laboratory currently has two prototype versions of Raman optical fiber probes
that are front-viewing. The first, shown in Figure III.11, contains 15 collection fibers,
resulting in a probe diameter of 2.5 mm. The second is a smaller diameter probe with 9
collection fibers and a 2.0 mm diameter. The probes are otherwise identical. The left hand
side of Figure III.11 is a longitudinal view of the probe tip, while the right hand side is a
cross-sectional view at the level of the fiber-filter interface. There is a central excitation fiber
with an aluminum jacket for optical isolation. The central excitation fiber has a 200 gm core
with a 0.22 NA. The collection fibers are also 200 gm core, but have a 0.27 NA which is
closely matched to that of the spectrograph. The filters are secured to the fibers with sodium
silicate and the entire fiber bundle/filter module is encased with black Teflon for binding and
protection. The distal tip of the probe contains an anti-reflection coated sapphire ball lens
(MKPhotonics, Albuquerque, NM) secured in a crimped stainless steel tube with epoxy.
Sapphire was chosen as it exhibits no fluorescence and has sharp prominent Raman bands,
only one of which falls within the spectral range utilized for data analysis. The steel tube is
also affixed to the fiber-bundle/filter assembly. The probe length is 4 meters. All
components of the probe are constructed of medical grade materials that can withstand
standard cold gas ethylene oxide sterilization for surgical procedures.
The proximal end of the excitation fiber is terminated with a standard FC connector
that provides a relatively reproducible fiber geometry and straightforward laser coupling in
the clinical environment. The linear array of collection fibers are terminated with a modified
BNC connector and coupled to the spectrograph with a customized adaptor plate that was
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built in house. The BNC connector snaps into place on the adaptor plate, however, this
coupling is problematic for a number of reasons and is currently being updated. The
coupling does not ensure precise alignment of the linear array with the spectrograph slit and
alignment must be checked prior to data collection. Perpendicular alignment of the linear
area of collection fibers can usually be achieved with operating room (OR) lights. However,
OR lights are bright and can saturate the detector. Further, the BNC connector is the portion
of the clinical instrumentation that allows the majority of light to enter the system. Thus,
when acquiring data with a light tight box, as in Chapter V.B, the BNC coupling to the
spectrograph must be covered with a black cloth.
The first Raman optical fiber probe contained a dual ring of collection fibers. This
may prove useful for obtaining depth information on Raman scatterers by collecting light
from the inner and outer rings separately. The laboratory also has a side viewing probe
prototype. It is based on a design which replaces the sapphire ball lens with a half-ball lens
backed by a mirror. Lens and mirror are configured at 450 providing collection capabilities
similar to the front viewing probe. The performance of the side-viewing probe is currently
being tested. There are some problems with heating of the stainless steel tube associated
with the side viewing Raman probe.
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Chapter IV. Data Processing
Raman spectroscopy is a powerful tool for determining chemical information about a
biological specimen. It has been used in numerous applications to obtain both qualitative and
quantitative analyses of samples. As a result, many analytical techniques of varying degrees
of sophistication have emerged for analyzing Raman spectra. The challenge is to condense
the large amount of spectral information provided by Raman spectroscopy into an accurate
and easily interpretable form. Researchers have applied a range of techniques, from peak-
height ratios to multivariate models, to extract chemical information about a sample. The
purpose of this chapter is to discuss approaches that are commonly used to analyze Raman
spectra.
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IV. A. Data Preprocessing
Proper interpretation of Raman spectra requires several preprocessing steps to calibrate the
data and configure it into its most useful form. The Raman data acquired undergoes similar
preprocessing whether it is collected using the macroscopic laboratory system, the
microscope, or the clinical Raman system via the Raman probe. This ensures reproducibility
of the data between systems, users, and daily conditions.
IV. A. 1. Wavenumber Calibration
Each day, a wavenumber calibration must be performed to determine the Raman band
frequencies. Significant changes may occur in the pixel position of a particular band with
changes in the alignment of the instrumental system. The linear relationship between
wavelength and dispersion by the spectrograph provides an easy method for wavelength
calibration by using the spectral lines from atomic emissions, which are readily available
from pen lamps containing gases such as neon. However, accurate conversion from
wavelength (nm) to Raman shift (cmnf) requires precise knowledge of the excitation laser
wavelength. Even slight day-to-day drift in the laser wavelength can cause errors on the
order of a few wavenumbers, depending on the wavelength region used. For example, a
change from 830 nm to 830.2 nm, which is a typical daily variation observed with diode
lasers, results in a 2.9 cm' shift. Thus in Raman spectroscopy, a wavenumber calibration
can either be performed by measuring both the laser line frequency and spectral lines or more
simply the bands from a well-characterized Raman scatterer can provide calibration in a
single measurement. This single measurement automatically accounts for variations in laser
frequency because the Raman shifts are measured relative to the excitation wavelength.
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Toluene, a liquid, and 4-acetamidophenol, a solid, both provide excellent standards for
wavenumber calibration in our region of analysis. Their Raman spectra, acquired with 830
nm excitation, are shown in Figure IV. 1. Because of the inverse relationship between Raman
shift and wavelength, the correlation of CCD pixel to wavenumber is most accurately
established by calibration through a forth order polynomial. This relationship is then applied
to the data, providing Raman band assignments.
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Figure I.1. Raman spectra of species used for wavenumber calibration: a) toluene and b) 4-
acetamidophenol.
6000. 2. Spectral Response Correction
It is also necessary to correct Raman spectra for the system wavelength response. This
allows comparison of spectra taken from different experimental systems or from the same
system on different days. Correction is accomplished by collecting light from a wavelength-
calibrated tungsten white light source. Our current white light source is a tungsten halogen
l amp (LS-1, Oce an Optics, (m-L). The light is scattered from a reflectamandard t hat has a
flat spectra l r esponseically BaSO4. The r eflectance standard is tightly packed and placed
in the sample position. Division of the data by this calibration white light spectrum corrects
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for spectral variations induced by optical component absorption losses, filter responses, notch
filter position or angle, the grating efficiency, the quantum efficiency of the CCD detector,
and fixed pattern noise. White light spectra from the macroscopic and microscopic
laboratory systems as well as the clinical Raman system are shown in Figure IV.2.
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Figure IV.2. White light spectra acquired with different instruments: a) the clinical system and Raman
optical fiber probe, b) the macroscopic and c) microscopic laboratory systems.
IV. A. 3. Filtering
When a cosmic ray, a particle from outer space such as a helium nucleus, interacts with the
CCD, it creates charge in those pixels it passes through. As a result, sharp spectral features
often appear in the data in addition to the Raman bands. Cosmic rays distort the intensity of
Raman bands and produce errors in data analysis. Contributions from cosmic rays are
removed using a derivative filter. Derivative filters provide a quantitative measurement for
the rate of change in pixel brightness. Because cosmic rays are quite narrow compared to
Raman peaks, derivative filtering is an effective method for their removal. Specifically, if
any term in the derivative of the spectrum is greater than 2.5 times the average derivative of
the neighboring 15 pixels, then the corresponding term in the spectrum is replaced with the
average of the two values 3 pixels away on either side.
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IV. A. 4. Fluorescent Background Removal
Raman spectra of biological samples are often accompanied by strong background
fluorescence. This background fluorescence varies from sample to sample and when
particularly strong inhibits our ability to interpret the Raman spectrum. The origin of the
fluorescence from tissue at 830 nm excitation is presently unknown, although collagen,
elastin, calcifications, ceroid, and necrotic materials are all thought to fluoresce at this
excitation wavelength. The background fluorescence interferes with multivariate analysis
methods and must be removed prior to data analysis. This can be accomplished by a variety
of methods including Fourier transforms, differential Raman spectroscopy, point difference
derivatives, spline fitting, and Savitsky-Golay derivatives [Baraga et al. 1992; Shaver 2001].
Since the fluorescence background has much broader features than the Raman bands, we
typically employ a fifth order polynomial fit and subtraction for background removal.
Previous experiments in our laboratory have shown that the background can be satisfactorily
removed by using this approach and that a fifth-order polynomial accurately emulates the
slowly varying fluorescence spectrum [Brennan 1995; Brennan et al. 1997]. Resultant
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Figure IV.3. Background removal: a) Raman spectrum (solid line), fifth order polynomial fit (dotted line) and
b) resultant Raman spectrum with fluorescence background removed.
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Raman spectra will always have negative regions when using this approach. Figure IV.3
shows a measured Raman spectrum of breast tissue, acquired on the macroscopic laboratory
system. Also shown are the fifth order polynomial fit and resultant Raman spectrum with
background removed. The models used to interpret the Raman data, discussed in section
IV.C, must be processed in the same manner, using fifth order polynomial subtraction.
However, the process of background removal produces slight distortions in the Raman
spectrum resulting in errors in analysis. There are ongoing investigations in our laboratory to
quantify the effect of increasing background fluorescence on the prediction error. Also,
methods are under development to reduce the slight error induced by the fifth order
polynomial background removal.
IV. A. 5. Normalization
There are many approaches to intensity normalization that can be taken, depending on the
application. Strict quantitative analysis requires accurate normalization. This can be
accomplished through the use of an internal standard that produces a well-defined Raman
band of known intensity for the experimental setup in use. Such an internal standard can be
included in the sample preparation or in the case of optical fiber probes, can potentially be
introduced into the optical design [Zheng et al. 2001]. An external standard may also be
used. However, great care must be taken to ensure standard sample position reproducibility.
Qualitative or relatively quantitative analyses are not as restrictive and alternative
normalizations can be used to provide intra-model calibrations. For example, Raman spectra
can be normalized to the area of a particular vibration or the spectra can be scaled to have a
particular maximum intensity. Thus far, we have scaled our spectra to have a maximum
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intensity of one and have not included intensity information in our data analysis. The Raman
optical fiber probe, discussed in Chapter III, provides a reproducible geometry for data
collection, allowing examination of spectral data that has not been normalized. However, as
long as the normalization technique is standardized and consistent, the data can be
appropriately interpreted.
IV. A. 6. Mean Centering
It is often useful to mean center data prior to the application of many analytical algorithms
other than ordinary least squares (OLS) and classical least squares (CLS), discussed below.
Mean centering refers to subtracting the mean spectrum of the data set from each spectrum in
the data set. Conceptually, mean centering accentuates the differences among spectra.
Mathematically, it reduces the complexity of the data by one degree of freedom and prevents
certain spectra in the data set from being weighed more than other spectra. Statistically, it
maps the data onto an abstract space where the mean of the mean centered data does not have
any directionality [Kramer 1998]. For certain techniques, such as principal component
analysis (PCA) and partial least squares (PLS), mean centering is recommended. In the
absence of mean centering, the first spectral component of analysis will be the statistical
mean of the data set.
IV. A. 7. System Specific Calibrations
Certain experimental systems have additional calibration steps specific to the instrumentation
or application. In the case of data collected with the confocal Raman microscope, the
substrate background, typically MgF2, must be subtracted prior to fluorescence background
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removal. Although a confocal data collection geometry minimizes contributions from the
substrate background, its removal is still necessary. Similarly, data collected on the clinical
system with the light tight box employs a background removal step. Data collected on the
clinical system using the Raman probe must also utilize methods for dealing with
confounding signals from optical fibers. Although more than 95% of the Rayleigh scattered
excitation light is eliminated via long-pass filters on the collection fibers, the remaining fiber
background, mainly quartz, must be removed from the raw tissue data. The fiber background
is characterized by collecting the laser light reflected from a block of aluminum. This
spectrum is then subtracted from the white light corrected tissue data to remove the probe
background. A sixth order polynomial is employed for fluorescence background removal
when using the Raman optical fiber probe [Motz 2003].
IV. B. Chemometric Techniques
The general term for techniques used to derive chemical information from data is
chemometrics. Such analysis methods can be separated into two distinct classes, univariate
and multivariate. A time honored technique for extracting sample information is by
examination of a particular peak height. This is an example of a univariate technique as the
analysis depends on the value of a single variable of interest [Shaver 2001]. However, this
approach only takes advantage of a small portion of the data available. In complex biological
samples, where several distinct moieties may contribute intensity to a particular Raman band,
it is necessary to incorporate all of the spectral information in order to differentiate moieties.
Further, to capitalize on the high information content provided by Raman spectroscopy, more
sophisticated modeling techniques that incorporate the full spectral range of data available
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are required. The key is to compress the information into a manageable, yet still informative
form.
The notation for the equations in this thesis uses bold upper case letters to denote
matrices, bold lower case letters for vectors and lower case letters to indicate scalars. The
superscript T denotes matrix transposition while the superscript (-1) indicates matrix
inversion.
Extracting meaningful information from a complex data set, such as that of biological
tissue, can be accomplished by use of a set of mathematical techniques known as multivariate
analysis. Raman data can be modeled using linear analysis. Two assumptions are associated
with this type of modeling. One is that the Raman spectrum of a mixture of chemicals is a
linear superposition of the mixture's component spectra. The second is that there is a linear
relationship between signal intensity and chemical concentrations [Manoharan et al. 1992].
Manoharan and co-workers conducted a study on Raman spectra of mixtures similar in
composition to that of biological tissue and verified that both of these conditions hold within
experimental accuracy. For breast tissue, the linear superposition can be formulated:
Sbreast tissue=Cfat 'Pfat + CcollagenPcollagen + caroteneoPklcarotene + .... - - -(IV. 1)
Where Sbreast tissue is the Raman spectrum of breast tissue, ci is the concentration of component
i, and Pi is the Raman spectrum of component i. For an entire data set, Eq. IV.1 can be
expressed in matrix form:
S=C.P (IV.2)
Where S is the matrix of Raman spectra, C is the matrix of component concentrations and P
is the matrix of basis spectra. When the number of samples is n, the number of components
is p, and the number of wavelength points in each spectrum is m, S is an nxm matrix, C is an
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nxp matrix and P is a pxm matrix. The basis spectra, P, can be the Raman spectra of the pure
chemical constituents in the mixture, the Raman spectra of individual morphological
components of the tissue, or even mathematically derived lineshapes. The spectral matrix S
is a measured set of data for which we want to obtain the concentration information C. This
can be obtained through a series of matrix manipulations, resulting in
C=S.B (IV.3)
Where B is the matrix of orthogonal projection vectors (or b-vectors). For each chemical in
the data set, there exists only one ideal projection vector that models the data set most
accurately. When each multivariate technique is applied carefully, the projection vectors
obtained with different methods of analysis should all closely approximate the ideal
projection vector.
Multivariate analysis for extracting concentrations is typically performed in two
steps, calibration and prediction. Calibration is the process of developing a mathematical
relationship between physical quantities, for example the spectra and concentrations or the fit
coefficients and disease classification. Prediction is the process of applying the mathematical
model developed during calibration to extract information from spectra. Choice of the
optimal linear multivariate calibration technique depends upon the extent of the calibration
data. Explicit techniques are those in which the linear model is completely defined, and
therefore the linear superposition properties can be directly applied. Some examples are OLS
and CLS [Haaland and Thomas 1988]. In other techniques, called implicit techniques, not all
of the component spectra or concentrations are known [Geladi and Kowalski 1986]. PCA
and PLS are examples of implicit techniques. Explicit methods are more robust, but they
require the composition of the mixture to be completely characterized. Implicit and explicit
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models each have their advantages. Because explicit models use information about every
species, they are capable of providing superior calibrations. However, implicit models
require information only about a single species and thus they can be significantly easier to
implement. In addition, explicit models suffer when a species is mischaracterized or omitted
or when spectral artifacts such as baselines are present. In these cases, implicit models tend
to be more robust [Thomas and Haaland 1990]. We will be concerned with only those
methods that have been applied to the analysis of breast tissue. These include PCA and OLS.
The quantitative methods of CLS, PLS, and principal component regression (PCR) all require
concentration information from a reference technique for model calibration, which is difficult
to obtain for solid tissue, such as breast.
IV. B. 1. Principal Component Analysis
PCA is useful when it is not possible to identify all of the component spectra or
concentrations a priori. It can be used as a proof-of-principal analysis to demonstrate that
there is sufficient information contained within a data set to yield accurate disease diagnosis.
PCA has been used to classify diseased tissue samples in several organ systems [Mahadevan
and Richards-Kortum 1996; Manoharan et al. 1998; Denium et al. 1999]. It uses the entire
Raman spectrum and does not assume any knowledge about the chemical composition of the
tissue. PCA resolves the spectra of an entire data set into a small number of orthogonal
principal component (PC) basis spectra. These PC spectra can have negative and positive
components and form a complete basis set that accurately describes all the data (within
limitations imposed by noise) if the PCs are multiplied by the proper weighting coefficients.
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These weighting coefficients, called fit coefficients, are analogous to chemical concentrations
however they provide much less direct chemical information.
We use a singular value decomposition (SVD) algorithm (Matlab V.6.5.0, The
Mathworks, Natick, MA) to determine the PCs of our data sets. SVD computes all n PCs,
one for each spectrum or CCD pixel. In SVD the data, S, an mxn matrix, can be
reconstructed by multiplying its eigenvectors, Q, by their k eigenvalues (also call scores or
fit coefficients).
S=U.X.QT (IV.4)
Here, U.X are the fit coefficients and QT is a (kxn) matrix whose columns are the PCs,
analogous to P in Eq. IV.2. X is a diagonal matrix containing square roots of the
eigenvalues, and U is an (mxk) matrix.
Data sets are typically mean centered prior to performing PCA in order to remove
features common to all spectra, thereby highlighting spectral variance. The first PC will
contain the maximum amount of variation in the data, with each subsequent PC spectrum
representing sequentially less variation. The contributions of each PC to subsequent samples
can then be calculated:
C -U.X=S.Q.(QT.Q)4=S.Q (IV.5)
PCA provides little physical information in and of itself; however, it is adept at isolating
spectral trends that correlate with physical information and thereby provides a basis for
development of diagnostic algorithms. Furthermore, by comparing the lineshapes of the
diagnostic PC spectra with the spectra of pure chemicals, it is possible to ascribe some
meaning to them. For example, features related to Raman bands of particular chemicals can
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be identified in the PCs used for breast cancer diagnosis. A detailed discussion is presented
in section III.C.2.
To further illustrate the information conveyed by PCA, an analysis was preformed on
the fresh-frozen breast data presented in Chapter V. Figure IV.4 displays the first 3 PCs of
the data set. The data was not mean centered prior to PCA and thus the first PC, shown in
Figure IV.4a is the statistical mean of the data set. PC 1 represents 41% of the data variance
and is very similar to the morphologically derived Raman spectrum of fat. PC 2 also
resembles a morphologically derived Raman spectrum, that of collagen. It represents 11% of
the data variance. PC 3, shown in Figure IV.4c, accounts for less than 1% of the data
variance. It exhibits more complex structure as well as negative and positive components
thus illustrating the difficulty in interpreting PCs and the limitations of this approach.
Interestingly, collagen and fat are the two components found to be diagnostic in our
modeling studies, presented in Chapter V.
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Figure IV.4. Principal component basis spectra of fresh-frozen breast data set. a) PC 1 (solid line) and fat
(dotted line). b) PC 2 (solid line) and collagen (dotted line). c) PC 3
IV. B. 2. Ordinary Least Squares Regression
OLS is used to extract concentrations of all important components present in the samples. As
input, it requires Raman spectra of all components that contribute signal to the spectral data
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set. When the number of spectra and the number of variables in the spectra are equal and the
matrix P is invertible, we can directly obtain concentrations from
C=S.P"- (IV.6)
However, the number of spectra and the number of variables in the spectra are rarely equal
resulting in a matrix P that is not invertible. In fact, it is preferable to have a data set
composed of many more spectra than variables. To obtain the concentration in this case, we
multiply Eq. (IV.2) by the transpose of P:
S.PT=C.P.PT (IV.7)
If ppT is invertible, we can derive an equation for the concentration matrix, C:
C=S.PT.(P.PT) ' (IV.8)
And thus via comparison with Eq. VI.3, a matrix of projection vectors:
B=P.(P.PT)-' (IV.9)
OLS is a simple but powerful technique in spectral analysis. However, an error in the
number of model components can result in erroneous regression results. Additionally,
spectra of certain chemicals vary with environment, which can also lead to inaccurate OLS
analysis. In the next section, development of our spectral model used in OLS analysis is
presented.
IV. C. Spectral Modeling: A Morphologic Assay of Breast Tissue
IV. C. 1. Motivation and Assumptions
Although it is possible to use simple correlation analyses of particular Raman bands or
lineshapes to diagnose disease, there is a wealth of information in the spectra that enables
enhanced understanding of disease etiology. Thorough understanding of the
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chemical/morphological Raman spectrum of breast tissue is a necessary step in developing
Raman spectroscopy as a tool for breast cancer diagnosis. To understand the relationship
between the Raman spectrum of breast tissue and its disease state we developed a Raman
spectroscopic model [Shafer-Peltier et al. 2002]. This model is based on the morphological
structures that comprise breast tissue.
Construction of a morphological model of breast tissue relies on three assumptions.
First, as discussed above, that the Raman spectrum of a mixture is equal to the weighted sum
of the individual components of the mixture. Second, that biological morphological features,
such as cells, have a similar Raman spectrum from one patient to another. Finally, that the
elements included in the model are sufficiently distinct to enable their differentiation based
on their Raman spectrum and a given SNR in the data.
Our model identifies the morphological components present in breast tissue through
their unique Raman spectra and uses them as basis spectra to describe the morphological
features of macroscopic spectra. These basis spectra are derived from Raman microscopy of
the epithelial cell cytoplasm, the cell nucleus, fat, [-carotene, collagen, calcium
hydroxyapatite, calcium oxalate dihydrate, cholesterol-like lipid deposits and water. The
resulting fit coefficients yield the contribution of each basis spectrum to the macroscopic
tissue spectrum, thereby elucidating the chemical/morphological makeup of the lesion. The
model explains the spectral features from a range of normal and diseased human breast tissue
samples, thereby relating the Raman spectrum of a breast tissue sample to diagnostic
parameters used by pathologists.
Morphologically derived basis spectra have several advantages over spectra obtained
from pure chemicals. First, the spectra are collected in situ and are therefore subject to
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perturbations naturally present when tissue is examined in vivo. In other words, pure
chemicals are not identical to those found in tissue. For example, most proteins are
commercially available in a powdered form, not hydrated as they are in human tissue.
Second, the number of components in the model is reduced to spectra of a few key
morphological features, rather than the large number of chemicals that are present in tissue.
This simplification has the potential to reduce error in the model fits by limiting the spectral
overlap of the model. For instance, collagen is present in human tissue in many different
forms, each producing a slightly different Raman spectrum. The collagen found in breast
tissue is predominately composed of type I collagen with minor contributions from types III,
IV, and V [Alini and Losa, 1991]. To avoid data over-fitting, a morphological spectrum of
collagen, encompassing the average of the different types, is included in our model. Also,
identifying each chemical present in a complex biological environment, such as cell
cytoplasm, is challenging. Finally, the model interprets the traditional chemical information
contained in Raman spectra into terms that are commonly used by pathologists during
histologic analysis. However, Raman spectra of pure chemicals do provide insight into the
make up of morphological features and when necessary, synthesized or commercially
available chemicals were used.
IV. C. 2. Samples Preparation and Data Acquisition
Samples of breast tissue were obtained from surgical biopsy specimens, snap frozen in liquid
nitrogen, and stored at -85 C until spectroscopic examination. Samples were then mounted
on a cryostat chuck using Histoprep and sliced into 6 gtm to 8 m thick sections using a
microtome. These sections were mounted on MgF2 flats, selected because of their small
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Raman background signal, and kept moist with phosphate buffered saline (PBS) at
physiological pH.
Raman spectra underwent processing to ensure reproducibility of the data from day to
day. First, they were corrected for the spectral response of the system using a tungsten light
source. The data were frequency calibrated using the known Raman lines of toluene. The
MgF2 background spectrum was subtracted and the broad fluorescence background was
removed by fitting the spectrum to a fifth order polynomial and subsequent subtraction of
this polynomial. Also, contributions from cosmic rays were removed, if necessary, using a
derivative filter.
Our model was built using the phase contrast microscope, discussed in Chapter III, to
identify morphological features and collect confocal Raman spectra from those features.
Raman maps were also employed for comparison with serial H&E stained sections. This
allows identification of morphological features difficult to locate with phase contrast alone,
for example fibroblasts buried in the extracellular matrix. As an example of this approach, a
Raman map of a normal breast duct and the corresponding phase contrast image are shown in
Figure IV.5. The circular structure of the duct can be discerned in the phase contrast image,
Figure IV.5a, however the image shows few other features. By plotting the contribution of
certain morphological features to the Raman map, we observe a supportive collagen network
surrounding the duct. The single layer of epithelial cells forming the duct itself and the
location of the nuclei within these cells can be seen in images IV.5c and IV.5d. Also the
presence of fat in the lumen of the duct is visible in image IV.5e.
Libraries of spectra for each morphological feature were generated. When possible,
examples of each morphological element were identified from a variety of patients and
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Cell Nucleus Fat
Figure IV.5. Raman map of a normal breast duct with the corresponding a) phase contrast image.
Each Raman image represents the contribution of a specific morphological element to the region
mapped: b) collagen, c) cell cytoplasm, d) cell nucleus and e) fat.
disease states. Raman spectra from normal, benign and malignant samples were collected
into separate libraries for analysis. Each library typically contained 60 to 80 spectra from 5
or 6 patients. If spectra in a library did not vary greatly or consistently, the spectra were
averaged to create the morphologically derived basis spectrum used in our model. If
consistent differences were observed, as was the case for the cellular components, the
number of independently varying contributors was identified with peA and used to extract
independent basis spectra. In cases where single spectra had unique Raman bands when
compared with other spectra in that morphological category, those spectra were removed
from the category and analyzed independently to ensure that their spectral features could be
explained by other elements in the model. If the spectral features could not be explained by
the current morphological model, a new category was added and the database of Raman
maps was searched for similar spectral signatures. When matches were found, phase contrast
images and serial stained sections corresponding to the Raman map were reviewed.
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Using our library of Raman maps, 9 key basis spectra were identified to comprise our
spectral model. Their Raman spectra are shown in Figure IV.6. Some features identified
during the Raman mapping experiments were not included in the model because they were
not found to contribute appreciably to macroscopic data (1 mm3 volume) acquired from
biopsy samples. This could be because they are not present in large quantities or because
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Figure IV.6. Morphological spectral model of breast tissue.
they have small Raman scattering cross-sections and thus do not contribute appreciably to
bulk tissue spectra.
IV. C. 3. Epithelial Cell Cytoplasm and Cell Nucleus
There are several types of cells in normal breast tissue: epithelial, myoepithelial, and
fibroblasts. Inflammatory cells are present when there is a host response to an irritant.
Malignant cells are typically derived from epithelial cells that have undergone a number of
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genetic transformations. Thus, the
IV.7a
degree of inter-patient and disease
dependent variation was largest for : IV.7b
the epithelial cell cytoplasm basis Z'
spectrum. Figure IV.7 displays IV.7
Raman spectra of different cells
IV.7d
occurring in the breast. Shown are
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the spectra of an epithelial cell in a
Raman Shift (cm 'l )
normal duct, an epithelial cell in a Figure IV.7. Raman spectra of cells occurring in the breast:
a) a fibroblast occurring in normal stroma, b) an epithelial cell
in a focus of fibrocystic disease, c) an epithelial cell in a
focus of fibrocystic disease, a normal duct, and d) a malignant epithelial cell.
malignant epithelial cell, and a fibroblast occurring in normal stroma. The main difference
among Raman spectra of a range of cells was determined to result from varying ratios of the
cell cytoplasm to the cell nucleus. Differences in this ratio are most emphasized when
comparing normal and malignant cells.
Because the ability to collect pure spectra from the cell cytoplasm and the cell
nucleus is somewhat limited by the collection volume of the Raman confocal microscope, the
two basis spectra were separated mathematically. To separate the two components, spectra
of hundreds of cells from 8 different patients were collected using the Raman microscope.
Initially areas in the Raman map corresponding to cell nucleus and cell cytoplasm were
identified by comparison to the Raman spectrum of DNA, purchased from Sigma. Next, two
libraries were constructed, one high in DNA, corresponding to spectra acquired from nuclear
regions and one with little or no DNA, collected from regions in the cytoplasm. The mean
DNA-rich spectrum was then subtracted from the mean cytoplasm spectrum, thereby
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Figure IV.8. Raman spectra of cellular components. a) DNA,
b) cell nucleus, c) actin and d) epithelial cell cytoplasm.
subtracting the epithelial cell cytoplasm model fit from
removing all the residual cell
nucleus bands from the cytoplasm
rich spectrum and all the cytoplasm
contributions from the cell nucleus
spectrum. The resultant two
spectra, cell nucleus and epithelial
cell cytoplasm, were used to re-fit
the original cell spectral data. The
final cell nucleus model basis
spectrum was derived by
each Raman spectrum in the original
cell data set and calculating the mean of the residual spectrum. The same procedure was
followed to produce the epithelial cell cytoplasm spectrum. This iterative process minimizes
artifacts due to the inability of the Raman spectrum of commercially available DNA to
accurately model the cell nucleus. The model basis spectra representing epithelial cell
cytoplasm and cell nucleus are shown in Figure IV.8. Shown for comparison, are Raman
spectra acquired from commercially available actin and DNA
Other differences between the cells found in breast tissue are incorporated into other
model components. For instance, signal from collagen can be seen in the Raman spectrum
from a fibroblast. Fibroblasts are cells responsible for making and maintaining the
extracellular matrix. In order to do so, they produce collagen, fibrinogen, and
glycosaminoglycans.
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IV. C. 4. Fat
Fat is one of the strongest contributors to the Raman spectrum of normal breast tissue. Fat is
present in large quantities and has a large Raman scattering cross-section. Fat storage in
humans primarily takes the form of triglycerides, especially triolein. The morphological
spectrum of fat is very similar to the Raman spectrum of triolein. The fat spectrum included
in our model is the average of 28 spectra collected from 5 patients. There was little
variability in the Raman spectrum of fat with either patient or disease state.
IV. C. 5. P-Carotene
5-carotene is resonance enhanced when excited with 830 nm light. As a result, it has an
extremely strong Raman signal. It is lipophillic and is often found in conjunction with fat
throughout the breast. To eliminate the need for extracting the fat content from the hundreds
of morphologically-derived -carotene spectra, we used the spectrum acquired from
commercially available -carotene. Using our morphologically-derived Raman spectra of P-
carotene, we confirmed that the commercially available sample was an accurate
representation of the -carotene found in tissue.
IV. C. 6. Collagen
Collagen is the major protein of the white fibers of connective tissue, cartilage, and bone. It
is insoluble in water, but can be altered to a soluble gelatin form by boiling in water, dilute
acids, or alkalies. It is high in glycine, alanine, proline and hydroxyproline, but is low in
sulfur and has no tryptophan. Collagen comprises a family of genetically distinct molecules
all of which have a unique triple helix configuration of three polypeptide subunits known as
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structural proteins, such as Figure IV.9. Raman spectra of collagen: a) commercially
available collagen type I and b) morphologically-derived
fibrinogen, fibronectin, and collagen, mainly type I with minor contributions from types
III, IV, and V.
proteoglycans, are also present but in
minute quantities and with such small Raman scattering cross-sections that they do not
contribute significantly to the bulk Raman spectra. Figure IV.9 compares the mean spectrum
of morphologically-derived collagen, mainly type I with minor contributions from types III,
IV, and V with the Raman spectrum of commercially available collagen type I [Alini and
Losa, 1991]. The morphologically-derived collagen spectrum is the mean of 215 spectra
taken from 7 different patients.
IV. C. 7. Microcalcifications
Two major types of microcalcifications are found in breast tissue. Type I deposits consist of
calcium oxalate dihydrate, a birefringent colorless crystal, while type II deposits are
composed of calcium phosphates, mainly calcium hydroxyapatite. Type II
microcalcifications are typically basophilic on light microscopic examination of H&E stains
and nonbirefringent. Both type I and type II microcalcifications are strong Raman scatterers.
There is no reliable way to distinguish between type I and type II microcalcifications in a
-142-
II
clinical mammogram, but the type is thought to correlate with disease [Radi 1989]. Calcium
oxalate dihydrate crystals are most frequently seen in benign ductal cysts and are rarely
found in foci of carcinoma, while calcium phosphate deposits are most often seen in
proliferative lesions, including carcinoma. This distribution is consistent with the hypothesis
that type I microcalcifications are a product of secretions, whereas type II calcium deposits
result from cellular degradation or necrosis. The Raman spectra of type I and II
microcalcifications are distinct and shown in Chapter VI.
Despite the significant role they play in breast cancer, microcalcifications are not
commonly found in our frozen breast tissue specimens. This is because calcifications are
important for medical diagnosis and therefore tissue containing calcifications is not
commonly released for scientific study. As a result, we expanded our studies to include
deparaffinized tissue sections. Calcium hydroxyapatite was identified in fresh frozen
specimens from 3 patients and in deparaffinized tissue sections from 11 patients. The
calcium hydroxyapatite basis spectrum included in the model is an average of these spectra.
Calcium oxalate was only observed in one deparaffinized tissue sample. Therefore, calcium
oxalate dihydrate was synthesized for incorporation into our model [Kontoyannis et al.
1997]. In subsequent microcalcification studies on deparaffinized sections, the spectrum of
calcium oxalate dehydrate was found to be very reproducible. Both calcification spectra
resemble Raman spectra published in the literature [Kodati et al. 1990, Kodati et al. 1991].
IV. C. 8. Cholesterol-like Lipid Deposits
The necrotic core is essentially the product of cellular degradation. Consequently, its
composition varies significantly from location to location even within a single duct. Necrosis
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can occur within a malignant duct or in the center of a tumor. Analysis of Raman spectra
from three patients indicated that the necrotic core contains: fat, collagen, calcium
hydroxyapatite, cholesterol, cholesterol linoleate and cellular material. As the ratios of these
elements can vary significantly, the spectrum included in our model, cholesterol-like,
represents the common elements of these spectra not represented elsewhere in the model.
The spectrum includes features indicative of cholesterol and cholesterol linoleate, although
there are small contributions from cellular material and triglycerides. The necrotic core is
not the only element in breast tissue containing cholesterol and cholesterol linoleate, for
example, the cell membrane contains both these chemicals.
IV. C. 9. Water
Although not a strong Raman scatterer,
water constitutes -80% of human tissue
by weight and thus our data contains '
contributions from water. The Raman X
N
spectrum of water is well known and in
our region of data acquisition has a z
our region of data acquisition has a
ll1glv, rIeLVely UlUaL JaXilUi UDanU 600 800 1000 1200 1400 1600 1800
Raman Shift (cm-1)
centered at 1650 cm ' . The Raman Figure IV.10. Raman spectra of water: in the breast
spectral model (solid line) and in the artery spectral model
spectrum of water is shown in Figure (dotted line).
IV.10. Also shown in Figure IV.10 is the Raman spectrum used in the Raman artery studies.
The two spectra exhibit different background structure and SNRs. Studies to determine
which spectrum more accurately fits our Raman data should be undertaken.
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IV. C. 10. Inter-patient Variation of Elements
Model development via averaging spectra from many patients and pathologies ensures that
our model includes the common elements to all morphological features. However, one of the
keys to successful morphological modeling is that there is minimal inter-patient variation in
the model elements. For some model components there is very little inter-patient variation.
For instance, the extracellular matrix spectrum is primarily collagen, regardless of the
patient. Likewise the fat spectrum is similar to triolein, although small variations can be seen
across samples. For other model components, such as calcium hydroxyapatite and
cholesterol-like, more variation is observed. In our present clinical data, subtle variations are
typically overwhelmed by noise. However, as instrumentation and data analysis techniques
improve, new components corresponding to smaller chemical variations will need to be
included in our model.
IV. C. 11. Future Directions: Quantitative Analysis
In order to collect Raman spectra for truly quantitative analysis, data must be independent of
the experimental system. In addition to the steps discussed above, the system throughput
must be assessed and data must be corrected for the CCD gain so that the number of
collected photoelectrons is determined. Our current morphological model of breast only
provides relatively quantitative data and is therefore, not subject to these more advanced
considerations. Although strict quantification is desirable, it is challenging to establish
Raman scattering cross-sections for the components present in biological tissue. However,
with instrumental advances and a deeper understanding of the theoretical accuracy of our
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approach we have planned a study to make our morphological models quantitative. In this
study, data will be acquired from thin sections of fresh-frozen breast tissue using our Raman
microscope. This data will be acquired using a low magnification objective to ensure that the
spectroscopic signal is representative of the entire breast tissue section. Data will not be
collected confocally and spectra will be acquired for long integration times, conferring high
SNR Raman data. Addition of a photodiode to the laboratory microscopy system allows for
correction for laser intensity variations. Each thin section of breast tissue spectroscopically
examined will then be reviewed by a pathologist. A combination of staining techniques and
morphometric analysis will be used to obtain an estimate of the volume occupied by each
morphological feature represented in our Raman spectral model. These volumes will then be
correlated with the fit coefficients from the corresponding spectrum. Half of the data will be
used to scale the basis spectra such that the fit coefficients are representative of the
pathologically determined volumes. The remaining data will be used for validation of the
intensity corrected model. I anticipate that some model elements, such as fat and
microcalcifications, will quite accurately reflect their morphological volumes while others,
such as epithelial cell cytoplasm and cholesterol-like, will not. This will allow us to identify
areas of the model which are representative of several morphological features and provide a
basis for model refinement. The prediction error equation, presented below, can be used to
estimate reasonable errors.
-146-
IV. D. Diagnostic Algorithm Development
IV. D. 1. Calibration
Many techniques have been developed to aid researchers in producing decision algorithms to
classify data according to specific parameters. These include discriminant analysis [Fisher
and Van Belle, 1993], logistic regression [Fisher and Van Belle, 1993; Pagano and
Gauvereau, 1993], and neural networks [Robb and Munk, 1990]. Discriminant analysis and
logistic regression are very similar linear techniques. Both assume that the samples are
binomially distributed within each classification. Discriminate analysis, which applies
Bayes' Theorem, is the more restrictive in its assumptions. It allows only for normally
distributed input variables, whereas logistic regression allows for discrete (e.g. only integer
values) or categorical (e.g. cancerous/non-cancerous) variables. We typically employ
logistic regression in our algorithm development as it can easily incorporate binary
categorical information into the decision scheme. Neural networks simulate the processing
of signals in the brain. In such a system, information is processed by a network of
interconnected units according to a pattern established during the calibration process.
Neural networks do not require the data to be normally distributed and can be used to
describe non-linear systems as well as linear ones. However, it is especially important to
perform proper calibration and validation of neural network based decision algorithms
because physical interpretation of the coefficients is difficult and robustness is not always
easy to achieve.
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IV. D. 2. Logistic Regression
Logistic regression is well suited to the purpose of developing classification algorithms from
Raman spectral data as it allows us to classify samples according to discrete categories
[Sharma 1996]. It is used to correlate the fit coefficients, obtained via modeling, with disease
classifications provided by a pathologist. Pathology serves as the gold standard in all of our
diagnostic algorithm development. Logistic regression is used extensively throughout this
thesis for algorithm development. The underlying assumption of logistic regression is that
the probability, pi, that the ith sample in a set of spectral data belongs to a particular category,
for example that the sample is malignant, is described by the logistic function of the form:
pi=(1+exp(a+Yzjxj))-' (IV. 10)
With xj the score or fit coefficient associated with the jth basis spectrum. The parameters pj
and a are to be determined. pi varies from zero to one in a sigmoidal fashion as a function of
xj. It is small for large values of xj and approaches unity for small values. Logistic
regression introduces the likelihood function, L, defined as the probability of observing a
specific set of diagnoses in a set of samples. This can be calculated as the product of the
probabilities, Pi, that each individual sample belongs to a given category:
L= Pl p2-p3. · · Pn (IV. 11)
The first step in implementing logistic regression is to choose a particular basis set and apply
these basis spectra to a set of calibration data to obtain a set of fit coefficients, xj, for each of
the i samples. In this thesis we use both the spectral model, described above, as well as PCA
to generate fit coefficients for algorithm development. To determine values for the Rjs and ca,
the maximum likelihood principle is used. It states that the values for the parameters of the
likelihood function should be chosen to maximize the probabilities predicted for obtaining
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the specific set of diagnoses for the sample set. The expression for L is obtained by inserting
Eq. IV.10 into Eq. IV.11 and the values for the js and a are found by applying this
expression to the calibration data set. The values for the Rjs and a are chosen to maximize
the agreement between L and the known classifications of the calibration data set. Once the
values for the js and a have been obtained, Eq. IV.10 can be used to predict the probability
that a new sample falls into a given category. Different combinations and numbers of
spectral components should be assessed in selecting the relevant number of parameters with
diagnostic potential.
Once a diagnostic algorithm is developed, its performance must be assessed. This
can be accomplished by calculating the sensitivity and specificity of the approach.
Sensitivity refers to the proportion of individuals with the disease who are correctly
identified by the diagnostic algorithm. Specificity is the proportion of individuals without the
disease who are correctly identified by the diagnostic algorithm. Sensitivity and specificity
are typically expressed as percentages. If the sensitivity and specificity are both 100%, then
the diagnostic algorithm is equivalent to the gold standard. However, in practice, sensitivity
is gained at the expense of specificity and vice versa. The trade off between sensitivity and
specificity is often displayed as a Receiver Operator Characteristic (ROC) curve. Whether
we aim for a high sensitivity or high specificity depends on the condition we are trying to
detect and the implications for the patient of a false negative or false positive test result. For
conditions that are easily treatable, a high sensitivity is preferable. However, for conditions
that are serious and untreatable, a high specificity is preferable in order to avoid making a
false positive diagnosis.
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IV. D. 3. Validation
It is necessary to check the accuracy of a diagnostic algorithm after it is built. An
independent data set, which does not include the data used for calibration, is often used for
testing the robustness of a diagnostic algorithm. If the diagnoses obtained by using a
prediction scheme in a prospective manner and the diagnoses provided by a pathologist are
statistically similar, the diagnostic algorithm is validated and considered clinically accurate.
This process of testing an algorithm is called validation.
Although it is desirable to use an independent data set for validation, this requires a
large number of samples, often difficult to achieve with biological tissues. When the number
of samples is not sufficient to perform an independent validation, cross-validation can be
performed. Cross-validation allows for the efficient use of a data set because only a small
number of samples are reserved, and the spectra of the remaining samples are used for
calibration. The developed algorithm is then used to extract diagnoses from the spectra of
the reserved samples and the disease classifications are compared with the pathological
diagnosis. One example of cross-validation is the leave-one-out method, in which one
spectrum at a time is left out of the calibration. In this process, the diagnostic algorithm is
calibrated using logistic regression excluding a single spectrum. The excluded datum is used
for validation and the prediction made on it is compared to the diagnosis provided by a
pathologist. Each spectrum is, in turn, excluded and the procedure repeated. By cycling
through left-out samples in this way, a relatively small data set can be used efficiently and
without bias to establish the robustness of a model. Several other variations of cross-
validation analysis exist. Data from a single patient may be omitted or the data can be
divided into a number of sets. In these versions of cross-validation, the diagnostic algorithm
-150-
is calibrated using logistic regression on all spectra except those from a single patient or a
single.set. Again the excluded data is used for validation. The patients or sets are then
rotated, with each in turn serving as the validation set. When separating data into sets, it is
important that multiple spectra from a single patient are kept as part of the same data set and
also that data collected during different acquisition time periods is carefully mixed between
the sets. Finally, normal, benign, and malignant samples should be evenly distributed among
the sets. All algorithm development presented in this thesis employs leave-one-out cross-
validation in which a single spectrum is excluded. Algorithms are also validated
prospectively on independent data sets.
IV. E. Real-Time Analysis
A final step in the development of clinical Raman spectroscopy is the ability to provide real-
time diagnosis. Real-time analysis is also a useful experimental tool. As such, we have
developed clinical Raman instrumentation that provides real-time diagnoses [Motz et al. in
press]. Following accumulation of the data, the spectrum is analyzed with the appropriate
model. Data, model fit, and fit coefficients are then displayed. A diagnostic plot is also
shown indicating the samples' disease state. Different diagnostic algorithms and spectral
models can be chosen depending on the application. LabVIEW is the primary platform for
data acquisition and analysis in the real-time clinical Raman system. In addition to providing
flexibility for interfacing with various devices in the system, LabVIEW allows automation of
spectral calibration and data analysis in Matlab, V.6.5.0 (The Mathworks, Natick, MA).
Diagnosis is obtained in less than 1 sec. following data acquisition.
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Real-time feedback can be used to direct biopsy, thereby reducing the likelihood of a
non-diagnostic biopsy that would require repeat needle or surgical biopsy. Also, with the
development of minimally invasive breast cancer therapies, such as radiofrequency ablation,
which relies on insertion of a thin metal probe into the breast, there is the potential that
diagnosis and treatment of some lesions could be performed in a single procedure. Our real-
time Raman system has been used successfully for a variety of preliminary clinical studies.
Applications include targeting moieties of interest during data collection and real-time in vivo
diagnosis. The system was used ex vivo to target microcalcifications in breast biopsies,
discussed in Chapter V.B.5, and in vivo to provide margin assessment at breast cancer
surgery, Chapter VII.
IV. F. Analytical Method of Estimating Chemometric Prediction Error: Ac
We present an analytical formula that estimates the uncertainty in concentrations predicted
by linear multivariate calibration, particularly OLS. We emphasize the analysis of
spectroscopic data. The formula is expressed in terms of easily quantifiable experimental
parameters and is straightforward to evaluate. To test this formula, we performed OLS
analysis upon simulated spectra and upon experimental Raman spectra of dissolved
biological analytes in water. In each instance, the root-mean-squared error of prediction was
compared to the estimate from the formula. We observe excellent agreement between the
formula and data for these simple systems. The ability to make predictions concerning the
concentration error is valuable to the process of developing and refining analytical
measurements.
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IV. F. 1. Introduction
Raman spectroscopy provides detailed quantitative information about sample composition
and thus is a promising technique for the examination of biological systems [Raman and
Krishnan 1928; Pupples et al. 1990; Mahadevan-Jansen and Richards-Kortum 1996; Hanlon
et al. 2000]. However, it is often difficult to interpret Raman spectra of biological samples
due to their complexity. Noise as well as the presence of multiple components, resulting in
overlapping Raman bands, complicates attempts to use Raman peak intensities for accurate
quantitative analysis. This has led to the application of multivariate techniques, which utilize
the entire spectral range, to the analysis of Raman spectra [Shaver 2001]. Multivariate
analysis is part of the general field used to derive chemical information from data, known as
chemometrics. The goal of multivariate methods of analysis is to find a projection vector
that extracts concentration information from the data. The concentration errors resulting
from chemometric analysis are typically assessed by comparison with a reference
measurement. Reference measurements have the disadvantage of introducing an additional
source of error, contained in the reference concentration. Further, in many biologic samples,
such as tissue, obtaining reference concentrations is not straightforward. Although, reference
measurements can be used to assess the overall error of an approach, they provide little
insight into the origins of that error.
We have derived a formula for the chemometric prediction error in a noise-limited
data set. This formula relates easily measurable experimental parameters to concentration
uncertainty. These parameters are the noise in the data, the signal of the component of
interest at unit concentration and the overlap factor. The overlap factor accounts for the
similarity between the Raman spectrum of the component of interest and the spectra of all
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other moieties present in the sample. By understanding the sources of prediction error,
efforts can be made to reduce it scientifically. Further analytic methods for calculating the
concentration error allow smart experimental design to detect moieties of interest with the
appropriate accuracy. Most importantly, the formula provides a means to predict the smallest
concentrations measurable or the signal to noise ratio necessary to observe a moiety of
interest with the appropriate accuracy.
The prediction error formula presented in this manuscript is derived for OLS
regression. OLS is a simple, yet powerful technique in spectral analysis [Haaland and
Thomas 1988]. It is useful when it is desirable to know the concentrations of all constituents
present in the sample. Although OLS provides detailed information about sample
composition, it requires knowledge of the number of important components in the sample as
well as their Raman spectra. The Raman spectra of the constituents form a set of basis
spectra that are fit to the data in a linear least-squares fashion. In this procedure, the sum of
the squares of the residual, the difference between the model fit and the data, are minimized
to obtain the optimal fit. The amount that each basis spectrum is weighted in order to
achieve this fit, the fit coefficient, provides the concentration of that species.
Although derived for OLS, the formula can readily be extended to other multivariate
techniques, as long as the projection vectors for OLS and the other method of analysis are
similar. For each species in the data set, there exists only one ideal projection vector that
models the data set most accurately. When distinct multivariate methods are applied
successfully, the projection vectors obtained with different techniques should closely
approximate each other. If there are differences between the projection vectors, this
methodology will not provide accurate errors for other multivariate techniques.
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In this section we derive an analytical formula for the prediction error. The
concentration errors given by this formula are compared with those provided by a chi-
squared analysis, a standard but more cumbersome method of calculating error. Next, the
analytical expression is validated through both simulated and experimental data. In the
simulations, excellent agreement is obtained for various levels of noise, as well as different
concentration mixtures. Experimental data, acquired from biological analytes dissolved in
water, also exhibits good agreement with the analytical formula. The ability to predict the
smallest concentrations measurable or the signal to noise ratio necessary to observe a moiety
of interest is an important step towards quantitative biomedical Raman spectroscopy.
IV. F. 2. Sample Preparation and Data Acquisition
IV. F. 2. a) Raman Spectroscopic Measurements
Data were acquired using the macroscopic Raman laboratory system that has been described
in Chapter III. In short, the excitation laser beam, 830 nm, is focused and directed to the
sample via a mirror at a 60 ° angle. The Raman scattered light is detected by a deep-depletion
CCD detector cooled to -110 °C. Raman spectra in this study were acquired with a 500 s.
integration time for basis spectra (1s. per frame x 500 frames) and a 1 s. integration time for
data. Data and basis spectra were collected with the same integration time per frame in order
to remove distortions in intensity caused by the shutter. All data have a spectral resolution of
8 cmrr. The average laser excitation power was 100 mW. Laser power was continuously
monitored by a PDA55 photodiode (ThorLabs) which reads out every 10 ms. Photodiode
values were averaged for the time of data collection.
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IV. F. 2. b) Simulated Data
Basis spectra, collected during this study or previously, were used as 'noiseless' Rarian
spectra to generate simulated data. Both the amount of noise and the basis spectra mixtures
were varied in our simulations. Simulated data corresponding to different concentration
mixtures were obtained from mathematical manipulation of basis spectra. In order to attain
sufficient sample statistics and avoid statistical abnormalities sometimes encountered with
small data sets, 500 sources of noise were added to the basis spectra for each simulation. To
generate uncorrelated spectral noise of varying magnitudes, values returned by the randn
function in Matlab (The Math Works, Inc., Natick, MA) were multiplied by a constant. The
data was then analyzed using OLS and the root mean standard error of prediction (RMSEP)
was compared to the prediction error given by the analytical formula.
IV. F. 2. c) Experimental Data
All chemicals used in this study were purchased from Sigma (St. Louis, MO). Glucose and
creatinine were chosen for experimental data as they are water soluble and do not appear to
interact with one another. Stock solutions of both analytes at 0.4 M were created with
deionized water. These stock solutions were then used to obtain basis spectra as well as
create all mixtures examined in this study. Data were acquired from mixtures of varying
concentrations of glucose and creatinine. For each mixture examined, 500 Raman spectra
were sequentially collected. Errors in reference concentrations of the mixtures, resulting
from fluctuations in pipeting volumes, were probably less than a part in 500. The magnitude
of noise was calculated from the experimental residuals, which were devoid of Raman
features.
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IV. F. 2. d) Data Processing
Data processing was preformed in Matlab 5.31. Spectra were Raman shift frequency-
calibrated using known spectral lines of toluene. Individual spectra were divided by the
photodiode output to correct for fluctuations in laser power. A fifth order polynomial was fit
to the spectra by least-square minimization and subsequently subtracted to remove the slowly
varying background [Brennan et al. 1997]. Cosmic rays were removed through the use of a
derivative filter. Model fitting was performed using a linear combination of basis spectra
with a non-negativity constraint. The fit coefficients, provided by the model, were used to
predict sample concentrations and calculate RMSEP values.
IV. F. 3. Theory
Multivariate methods of analysis provide concentration measurements via a projection vector
that extracts concentration information from the spectral data set, as in Eq. IV.3. We assume
that the noise in the spectral data set is the only source of error. This is an appropriate
assumption for Raman spectra of biological tissues as the shot noise resulting from the
fluorescence background is the dominant source of noise. If we have an accurate B matrix,
the noise in matrix S induces errors in the predicted concentration. The errors can be
expressed:
C+ACnois=(S+SN) -B (IV. 12)
where ACnoise is the matrix of error in concentration and SN is the matrix of noise in the signal
matrix S. By subtracting Eq. IV.3 from Eq. IV.12, we obtain:
ACoise = SN.B (IV.13)
Since the projection vector B is universal, we can insert the projection vector for OLS, given
in Eq. IV.9 into Eq. IV.13 to obtain:
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ACnoise=SNOP T (P.PT)4I (IV.14)
When the number of samples is r, the number of components p and the number of
wavelength points in each spectrum m, S is an rxm matrix, C is an rxp matrix, and P is a pxm
matrix.
In concentration predictions, prediction errors indicate the quality of the approach.
For each sample, the prediction error is the difference between the predicted concentration
and the concentration measured by a reference technique. This is formulated:
Ac Cpredictioni-Creference=J (IV. 15)
where Aci is the prediction error for the i-th sample, Cprediaioni is the predicted concentration
for the i-th sample, and cferfenc, is the concentration measured by the reference technique for
the i-th sample. For a set of samples, the prediction error for a data set is the standard
deviation of the prediction errors for all samples:
AC=(Cprediction,i-refeene,i)/N (IV. 16)
Where AC is the predicted error for the data set and N is the number of samples in the data
set. AC is also called the RMSEP. The prediction accuracy is defined as the ratio of the
mean concentration to the prediction error (C/AC). By using the definition of standard
deviation, the prediction error of the k-th element due to noise, Acnise, is expressed:
ACnoise,k=4diagk(ACnoise ACoi se ) /N (IV. 17)
where diagk(X) is the diagonal k-th element of matrix X. Each diagonal element of the
ACnoiseT . ACnoise is related to the error in the concentration measurement of each component.
Inserting Eq. IV.14 into Eq. IV.17, we obtain:
ACnoiS,k=/diagk{ [(p.pT)l] T.p.SNT SNS.p T (P.PT)-I }/N (IV. 18)
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In the covariance matrix of shot noise, the diagonal elements are dominant. By using an
approximation which neglects the off diagonal elements of the covariance matrix:
SNT-SNn2.NI (IV. 19)
where n is the magnitude of the noise and I is the N-by-N identity matrix, Eq. IV.19 can be
greatly simplified:
ACnOise,kEn4diagk { (p.pT)- } (IV.20)
The matrix of basis spectra, P, contains spectra of pure components at unit concentrations.
We can expand the matrix P so that:
Q=P/s (IV.21)
where Q is the matrix of generalized component spectra and s is the signal intensity. P/s is
purely lineshape without intensity information. The signal intensity is the Euclidean norm of
the spectrum of the k-th pure component [Strang 1988].
s=4diagk(P.PT) (IV.22)
By inserting Eq. IV.21 into Eq. IV.20 we obtain:
Ack-(nldiia gk(Q.QQT))/s (IV.23)
The ratio of concentration ck and error in concentration Ack is the prediction accuracy. In this
equation, there are two significant factors that determine the prediction error: the signal to
noise ratio and the spectral overlap. The first term, s/n, is the signal to noise ratio of the
target chemical. It is determined by the integrated signal (norm) of the component of interest
at unit concentration and the noise (standard deviation) in the data set. The prediction
accuracy increases linearly with the SNR, which has been confirmed previously [Berger and
Feld 1997]. The second term describes the effect of overlap in basis spectra. Q is the matrix
of generalized component spectra, the basis spectra without intensity information. When the
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covariance matrix of Q has dominant diagonal elements, the spectral overlap is small and the
overlap factor is close to 1, its maximum possible value. When the non-diagonal elements
are comparable in magnitude to the diagonal elements, the spectral overlap is significant and
the overlap factor is close to 0. The spectral overlap is affected by the number of basis
spectra as well as their resolution and spectral range. Defining the overlap factor, olf, as:
olf=l/4diagk(Q QT)- (IV.24)
The prediction error equation can be written as:
1 ne ormula assumes tnat the noise in
the spectral data set is the only source
of error and that the basis spectra are
noise free [Koo 1996]. These are
reasonable assumptions, as the shot
noise resulting from the fluorescence
background is the dominant source of
noise in the Raman spectrum of
biological tissues and basis spectra are
Io o oo 2o ooaocollected for long integration times and600 800 1000 1200 1400 1600 1800
Raman Shift (cm-) may be averaged over many samples.
Figure IV.11. Comparison of the experimentally observed
noise (below) and the simulated noise (above). The formula also assumes that the
noise is uncorrelated. In other words, the noise behaves as white-noise, which is evenly
distributed throughout the spectral range. Although our spectra are governed by shot-noise,
the broad fluorescence background we observe with tissue measurements slopes gently
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across our spectral region of interest. This background produces the dominant source of
noise in our data and thus our experimental noise is similar to white- noise. A comparison
between the uncorrelated noise used in the simulations and the experimentally observed noise
is shown in Figure IV. 11.
IV. F. 4. Comparison with Chi-Square Analysis
Chi-square analysis is a well established method for assessing the accuracy of a modeling
technique. We compare this approach with our analytical formula for calculating
concentration error. A simple simulation using only the spectrum of glucose, at a signal of
""A no :s . ...---- J_ To1^ : .: .... 1- --
'.Y I / UTILS, IS exaUmmeu. I ilUS slmula1Ion,
noise is the only source of concentration
error, there is no overlap factor. Shown in
Figure IV.12, is the parabola generated by
constraining the glucose fit to the simulated
spectrum with a magnitude of noise of 0.094 0.5 1 1.5Concentration
counts. The equation of this parabola is Figure IV.12. Chi-square error analysis.
given by X2=(5.6(C-1) 2+1)546, where 546 represents the degrees of freedom in our system.
The error for a one component system, is inversely one half of the second derivative of X2
with respect to C [Bevington and Robinson 1992]. This results in a concentration error of
0.018 comparable with that given by the prediction error formula, 0.019.
Although the chi-square approach provides a means to calculate concentration error,
complex systems with several basis spectra result in time consuming and cumbersome
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analysis. The formula presented in this thesis allows rapid and straightforward calculation of
prediction error and relates this error to quantifiable experimental parameters.
IV. F. 5. Simulated Data
The prediction error expression can easily be validated with simulated data. Further,
simulations are used as a direct comparison with experimental data. Simulations also allow
examination of deviations from the formula due to system drift and data pre-processing
techniques. Both the amount of noise and the basis spectra mixtures were varied in our
simulations.
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Figure IV.13. Results of a simulation with a low amount of spectral overlap. a) Comparison of the RMSEP
of the simulated data (dots) and the prediction error given by the analytical formula (line) as a function of
noise. b) Basis spectra of creatinine and glucose used in the simulation. Shown above are simulated
mixture spectra with the minimum and maximum amounts of noise employed in the analysis.
Figures IV.13 and IV.14 show plots of prediction error as a function of the magnitude
of noise in the data. These Figures correspond to simulations with different degrees of
spectral overlap. The signals have been scaled to be comparable between the two
simulations, shown in Figures IV.13 and IV.14, in order to highlight the effects of noise and
spectral overlap. Figure IV.13a displays results of a simulation using glucose and creatinine
in equal proportions. These two basis spectra have little spectral overlap, seen in Figure
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IV.13b, and thus an overlap factor of 0.99. Also shown in Figure IV.13b are the simulated
mixture data with the maximum and minimum magnitudes of noise examined. The solid
lines in Figure IV.13a represent concentration errors given by the analytical formula while
the dots are the RMSEP values obtained from OLS modeling of the simulated data. The
simulated data exhibits excellent agreement with the prediction error formula. Figure IV.14a
displays results of a simulation using cholesterol and two cholesterol esters, cholesterol
linoleate and cholesterol oleate, in equal proportions. As seen in Figure IV.14b, these three
basis spectra are very similar and have a large amount of spectral overlap. The overlap
factors of cholesterol, cholesterol linoleate, and cholesterol oleate are 0.54, 0.37 and 0.34,
respectively. The concentration errors in this analysis are much larger due to the high degree
of spectral similarity in the system. Again, we obtain excellent agreement between the
simulated data and the analytical formula. As expected, the prediction error increases
linearly with the amount of noise in both simulations. From these simulations, we conclude
that Eq. IV.25 provides accurate error estimates over a wide range of experimental
conditions.
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Figure IV.14. Results of a simulation with a high amount of spectral overlap. a) Comparison of the RMSEP
of the simulated data (dots) and the prediction error given by the analytical formula (line) as a function of
noise. b) Basis spectra of cholesterol, cholesterol linoleate and cholesterol oleate used in the simulation.
Shown above are simulated mixture spectra with the minimum and maximum amounts of noise employed in
the analysis.
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Simulated data sets were constructed to closely mimic the experimental data
presented below. An amplitude of noise consistent with the noise observed experimentally
was used (n=13.4 counts). In this simulation, basis spectra mixtures are varied. Results are
displayed in Table IV.1. Concentrations are obtained by averaging the fit coefficients for all
500 spectra and thus are expected to be within known concentrations by a factor of the
prediction error divided by the square root of 500. Again, these simulations agree well with
the prediction error formula and provide a means for direct comparison with experimental
data.
IV. F. 6. Experimental Data
Experimental results are also displayed in Table IV. 1. Although simulated data confirms the
Simulated Data Experimental Data
Glucose (mM) Creatinine (mM) Glucose (mM) Creatinine (mM) Glucose (mM) Creatinine (mM)
400.0 0.0 400.0 0.3 399.9 0.2
0.0 400.0 0.7 400.0 1.2 400.6
100.0 300.0 100.1 300.0 99.2 299.8
200.0 200.0 200.1 200.0 197.2 201.1
300.0 100.0 300.1 100.0 294.3 100.4
AC.us. Acmaad RMSEPi. RMSEPrj., RMSEPgwe RMSEPctj..
1.5 0.7 1.5 0.4 2.8 0.5
1.5 0.7 0.9 0.7 1.6 1.5
1.5 0.7 1.5 0.7 2.3 1.4
1.5 0.7 1.5 0.7 2.3 1.1
1.5 0.7 1.5 0.7 2.0 0.9
Table IV.1. Comparison of theory, simulations and experimental data of different concentration mixtures of
glucose and creatinine.
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accuracy of the formula, rarely are the ideal assumptions about errors observed with real
data. Many factors cause these deviations such as spectrometer drift and nonlinear response
as well as distortions due to data pre-processing. Experimental data tests our ability to
achieve the theoretical error, provided by the analytical formula, with our instrumentation
and data pre-processing techniques. As expected, the experimental data shows deviations
from the theoretical predictions. However, the experimental results exhibit reasonable
agreement with the analytical formula. The RMSEP is typically within a factor of two of
theory and the absolute concentration is bracketed by the prediction error, although not by
the prediction error divided by 500. It should be noted that the values in Table IV.1.
represent ideal experimental conditions and cannot be reliably collected using our current
instrumentation. Deviations are thought to be due to limitations in the ability to correct for
fluctuations in laser power, pipeting errors and data pre-processing techniques, such as
background and cosmic ray removal. Studies are currently underway to assess the impact of
each of these factors.
IV. F. 7. Conclusions
We have derived an analytical formula that estimates the uncertainty in concentrations
predicted by linear multivariate calibration, particularly OLS. The equation is expressed in
terms of easily quantifiable experimental parameters and is straightforward to evaluate. Both
simulated spectra and experimental data have been used to validate the formula. This
approach allows calculation of the ideal concentration error and is not subject to errors
introduced from reference measurements or data pre-processing techniques. Thus, it
provides insight into the fundamental limits of concentration accuracy as well as the sources
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of prediction error. The ability to predict concentration errors without the use of a reference
measurement is particularly useful in biological systems. With this formula, one can
calculate, a priori, the level of signal to noise ratio needed in order to achieve a specified
level of prediction accuracy. The ability to predict the smallest concentrations measurable or
the signal to noise ratio necessary to observe a moiety of interest is an important step towards
quantitative biomedical Raman spectroscopy.
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Chapter V. Raman Spectroscopic Breast Cancer Diagnosis: Ex
Vivo Studies
We employ Raman spectroscopy to diagnose normal, benign and malignant lesions in
specimens of human breast tissue. In this Chapter, Raman spectra are acquired from intact,
ex vivo samples of human breast tissue. The volume sampled is 1 mm3. Data are fit to a
linear combination of the model basis spectra. The resulting fit coefficients provide insight
into the chemical/morphological makeup of the tissue and are used to develop diagnostic
algorithms. A diagnostic algorithm was developed in the laboratory with samples of fresh-
frozen breast tissue. 130 tissue sites from 58 patients are examined with four pathologies
predominating: normal, fibrocystic change, fibroadenoma, and infiltrating carcinoma. The fit
coefficients corresponding to fat and collagen, represented by two basis spectra, are found to
be the key diagnostic parameters in distinguishing pathologies. The resulting diagnostic
algorithm, that encompasses all data and classifies samples according to specific pathological
diagnoses, yields a sensitivity of 94% (29/31), a specificity of 95% (90/95) and an overall
accuracy of 85% (107/126). The excellent results of this study thus supported moving the
technique to a clinical setting for further testing of its efficacy in breast cancer diagnosis. As
such, we undertook two clinical studies. The first, presented in this Chapter, was preformed
immediately following tissue excision. Motivation and preliminary results are presented in
Section V.B. The second, presented in Chapter VII, demonstrates in vivo data collection.
-169-
V. A. Raman Spectroscopy of Fresh-Frozen Breast Tissue
Breast cancer accounts for nearly one in every three cancers diagnosed in American women.
In the US, approximately 212,600 new cases are diagnosed each year and 40,000 women die
from the disease [NCI 2003]. Mammography is the most common technique for detecting
non-palpable, highly curable breast cancer. It employs x-rays to quantitatively probe density
changes in breast tissue. However, these density changes are not uniquely correlated with the
probability of breast cancer. Because of this, mammography serves as a screening technique
rather than a diagnostic tool. This is evidenced by the fact that 70 to 90% of
mammographically detected lesions are found to be benign upon biopsy [Johnson et al.
1999]. Thus, if a lesion is found through either clinical breast examination or
mammography, the suspect tissue is always biopsied. Breast biopsy is often performed by a
surgical excision to remove the entire lesion, but more recently, a less invasive procedure
using a needle to remove a core sample of the lesion has gained acceptance. Core needle
biopsy removes only a cylinder of tissue typically 1 mm in diameter and several centimeters
long. Although less invasive than surgical biopsy, it requires the collection of at least five
specimens to ensure proper sampling and often as many as twelve cores of tissue are
removed [Lieberman et al. 1994]. As a consequence of the limitations of current techniques,
each year a large number of breast biopsies are performed on lesions ultimately diagnosed as
benign. The complete diagnostic process, from start to finish, may take months and include
multiple biopsies.
The desirability of reducing the number of benign excisional biopsies preformed,
patient trauma, time delay, and the high medical costs associated with biopsy has motivated
researchers to explore minimally invasive optical methods for diagnosing breast lesions. The
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studies below assess the ability of Raman spectroscopy to diagnose breast cancer.
V. A. 1. Sample Preparation and Data Acquisition
All studies involving human tissue were approved by the University Hospitals of Cleveland
and Case Western Reserve University Institutional Review Board and the Massachusetts
Institute of Technology Committee On the Use of Humans as Experimental Subjects.
Samples were provided by the Cooperative Human Tissue Network from surgical biopsy
specimens, reduction mammoplasties and prophylactic mastectomies.
V. A. 1. a) Tissue Preparation
Breast tissue was obtained from patients undergoing surgical procedures. Upon removal, the
samples were snap frozen in liquid nitrogen and stored at -80 °C until examination. Samples
were passively thawed at room temperature and kept moist with phosphate buffered saline
(PBS). Following spectral acquisition, specimens were marked with India ink to indicate the
region sampled, and fixed in formalin. The fixed tissue samples were routinely processed,
paraffin embedded, cut through the marked locations in 5 gm thick sections, and stained with
H&E. The histological slides were examined by an experienced breast pathologist who was
blinded to the outcome of the Raman spectroscopy analysis. A total of 130 spectra from 58
patients was examined using Raman spectroscopy, 49 spectra from normal breast tissue, 47
from benign lesions, 3 from lesions diagnosed as DEH, and 31 from malignant lesions.
Normal tissue from 25 patients was examined (20 female/2 male/3 unknown; 8 Caucasian/12
Black/5 unknown) with a mean age of 34.3 years and an age range of 13-75 years.
Fibrocystic change was studied in 16 patients (10 female/1 male/5 unknown; 5 Caucasian/3
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Black/8 unknown) with a mean age of 40.3 years and an age range of 13-75 years. Tissue
diagnosed as fibroadenoma was obtained from 6 patients (4 female/2 unknown; 2 Black/4
unknown) with a mean age of 20.8 years and an age range of 13-40 years. All malignant
samples were diagnosed as infiltrating carcinoma (10 ductal/2 lobular/1 ductal and lobular/ 1
mammary, not otherwise specified). Infiltrating carcinoma was examined in 16 patients (8
female/8 unknown; 5 Caucasian/2 Black/9 unknown) with a mean age of 57.6 years and an
age range of 46-77 years. DEH was encountered in 2 female Caucasian patients with ages of
11 and 49 years. Patient information was not available for the sample diagnosed as fat
necrosis.
The mean ages and age ranges for the patients in this study reflect the natural age
incidence of each lesion [Rosen and Oberman 1992]. The peak age of incidence for stromal
fibroplasia, the predominant manifestation of fibrocystic change encountered in this study, is
in the 4th and 5th decades (30's and 40's). The peak age of incidence of fibroadenoma is
much earlier, the 3rd decade (20's), and fibroadenomas account for the majority of breast
lesions requiring biopsy in that age range. The peak age of incidence for infiltrating
carcinoma is the 6th decade (50's).
As multiple spectra are collected from each patient, some tissue samples are included
in both the normal and diseased categories, depending on the pathology underlying the exact
region of data collection. Specifically, three tissue samples with fibrocystic change also
contained normal breast tissue, one sample with fibrocystic change also contained DEH, one
sample with fibroadenoma contained adjacent fibrocystic change, and one sample contained
foci of infiltrating carcinoma, fibrocystic change and normal breast tissue.
-172-
__
V. A. 1. b) Raman Spectroscopic Measurements and Data Processing
Data were acquired using the laboratory Raman macroscopic system shown in Figure III.8
and detailed in Chapter III.E.2. Raman spectra in this study were acquired with a 10 to 30
sec. integration time, depending on signal intensity, with a spectral resolution of 8 cm' 1. The
average laser excitation power varied between 100 and 150 mW. No tissue damage was
observed, either grossly or upon histological review.
Data processing was preformed in Matlab 5.30. Spectra were Raman shift frequency-
calibrated using known spectral lines of toluene. A fifth order polynomial was fit to the
spectra by least-square minimization and subsequently subtracted to remove the slowly
varying fluorescence background. Cosmic rays were removed through the use of a derivative
filter. Raman spectra were divided by a white light spectrum to account for the spectral
response of the system. Model fitting was performed using a linear combination of basis
spectra with a non-negativity constraint. The contribution of each basis spectrum, obtained
from the spectral model described in Chapter IV.C, to the breast tissue specimens was
acquired by normalizing the fit coefficients (excluding water, as it is applied exogenously)
such that they sum to one. Logistic regression, a discriminate analysis technique, was used to
correlate the normalized fit coefficients with the diagnostic categories. Using logistic
regression, we examined the diagnostic capability of all combinations of the eight
morphological components in the model. The diagnostic algorithm presented below resulted
in the highest sensitivity and specificity. In order to cross validate our algorithm, we
employed a leave-one-out cross validation analysis. The diagnostic decision lines displayed
in the figures were obtained using logistic regression with all samples included. However, to
obtain the sensitivities and specificities reported in this thesis, logistic regression with leave-
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one-out cross validation was used. These methods of data analysis and diagnostic algorithm
development are detailed in Chapter IV.
Receiver operating characteristic (ROC) curves were generated by changing the
probability threshold for assigning a classification (e.g. changing the probability threshold for
cancer:non-cancer discrimination from 50%:50% to 45%:55%). Sensitivity and specificity
were calculated in increments of 5% from 0% to 100%. Figures display unique values of
sensitivity and specificity.
V. A. 2. Model Fits
To understand the relationship between a tissue sample's Raman spectrum and its disease
state, we examined the contribution of each model basis spectrum to spectra acquired from a
variety of pathologies. Model fits to Raman spectra acquired from normal, benign, and
malignant samples of breast tissue are shown in Figure V.1, along with the corresponding
images from H&E stained sections used to make the histopathologic diagnosis. The India
ink used to record the region of spectral examination can be seen as a black line on the tissue
surface in the H&E images. The difference between the measured spectrum and the model
fit, the residual, is shown below each spectrum in Figure V.1. The lack of significant
structure in the residuals demonstrates that the model accounts for the majority of the
spectroscopic features observed and describes the data well. The fit coefficients, also
displayed in Figure V.1, represent the amount that each model basis spectrum must be
weighted in order to recreate the tissue spectrum, thereby providing insight into the
chemical/morphological makeup of the tissue. Fit coefficients are a function of both the
concentration of a particular model component and its Raman scattering cross-section.
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Figure V.l. Normalized Raman spectra (solid line), model fit(dotted line), residual (shown below), fit
coefficients. and H&E images (size bars 100 Jlm) representative of a) normal breast tissue, b)
fibrocystic change, c) fibroadenoma, and d) infiltrating carcinoma.
Four of the 130 spectra in our data set were excluded from the analysis due to an
insufficient number of samples. Three of these spectra were acquired from samples
diagnosed by histopathology as DEH and one was acquired from a benign sample diagnosed
as fat necrosis. The sample diagnosed as fat necrosis exhibited an intense fluorescent
background. This is most likely due to lipids oxidized during tissue necrosis and, with a
larger data set,may prove to be diagnostic of fat necrosis.
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V. A. 3. Spectral Fit Coefficients and Tissue Morphology
The fit coefficients given by the model and normalized to sum to one, represent contributions
of chemicals and morphological features to the macroscopic tissue spectrum. Figures V.2a
and V.2b display histograms of the average fit coefficients associated with normal breast
tissue, fibrocystic change, fibroadenoma, and infiltrating carcinoma. In Figure V.2a data are
grouped according to pathologic diagnosis while in V.2b data are clustered by model
component. In Figure V.2b, each histogram cluster is normalized to the largest of the four
values in order to highlight the relative changes between pathologies. The amount of water
present in the lesions has been excluded, as PBS is applied to keep the samples moist during
examination, and thus the amount of water is not indicative of disease state. The presence or
absence and variation in concentration of a particular model component between samples
with similar pathologies is displayed in Figure V.2 as error bars which represent the root
mean square of the fit coefficients of the data set.
Examination of the fit coefficients for each pathology provides insight into the
chemical changes associated with breast disease. The fit coefficients of normal breast tissue
indicate that it is primarily composed of fat. Normal breast tissue contains both glandular
and adipose tissues [Rosen 19971. Glandular tissue consists of ducts lined by epithelial cells
and a supportive collagenous extracellullar matrix. Adipose tissue is primarily composed of
adipocytes, cells containing large amounts of cytoplasmic fat, although small quantities of
extracellular matrix are mixed throughout. In most women, ducts represent only a small
volume of the breast tissue and thus our model accurately characterizes normal breast tissue
as predominately comprised of fat with small contributions from collagen. Contributions
from fat are particularly prominent because relative to most other model components,
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adipose tissue has a large Raman scattering cross-section. The model does not show a
contribution from epithelial cells to normal breast tissue. However, this does not mean that
the normal samples do not contain epithelial cells, simply that they are not present in
sufficient quantities or with a strong enough Raman scattering cross-section to appreciably
contribute to the macroscopic Raman spectrum. The fit coefficients of the breast lesions
indicate a markedly different chemical/morphological composition than that of normal breast
tissue. First, the amount of collagen increases in all abnormal breast pathologies. This is
consistent with known breast pathology, as lesion formation is often accompanied by
fibrosis, a scarring process characterized by an increased stromal component, and thus by
both proliferation of fibroblasts and accumulation of collagen. The relative increase in
collagen is most pronounced in fibrocystic change, a benign condition which can manifest
itself as fibrosis, adenosis (increase in the number of ductules) or cyst formation (dilation of
ducts and lobules with fluid). Each of these changes can occur with or without the presence
of the others. In the fibrocystic lesions examined in the present study an increase in the fit
coefficients of the collagen, epithelial cell cytoplasm and cholesterol-like basis spectra
replace the large contribution from fat in normal breast tissue.
Fibroadenoma is a benign tumor of a completely different lineage than all other
lesions in this study [Houssami et al. 2001]. It is most closely related to phylloides tumors,
the malignant counterpart of which is not carcinoma but cystosarcoma phylloides, in which
the stroma rather than the epithelium is malignant. Lesions diagnosed as fibroadenoma
show an increased contribution from collagen due to fibroblast proliferation and
accumulation of collagen that results in expansion of the stroma [Cotran et al. 1989]. They
also show an increased contribution from both the cell nucleus and epithelial cell cytoplasm
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Figure V.2. Histogram displaying the average composition of samples diagnosed as normal (hatched),
fibrocystic change (gray), fibroadenoma (striped), and infiltrating carcinoma (solid). A) Data are
grouped according to pathologic diagnosis. B) Data are clustered by model component and each cluster
is normalized to the largest of the four values.
basis spectra as a consequence of the number of fibroblasts and epithelial cells present.
Similar to fibroadenoma, lesions diagnosed as intiltrating carcinoma show an
increased contribution from collagen, in this case due to fibroblast proliferation in response
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to stromal invasion by the malignant epithelial cells [Cotran et al. 1989]. The fit coefficients
of such lesions also display an increase in the amount of epithelial cell cytoplasm and cell
nucleus. Both infiltrating carcinomas and fibroadenomas exhibit large increases in the
number of cells relative to other lesions. However, a key signature of carcinoma is
enlargement of cell nuclei, and thus a higher nuclear to cytoplasm (N/C) ratio than in benign
conditions. Nuclear enlargement and atypia are hallmarks of cancer, thus the N/C ratio is a
diagnostic criterion routinely used by pathologists [Elston and Ellis 1991; Hoda and Rosen
2002]. In our studies, the spectroscopic parameter characterizing the N/C ratio is obtained by
dividing the fit coefficient of the cell nucleus basis spectrum by the fit coefficient of the
epithelial cell cytoplasm basis spectrum. Fibrocystic change has a mean N/C parameter of
0.01, fibroadenoma 0.04, and infiltrating carcinoma a much higher mean N/C parameter of
0.08.
Further differences between lesions diagnosed as fibroadenoma and infiltrating
carcinoma exist in the amount of fat present. Samples diagnosed as fibroadenoma have less
fat than those diagnosed as infiltrating carcinoma, as can be seen in Figure V.2. This is
because fibroadenoma is an expansile lesion that grows by pushing the fatty breast tissue
aside. Infiltrating carcinoma, on the other hand, infiltrates in between the fat cells, so some
adipocytes will be retained within the carcinoma.
Other breast pathologies are much less common and were not represented in the study
specimens. Three samples diagnosed as DEH have not been included in the diagnostic
analysis due to their small number. DEH is a proliferation of the ductal epithelium which
confers a significantly increased risk for breast cancer [Page and Dupont 1990]. The mean
N/C parameter of these three lesions is 0.05, intermediate between those of normal breast and
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infiltrating carcinoma, indicating the potential for detecting pre-cancerous changes in the
breast using Raman spectroscopy.
The histograms in Figure V.2 exhibit relatively little contribution from the two types
of calcifications found in breast tissue, calcium hydroxyapatite and calcium oxalate
dihydrate. Due to their diagnostic importance, microcalcifications in fresh breast tissue are
not typically made available for scientific research, and thus our study did not include lesions
containing microcalcifications. For this reason, we undertook a parallel study to examine the
diagnostic information contained in Raman spectra of microcalcification, discussed in
Chapter VI. Although small contributions from microcalcifications can be seen in some of
our data, as this technique moves into a clinical setting microcalcifications will be
encountered more frequently and in greater abundance.
Table V.1 displays the fit coefficient error associated with each model component.
Model Signal OLF AcnDM Acfimc cbmges Afibo ccr
N=0.0091 N=0.0406 N=0.0113 N=0.0337
Calcium Oxalate Dihydrate 2.68 0.96 0.004 0.016 0.004 0.013
Calcium Hydroxyapatite 2.85 0.93 0.003 0.015 0.004 0.013
Cholesterol-like 4.48 0.28 0.007 0.032 0.009 0.027
Water 7.04 0.64 0.002 0.009 0.003 0.008
1-Carotene 3.67 0.84 0.003 0.013 0.004 0.011
Fat 4.97 0.40 0.005 0.020 0.006 0.017
Collagen 8.12 0.45 0.003 0.011 0.003 0.009
Cell Nucleus 5.96 0.69 0.002 0.010 0.003 0.008
Epithelial Cell Cytoplasm 6.32 0.31 0.005 0.021 0.006 0.017
Table V.I. Fit coefficients errors for the fresh-frozen Raman breast data.
The method used for calculating prediction error is presented in section IV.F. Errors are
broken down by diagnosis, as spectra corresponding to different pathologies contained
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dissimilar amounts of noise. It is important to note that these errors represent the lowest
attainable accuracy and are not achieved experimentally.
V. A. 4. Diagnostic Algorithm
The fit coefficients not only provide insight into the composition of the tissue but are also
used to develop diagnostic algorithms. The morphological changes that characterize breast
disease are manifested as chemical changes that can be reproducibly assessed. We begin
with a pairwise analysis in which cancerous specimens are separately distinguished from
normal breast tissue, fibrocystic change, and fibroadenoma, respectively. We then employ
the insight gained through these individual comparisons to develop a single diagnostic
algorithm encompassing all pathologies. Logistic regression was used to correlate the fit
coefficients, obtained via modeling, with the diagnostic categories provided by a pathologic
examination. A leave-one-out cross validation analysis was also employed. In each case, the
diagnostic power of all 8 model
components, alone and in
combination, was assessed.
Normal breast and
infiltrating carcinoma can be
differentiated with 100%
sensitivity and 100% specificity
using the fit coefficients for
collagen and fat, FC(Coll) and
0.7
0.6
0.5
0.4
2 0.3
0.2
0.1
n
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9
FC(Fat)
Figure V.3. Diagnostic plot illustrating the excellent
separation between infiltrating carcinoma (squares) and normal
breast tissue (stars).
FC(Fat), respectively. Figure V.3
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shows a scatter plot of FC(Coll) and FC(Fat) corresponding to each of the normal and
malignant samples examined. The decision line for separating normal and malignant
samples is given by FC(Coll)=-1.71FC(Fat)+1.11. These two parameters result in the ability
to separate normal and malignant tissues and they are consistent with known architectural
changes that accompany breast disease. The normal data point that lies closest to the
diagnostic decision line was acquired from a specimen that contains adjacent fibrocystic
change. This may explain the increase in collagen and reduction in fat seen in this sample
compared to other normal samples. Although the diagnostic algorithm depicted in Figure
V.3 results in exact separation, any other model component, when combined with fat, also
provides perfect discrimination. This is because our model characterizes normal breast tissue
as composed almost exclusively of fat.
Figure V.4 displays the diagnostic algorithm resulting in the highest sensitivity and
specificity for distinguishing fibrocystic change from infiltrating carcinoma. Again, we are
: O·
U .
. 0 * "
0 0.1 0.2 U.3 0.4 0.5 U.b U.7 O.i O.
FqFat)
Figure V.4. The diagnostic algorithm for infiltrating
carcinoma (squares) and fibrocystic disease (diamonds).
able to separate fibrocystic change
and malignant lesions based on the
amount of collagen and fat. In this
case, the equation for the decision
line is FC(Coll)=-0.71FC(Fat)+0.51.
Based on these two parameters, we
are able to correctly predict 29 out of
31 malignant samples and 29 out of
31 samples diagnosed as fibrocystic
change. This results in a sensitivity
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of 94%, a specificity of 94%, and a positive predictive value of 94%. Although clear
differences in the spectroscopic parameter characterizing the N/C ratio exist between
fibrocystic change and infiltrating carcinoma, inclusion of the fit coefficients for epithelial
cell cytoplasm and cell nucleus did not improve the sensitivity and specificity of the
diagnostic algorithm. The sensitivity and specificity for differentiating fibrocystic change
and infiltrating carcinoma based solely on the N/C parameter are 65% and 90%, respectively.
Figure V.5 displays a scatter plot of the diagnostic algorithm resulting in the highest
sensitivity and specificity for differentiating fibroadenoma and infiltrating carcinoma. In this
case, fat is the only diagnostic parameter. Collagen is no longer diagnostic in differentiating
between these two data sets. Using the amount of fat, the two pathologies can be
differentiated with a sensitivity of 90%
and a specificity of 80%. Thus, the
algorithm provides a positive predictive .
,0.35 ·
value of 90% and accurately predicts 28 _
L·L .0.25 .
out of 31 malignant samples and 12 out .
0.15
of 15 samples diagnosed as
0.050 0.10 0.20 0.30 0.40
fibroadenoma. The equation for the
FC(Fat)
Figure V.5. The diagnostic algorithm for infiltrating
decision line is given by FC(Fat)=0.03. carcinoma (squares) and fibroadenoma (triangles).
As discussed above, fibroadenoma and infiltrating carcinoma have distinct natural
ages of incidence. Thus, age could provide useful information to enhance the diagnostic
algorithm. Unfortunately, in the present study we did not have patient information for all of
our samples. In future studies, it will be interesting to see the extent to which the inclusion of
patient age improves the diagnostic algorithm. Based on insight gained through the pairwise
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diagnostic comparisons, a single diagnostic algorithm encompassing all pathologies was
developed. The algorithm examines all the data simultaneously and separates samples
according to specific pathological diagnoses. As noted from the diagnostic algorithms
displayed in Figures V.3, V.4, and V.5, all pathologies can be separated based on the same
two parameters, fat and collagen. Further, in our studies there are clearly two tissue types
with relatively low fat and collagen values and two pathologies with higher values. From
this observation, the samples were initially divided into two groups based on their collagen
and fat contents. The equation for the decision line, drawn by logistic regression, is
FC(Coll)=-0.80FC(Fat)+0.55. The inclusion of additional model components did not
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FC(Fat)
Figure V.6. Diagnostic algorithm displaying the fat and collagen content for all pathologies
encountered in this study. Normal (gray stars), Fibrocystic Change (diamonds), Fibroadenoma
(triangles), Infiltrating Carcinoma (squares), Ductal Epithelial Hyperplasia (white stars).
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improve the accuracy of this separation. The resulting two clusters, one containing
infiltrating carcinoma and fibroadenoma lesions, which have relatively less collagen and fat,
and the second composed of normal and fibrocystic lesions, were then further subdivided.
Fibrocystic change and normal tissue were separated based on their fat and collagen contents.
The decision line for separating fibrocystic change and normal tissue is given by FC(Coll)=-
0.06FC(Fat)+0.10. As in Figure V.5, fibroadenoma and infiltrating carcinoma are separated
based on their fat content. The decision line for this separation, FC(Fat)=0.02, is based on a
different probability threshold than that in the individual comparison of fibroadenoma and
infiltrating carcinoma. This was done because of the prognostic importance of correct cancer
diagnosis and was accomplished by moving to a different location on the ROC curve.
Pathology Normal Fibrocystic Fibroadenoma Infiltrating
Dagnosis Change Carcinoma
Diagnosis \ (49 spectra) (31 spectra) (15 spectra) (31 spectra)
Normal 45 1 0 0
Fibrocystic Change 4 22 0 0
Fibroadenoma 0 7 11 2
Infiltrating Carcinoma 0 1 4 29
Table V.2. Comparison of pathologic diagnosis with that of the Raman diagnostic algorithm. The Raman
diagnostic algorithm results in an overall accuracy of 85% (107/126).
Figure V.6 displays a scatter plot of FC(Coll) and FC(Fat) for all pathologies
encountered in this study, as well as the decision lines that separate samples according to
diagnoses. Table V.2 compares the pathologic diagnosis with that of the Raman diagnostic
algorithm for our data set. The algorithm results in a sensitivity for detecting infiltrating
carcinoma of 94% (29/31), a specificity of 95% (90/95), and an overall accuracy of 85%
(107/126). Also shown in Figure V.6 are the fat and collagen fit coefficients for the three
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samples diagnosed as DEH. The sample diagnosed as fat necrosis was not analyzed due to a
poor SNR resulting from excessive shot noise generated via the intense fluorescent
background. In future applications, this diagnostic algorithm will be used in a prospective
manner, and the fit coefficients of collagen and fat simply plotted to determine where they
fall in the diagnostic plane.
Figure V.7 displays a ROC curve, shown as a dotted line, that illustrates the ability of
Raman spectroscopy to separate lesions diagnosed as infiltrating carcinoma from benign and
normal breast tissues. A ROC curve illustrates the tradeoff between sensitivity and
specificity by plotting the true positive rate against the false positive rate for the different
possible probability thresholds of a diagnostic test. The closer the curve comes to the 45-
degree diagonal, shown as a dashed line in Figure V.7, the less accurate the diagnostic test.
B This ROC curve clearly illustrates
the ability of Raman spectroscopy
to accurately diagnose breast
*r. 0., focancer and demonstrates how the
0. diagnostic scheme can be adjusted
0.2 //// to obtain the desired degree of
sensitivity at the cost of specificity.
0 0.2 0.4 0.6 0.8 1
1-Specificity From a practical clinical
Figure V.7. Receiver operating characteristic (ROC) curves
illustrating the ability of Raman spectroscopy to separate standpoint, Raman spectroscopy is
lesions diagnosed as infiltrating carcinoma from benign and
normal breast tissues, dotted line and lesions which need to be well suited to identify lesions that
excised (infiltrating carcinoma and fibroadenoma) from those
which don't (normal and fibrocystic change), solid line. need to be excised. Malignant
lesions such as infiltrating carcinoma need to be excised, whereas most benign lesions, such
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as fibrocystic change, do not. However, fibroadenomas, although benign, continue to grow
and produce significant morbidity unless excised [Kahn and Badve 2001]. Results using the
overall diagnostic algorithm to differentiate infiltrating carcinoma and fibroadenoma (lesions
to be excised) from fibrocystic change and normal breast tissue are displayed in Figure V.7
as a solid line. In this case, sensitivity and specificity, identified on the ROC curve by the
letter A, are 98% and 94%, respectively. This corresponds to a positive predictive value of
90% and a negative predictive value of 99%, indicating that if a lesion is not excised there is
only a 1% chance that it is cancerous. Alternatively, a different threshold can be set in which
all malignant lesions are excised, identified in Figure V.7 with the letter B. Using this
threshold, 10 out of every 100 benign lesions examined will be unnecessarily removed. This
results in a positive predictive value of 85% and a negative predictive value of 100% in this
small data set, signifying that if a lesion is not excised there is no chance that it is malignant.
This indicates that Raman spectroscopy has the potential to safely reduce the number of
excisional biopsies performed on lesions eventually diagnosed as benign.
V. A. 5. Effect of Age/Menopause on Diagnostic Algorithm
Female breast undergoes substantial biochemical alterations at menopause. Specifically, a
large amount of collagen is converted to fat, resulting in breast tissue that is overall less
dense on mammography. Because our diagnostic algorithm is based on the fat and collagen
content as assessed by Raman spectroscopy, we investigated trends in these two parameters
as a function of patient age (female breast density typically decreases with age). It is notable
that although the normal samples span a wide age range, our technique characterizes them as
predominately composed of fat. As explained above, this is because the Raman scattering
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cross-section is much higher for fat than for collagen. Thus, we only observe significant
contributions from collagen when it is present in large quantities, for instance in the setting of
dense stromal fibrosis. To rigorously confirm that our diagnostic algorithm is not influenced
by patient age, we examined the correlation between the spectroscopic parameter
characterizing the fat to collagen ratio, obtained by dividing FC(Fat) by FC(Coll), and age.
Fibroadenoma was excluded from this analysis because it is a juvenile disease and has a
much different age range than the other pathologies in our study. We found a correlation
coefficient of -0.140 for the spectroscopic parameter characterizing the fat to collagen ratio
and age. We also examined the relationship between the fat to collagen ratio and age within
individual pathologies. For invasive carcinoma, fibrocystic change, and normal samples, we
obtained correlation coefficients of -0.104, 0.137, and -0.025, respectively. Thus, we do not
observe age dependent trends in the fat and collagen contents of our data. Our results
indicate that Raman spectroscopy is much less sensitive to breast density and menopausal
status than many other optical techniques.
V. B. Raman Spectroscopy of Fresh Breast Tissue
The excellent results of our studies on fresh-frozen tissue demonstrated that Raman
spectroscopy can classify breast lesions with high accuracy. The study thus supported
moving the technique to a clinical setting for further testing of its efficacy in breast cancer
diagnosis. As a result, we expanded our studies to the examination of fresh breast tissue.
Data was collected in the University Hospitals of Cleveland pathology suite, typically within
half an hour of surgical tissue excision. The main goals of this study are to validate our ex
vivo diagnostic algorithm on a large data set which closely mimics an in vivo environment
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and to elucidate differences between the Raman spectra of fresh-frozen and fresh breast
tissues. Additional goals include expanding our diagnostic algorithm to include pathologies
not seen in our ex vivo laboratory data and targeting microcalcifications.
V. B. 1. Sample Preparation and Data Acquisition
This study was carried out in collaboration with Drs. Fitzmaurice, Shenk, Wang, and Klein at
University Hospitals of Cleveland and Case Western Reserve University. All studies
involving human tissue were approved by the University Hospitals of Cleveland and Case
Western Reserve University Institutional Review Board and the Massachusetts Institute of
Technology Committee On the Use of Humans as Experimental Subjects. Informed consent
was obtained from all subjects prior to the surgical procedures.
V. B. 1. a) Tissue Preparation
Breast tissue was obtained from patients immediately following surgical lumpectomy, re-
excision, or mastectomy procedures. Upon removal, the samples were sectioned per the
normal pathology protocol and Raman spectra acquired from locations chosen by the
pathologist. The number of spectra taken per patient was extremely variable, depending
primarily on the pathological manifestations grossly visible. Because it was not possible to
turn the lights off in the pathology suite, samples were placed in a light tight box prior to
examination. Following spectral acquisition, specimens were marked with India ink to
indicate the region sampled, and fixed in formalin. The fixed tissue samples were routinely
processed, paraffin embedded, cut through the marked locations in 5 gm thick sections, and
stained with H&E. The histological slides were examined by an experienced breast
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pathologist who was blinded to the outcome of the Raman spectroscopy analysis. A total of
150 spectra from 25 patients was examined using Raman spectroscopy, 42 spectra from
normal breast tissue, 82 from benign lesions, and 26 from malignant lesions. Benign
pathologies consisted of 73 fibrocystic lesions and 9 fibroadenoma tumors. Malignant
pathologies consisted of 6 infiltrating ductal carcinomas (IDC) and 20 lesions diagnosed as
ductal carcinoma in situ (DCIS). DCIS is a pathology we did not encounter in our fresh-
frozen studies.
V. B. 1. b) Raman Spectroscopic Measurements and Data Processing
Data were acquired using the clinical Raman system and Raman optical fiber probe shown in
Figure III.9 and detailed in Chapter III.E.3. Raman spectra in this study were acquired with a
10 to 30 s. integration time, depending on signal intensity, and a spectral resolution of 8 cmnf.
The average laser excitation power varied between 100 and 150 mW. No tissue damage was
observed, either grossly or upon histological review.
At the start of each day, calibration data were collected for spectral corrections.
Wavenumber calibration was established with a spectrum of 4-acetamidophenol. Chromatic
intensity variations were corrected by collecting the spectrum of a tungsten white light source
diffusely scatted by a reflectance standard (BaSO4). The remaining probe background
generated in the optical fibers was characterized by collecting the scattered excitation light
off of a roughened aluminum surface. This background was optimally subtracted from the
data in an iterative loop by using a scaling factor related to the tissue's optical properties
[Motz et al. 2004]. The tissue fluorescence background was modeled with a sixth-order
polynomial. Finally, the data was fit via non-negativity constrained least-squares
minimization with the spectral model developed previously for the diagnosis of breast cancer
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[Shafer-Peltier et al. 2002]. In order to accurately model the data, spectra of probe
components, epoxy and sapphire, were included in the model. Also, a background acquired
in the light tight box with no sample was included in the model. This background mainly
consisted of features due to light contamination. In accordance with our initial diagnostic
study, the contribution of each basis spectrum, obtained from the spectral model described in
Chapter IV.C, to the breast tissue specimens was obtained by normalizing the fit coefficients
such that they sum to one. However, in the present analysis, the two types of
microcalcifications, calcium hydroxyapatite and calcium oxalate dihydrate, were excluded
from this normalization as these species were not present in the tissue samples used for the
diagnostic algorithm development. We also observed increased contributions from
cholesterol-like in this data set and thus this component was excluded from normalization.
V. B. 2. Agreement with Fresh Frozen Diagnostic Algorithm
Data was analyzed with the diagnostic algorithm developed on fresh-frozen tissues, shown in
Figure V.8. Application of this algorithm in a prospective manner resulted in a sensitivity of
83%, correctly diagnosing 5 of 6 IDCs, and a specificity of 89% for separating cancerous
Pathology Normal Fibrocystic Fibroadenoma Infiltrating
Raman Diagnosis Change Carcinoma
Diagnosis (42 spectra) (73 spectra) (9 spectra) (6 spectra)
Normal 38 13 0 0
Fibrocystic Change 4 54 0 0
Fibroadenoma 0 0 1 1
Infiltrating Carcinoma 0 6 8 5
Table V.3. Comparison of pathologic diagnosis with that of the Raman diagnostic algorithm. The Raman
diagnostic algorithm results in an overall accuracy of 75% (98/130).
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Figure V.8. Diagnostic algorithm displaying the fat and collagen content for all pathologies encountered
in this study. Normal (stars), Fibrocystic Change (diamonds), Fibroadenoma (triangles), Infiltrating
Carcinoma (squares).
lesions from benign and normal tissues. This corresponds to an overall accuracy of 75%,
(98/130). As expected, the prospective use of the diagnostic algorithm yields results,
summarized in Table V.3, which are degraded when compared with the initial performance
of the diagnostic algorithm. The reduction in sensitivity in the fresh tissue studies may be
due to the small number of cancerous samples encountered. Although the algorithm only
incorrectly diagnoses 1 malignant sample, this results in a sensitivity of 83% due to the
dearth of cancerous data points in this study. The overall accuracy may be affected by
encountering a broader range of manifestations of each pathology. For example, in the fresh-
frozen studies, the predominant manifestation of fibrocystic change in our data set was
stromal fibrosis. In the clinical study of fresh tissue, all three manifestations of fibrocystic
change were observed, stromal fibrosis, cyst formation, and adenosis. This increase in tissue
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heterogeneity may contribute to the degradation of the overall accuracy in the fresh tissue
studies. Results may also have been degraded by a lower SNR in this data set. Most notably,
a reduced SNR may have affected the diagnosis of fibroadenoma because its area in the
diagnostic plane is smallest. Thus slight variations in FC(Fat) will result in misdiagnosis.
This effect may be evident in Figure V.8 as the 3 samples diagnosed as fibroadenoma that lie
slightly to the right of the diagnostic line. Analysis using the equation derived in Chapter IV
will shed light on the effect of error on algorithm performance.
Although the performance of the diagnostic algorithm is degraded when it is used
prospectively to distinguish cancerous and non-cancerous lesions, it remains quite robust
when used to identify those lesions which need to be excised. Prospective application of the
diagnostic algorithm to differentiate infiltrating carcinoma and fibroadenoma (lesions to be
excised) from fibrocystic change and normal breast tissue results in a sensitivity of 100%
(15/15) and a specificity of 95% (109/115). As in the fresh-frozen studies, this signifies that
if a lesion is not excised there is no chance that it is malignant.
This initial analysis excludes
0.7
patients who have undergone pre- 0.6
operative chemotherapy or are 0.5
0.4
undergoing re-excision surgery. Such o
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patients harbor pathological tissue 02
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is used as a neo-adjuvant therapy to Figure V.9. Scatter plot displaying the fat and collagen
content for data acquired from patients who underwent
pre-operative chemotherapy. Normal (stars), Fibrocystic
shrink large tumors. Tumor Change (diamonds), Infiltrating Carcinoma (squares).
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replacement by loose fibrosis is the most common pathologic event resulting from neo-
adjuvant chemotherapy [Moreno et al. 2002]. An increase in collagen is seen in all samples
from patients receiving pre-operative chemotherapy, shown in Figure V.9. A similar,
although less pronounced trend in collagen is seen in patients undergoing a re-excision
surgery, seen in Figure V.10. Pathological changes induced by surgical procedures depend
on the interval between the initial and re-excision surgeries. Variability in this interval may
account for the heterogeneity in fit coefficients observed in the re-excision specimens. Early
pathological findings are local
hemorrhage, disrupted tissue and
epithelial cell displacement, whereas,
fibrosis, fat necrosis and
inflammatory reaction are observed
later in time [Tardivon et al. 2002].
6_
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FC(Fat)
Figure V.10. Scatter plot displaying the fat and collagen chemotherapy and prior surgery are
content for data acquired from patients undergoing re-
excision surgeries. Normal (stars), Fibrocystic Change
(diamonds), Infiltrating Carcinoma (square).
these patients may be treated separately and a distinct diagnostic algorithm developed.
V. B. 4. Diagnostic Algorithm Encompassing New Pathologies
In this study, we acquired Raman spectra from 20 lesions diagnosed as DCIS. Although
DCIS was not a pathology encountered in our laboratory studies, the spectra were analyzed
with the diagnostic algorithm developed on fresh-frozen tissues, shown in Figure V.11. The
DCIS samples are widely distributed throughout the diagnostic plane. It is clear that
-194-
8
U.
0.6
0.5
0.4
( 0.3
0.2
0.1
0
FC(Fat)
Figure V.11. Scatter plot displaying the fat and collagen content for
all pathologies encountered in this study. Normal (stars), Fibrocystic
Change (diamonds), Fibroadenoma (triangles), Infiltrating Carcinoma
(squares). Ductal Carcinoma In Situ (circles).
additional model
parameters need to be
investigated for the
accurate diagnosis of DCIS.
Studies to incorporate
additional fit coefficients
and intensity information
into the diagnostic scheme
are currently underway.
V. B. 5. Stereotactic
Needle Biopsy to Target
Microcalcifications
In the ex vivo study, the real-time Raman system was used to acquire data from
microcalcifications contained in stereotactic needle biopsies of mammographically
suspicious breast lesions. Microcalcifications are a feature of particular diagnostic
significance on a mammogram and often geographically identify the location of the most
important abnormality within the breast to be targeted at biopsy IJohnson et al. 19991. Due
to their diagnostic importance, microcalcifications in fresh breast tissue are not typically
made available for scientific research. Thus, our laboratory studies on the use of Raman
spectroscopy to diagnose breast disease have not included lesions containing
microcalcifications Haka et al. submitted . For this reason, we investigated the ability of
Raman spectroscopy to diagnose microcalcifications by performing confocal microscopy of
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microcalcifications in thin sections of deparaffinized fixed breast tissue. detailed in Chapter
V I IHaka et al. 20021. This study resulted In high sensitivities and specificities and
demonstrated the diagnostic potential of Raman spectroscopy to differentiate
microcalcifications found in benign and malignant breast lesions that cannot currently be
distinguished by mammography. Our recent studies have focused on extension of these
results to unfixed microcalcifications contained in freshly excised breast tissue.
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Figure V.12. a) Specimen radiograph of a stereotactic needle biopsy of the breast with
microcalcilications (circle). 0) Raman spectrum acquired from the necdle biopsy c) Raman spectrum
also acquired from the tissue demarcated by a box in ligure V.12a. The spectrum exhibits features
indicativc of calcium hydroxyapatitc, particularly a peak at 960 em- 1 (arrow). d) Histopathology
corresponding to the Raman spectrum with a large contrihution from calcium hydroxyapatite showing
microcalcifications (arrow) within a benign lesion.
In our clinical studies of fresh tissue. stereotactic biopsies are examined with the real-
time Raman system. allowing us to acquire Raman spectra from microcalcifications in fresh
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breast tissue. Stereotactic biopsy, often used when mammography shows a cluster of
microcalcifications, is performed under x-ray guidance using intersecting coordinates to
ensure precise sampling of a mammographic abnormality. Radiography is routinely
performed on these needle biopsy samples to ensure that the microcalcifications seen at
mammography were sampled during the biopsy. Thus, by comparison with the
corresponding radiograph, the approximate location of microcalcifications within the sample
can be ascertained. Acquisition and real-time analysis of a Raman spectrum allows
pinpointing the exact position of the microcalcifications. Figure V.12a is a specimen
radiograph of a stereotactic biopsy that exhibits microcalcifications. A Raman spectrum
obtained from this specimen in the approximate region of the microcalcifications is shown in
Figure V.12b. Also shown are the real-time model fit, residual and relevant fit coefficients.
The lack of significant contribution from calcium hydroxyapatite or calcium oxalate
dihydrate, the two types of microcalcification found in breast, indicates that the probe is not
placed directly over the microcalcifications. By translating the probe along the biopsy
specimen and examining the calcification contribution at various locations, we were able to
identify the exact position of the microcalcifications and collect a Raman spectrum. The
Raman spectrum, acquired from the microcalcification highlighted by a small box in Figure
V.12a, is shown in Figure V.12c. The fit coefficient of 21% for calcium hydroxyapatite
signifies the presence of a type II microcalcification. This is evident in the spectrum as a
band at 960 cm, the V1(PO4 ) totally symmetric stretching mode. We also see contributions
from fat and collagen. Histopathology, shown in Figure V.12d, confirmed the presence of
microcalcifications at this site. The green ink in Figure V.12d indicates the region of data
acquisition for spectrum V.12b while the orange ink marks the position where spectrum
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V.12c was collected. As the diagnostic importance of microcalcifications has been shown in
our previous Raman microscopy studies, their inclusion in our current analysis should result
in increased sensitivity and specificity. The real-time Raman system provides a means to
obtain data from microcalcifications in fresh biopsy samples, allowing us to couple the
results from our Raman microscopy studies of microcalcifications with our ex vivo diagnostic
algorithm to create a powerful new tool for the diagnosis of benign and malignant breast
lesions.
V. B. 6. Future Directions
Upcoming studies will focus on further analysis of the clinical data set containing Raman
spectra of fresh tissues. New diagnostic algorithms will be developed which incorporate
additional model parameters, microcalcifications, and intensity information. These
algorithms will be used to identify DCIS and possibly different manifestations of a single
pathology. The incorporation of microcalcifications and intensity information are expected
to strengthen the performance of our diagnostic algorithms. The Raman optical fiber probe
provides a reproducible geometry for data collection, allowing examination of spectral data
that has not been normalized. Ultimately, we strive to obtain quantitative information by
incorporating the Raman scattering cross-sections of the model components into the data
analysis routine. Studies to extract quantitative morphological information will correlate fit
coefficients with the percent morphology as determined via pathology. This information can
also be used to provide insight into the lower detection limits of the approach.
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V. C. Summary
In this chapter our Raman spectroscopic model of breast tissue is used to characterize the
chemical/morphological composition of different breast pathologies. We analyze Raman
spectra from a range of ex vivo tissue specimens and pathologies to assess the ability of the
model to predict breast tissue disease state. The data demonstrate the efficacy of the model
in both diagnosing breast disease and in understanding the chemical/morphological variations
associated with disease progression. The results indicate that the technique has the potential
to be applied in vivo to accurately classify breast lesions.
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Chapter VI. Raman Microscopy of Microcalcifications
In our ex vivo studies, we see relatively little contribution from the two types of calcifications
found in breast tissue and included in our spectral model, calcium hydroxyapatite and
calcium oxalate dihydrate. Microcalcifications are a feature of particular diagnostic
significance on a mammogram and often geographically target the location of the most
important abnormality within the breast [Johnson et al. 1999]. Due to their diagnostic
importance, microcalcifications in fresh breast tissue are not typically made available for
scientific research, and thus our studies did not include lesions containing
microcalcifications. For this reason, we have investigated the diagnostic power of Raman
microscopy of microcalcifications in thin sections of deparaffinized fixed breast tissue [Haka
et al. 2002]. Using PCA, we were able to distinguish microcalcifications occurring in benign
and malignant ducts with a sensitivity of 88% and a specificity of 93%. This is a significant
improvement over current X-ray mammography techniques, which are unable to reliable
differentiation microcalcifications in benign and malignant lesion.
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VI. A. Microcalcifications
Two major types of microcalcifications are found in breast tissue. Type I deposits consist of
calcium oxalate dihydrate, a birefringent colorless crystal, while type II deposits are
composed of calcium phosphates, mainly calcium hydroxyapatite. Type II
microcalcifications are typically basophilic on light microscopic examination of H&E stains
and nonbirefringent.
There is no reliable way to distinguish between type I and type II microcalcifications
in a clinical mammogram, but the type of microcalcification is thought to correlate with
disease [Radi 1989]. Calcium oxalate dihydrate crystals are most frequently seen in benign
ductal cysts and are rarely found in foci of carcinoma, while calcium phosphate deposits are
most often seen in proliferative lesions, including carcinoma. This distribution is consistent
with the hypothesis that type I microcalcifications are a product of secretions, whereas type II
calcium deposits result from cellular degradation or necrosis.
Type II microcalcifications are estimated to occur two to three times more frequently
than type I [Rosen 1997]. Nonpalpable type II microcalcifications discovered by
mammography frequently geographically target the location of the most important
abnormality within the breast [Johnson et al. 1999]. As such, calcifications are a key
component that radiologists look for in a mammogram. Several algorithms have been
proposed that attempt to correlate parameters such as the shape, size, number, and roughness
of mammographically detected microcalcifications with disease [Markopoulos et al. 2001;
Betal et al. 1997; Shen et al. 1994]. However, these studies often exclude cases due to dark
mammographic backgrounds, low density calcific flecks, or densely clustered calcifications
and thus are limited to only certain patients and mammograms. To our knowledge, the
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highest reported sensitivity and specificity for a cross validated algorithm based on
mammography is 71% and 74% respectively [Betal et al. 1997]. Although these studies
show promising results, the diagnosis of breast carcinoma using mammographically detected
microcalcifications remains elusive. While the mammographic appearance of
microcalcifications bears some relationship to the histological type of the lesion, currently
diagnosis cannot be reliably made on this basis.
Because calcium deposits in breast tissue have only been categorized
morphologically, significant insight may be gained by examining them using a more rigorous
method. Raman spectroscopy is well suited to further the study of microcalcifications in
breast tissue, as it can provide a definitive chemical analysis of these morphologic structures
in vitro. In fact, Raman spectroscopy has been used successfully to study calcium deposits in
several other organs, such as the kidney and urinary tract [Kodati et al. 1990; Kodati et al.
1991; Kodati et al. 1993; Pestaner et al. 1996; Kontoyannis et al. 1997].
In this study, we have employed Raman spectroscopy to highlight differences in the
chemical composition or structure of microcalcifications that exist in different lesions in the
breast. Results from this study will further our understanding of the chemical changes
accompanying the onset and progression of breast disease and provide an important
parameter for the diagnosis of breast disease using Raman spectroscopy.
VI. B. Sample Preparation and Data Acquisition
VI. B. a) Sample Preparation
Raman spectra were acquired from 6 im thick deparaffinized sections of formalin fixed,
paraffin embedded breast tissue. Due to their diagnostic importance, microcalcifications in
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fresh breast tissue cannot typically be spared for scientific research and thus our study was
confined to examining microcalcifications in fixed tissue sections. Since microcalcifications
are relatively inert, the protein crosslinking effects of the fixative should be minimal.
Furthermore, Raman spectral lineshapes from the calcifications examined in this study are
consistent with previously published data acquired from unfixed tissue in other organ
systems [Kodati et al. 1990; Kodati et al. 1991; Kodati et al. 1993; Pestaner et al. 1996;
Kontoyannis et al. 1997]. Samples were mounted on MgF2 flats (Moose Hill Enterprises
inc., Sperryville, VA). Each microcalcification studied was photographed using a phase
contrast microscope. The phase contrast images and H&E stained serial sections were
reviewed by an experienced pathologist, who was blinded to the spectroscopy results and
rendered a histologic diagnosis of the disease state of regions where data was acquired. A
total of 30 type I and 60 type II microcalcifications in breast biopsies from 11 patients were
examined using Raman spectroscopy, 74 from histologically benign ducts and 16 from
histologically malignant ducts. Histologic diagnoses for benign ducts ranged from ductal
epithelial hyperplasia (DEH) (3), sclerosing adenosis (19), fibrocystic change (43), and
fibroadenoma (5), to Monckeberg's arteriosclerosis (4), while all 16 malignant ducts were
diagnosed as ductal carcinoma in situ (DCIS). No invasive carcinomas were encountered in
the regions where data was acquired. All 11 patients were Caucasian females with a mean
age of 53.4 years (range 41 to 85 years) and had undergone excisional breast biopsy for
suspicious microcalcifications found on mammography. These patients had no palpable
breast lesions and, with the exception of the fibroadenomas, had no mass lesion or other
significant findings on mammography.
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VI. B. b) Data Acquisition
Data was acquired using the laboratory confocal Raman microscopy system detailed in
Chapter III.F.2. In short, Raman excitation light, 830 run, is launched into a confocal
microscope and focused to a spot size of approximately 2J.1.m.All Raman spectra in this
study were acquired with a 60 sec. integration time and a spectral resolution of 8 cm-1• The
average laser excitation power used varied between 100 and 150 mW.
VI. C. Raman Spectra
Figure VI.la is a specimen radiograph which exhibits features indicative of the presence of
microcaIcifications, while Figure VI. 1b displays a phase contrast image collected from a thin
section of this specimen. The Raman spectrum of a type I microcaIcitication acquired from
the deposit highlighted by a smaIl box in image VI. 1b is shown in Figure VI. 1c. Based on
the overall histology of this sample as we]] as the specific features apparent in the phase
contrast image, this lesion was diagnosed as fibrocystic change. Vibrational features
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Figure VI.I. a) Specimen radiograph and b) phase contrast image taken from a section of the same sample.
c) Raman spectrum of a type I calcification arising in association with secretions in the lumen of a duct cyst
in a focus of fibrocystic disease. The region from which the Raman spectrum was acquired is highlighted by
a box.
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characteristic of calcium oxalate dihydrate can be seen at 912 cm-1, 1477 cm-1, and 1632 cm-
These Raman features are attributed to C-C stretching, and C-O symmetric and
asymmetric stretching respectively and are consistent with previously published Raman
spectra of calcium oxalate dihydrate [Kodati et al. 1990; Pestaner et at. 1996; Kontoyannis et
at. 1997].
Figures VI.2a and VI.2b display a phase contrast image of a type II microcalcification
in a malignant duct and the corresponding specimen radiograph. Figure VI.2c shows the
Raman spectrum acquired from the deposit highlighted in image VI.2a by a small box.
Through examination of this spectrum, it is evident that the microca1cification is not
composed of pure calcium hydroxyapatite. The Raman spectrum of pure stoichiometric
calcium hydroxyapatite contains four phosphate internal vibrational modes as well as bands
due to the hydroxyl ion stretching and librational modes. Two of the phosphate vibrational
modes are out of the spectral range we have chosen to examine as well as both of the
hydroxyl ion modes. The large band at 960 cm-1 is the vI(P04) totally symmetric stretching
mode of the 'free' tetrahedral phosphate ion. Another phosphate VI mode occurs at 948 em-I
VI.2c
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Figure VI.2. a) Specimen radiograph and b) phase contrast image taken from a section of the same sample. c)
Raman spectrum of a type II calcification in a malignant breast lesion. The region from which the Raman
spectrum was acquired is highlighted by a box.
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but is obscured by the broad phosphate stretching mode at 960 cm '1. Overlapping Raman
structure resulting from five v3(P0 4) bands can be seen between 1028 cm '1 and 1061 cmn' .
The sixth v3(PO4) mode appears at 1075 cm'. The phosphate features present are consistent
with previously published Raman spectra of calcium hydroxyapatite [Kodati et al. 1991;
Kodati et al. 1993; Kontoyannis et al. 1997]. In addition to the phosphate peaks resulting
from calcium hydroxyapatite there are several other vibrational modes present in this
spectrum. Protein contributions can be seen at 1445 cm ' and 1650 cml. Also the sharp
peak present at 1004 cm' l can be attributed to phenylalanine. Small contributions from lipid
are manifest as a C-C stretch and C-H (CH2) bend at 1130 cm 1 and 1300 cm 1 respectively.
Initially, data acquired from type I and type II microcalcifications were separated
based on their Raman spectra. The presence or absence of vibrational intensity at specific
wavenumbers was used to distinguish between type I and type II microcalcifications. Spectra
containing large peaks at 912 cmrf and 1477 cm', characteristic of calcium oxalate dihydrate,
were grouped into the type I category while spectra displaying intensity at 960 cm' 1,
characteristic of calcium hydroxyapatite, were grouped into the type II category. In the
current analysis, the separation into type I and type II microcalcifications was performed by
visual inspection. However, an automated computer algorithm which normalizes the spectra
and distinguishes them based upon an intensity value of one occurring at either 960 cm',
type II, or 1477 cm ' , type I, could easily be implemented. All 30 type I microcalcifications
we examined were formed in loci of fibrocystic disease and thus all 30 type I
microcalcifications were diagnosed as benign. This is consistent with the fact that type I
microcalcifications are formed as a product of secretions and are typically located in cystic
lesions. Although type I microcalcifications have been found in malignant lesions,
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specifically lobular carcinoma in situ, it is exceedingly rare [Frappart et al. 1984; Frappart et
al. 1986].
VI. D. Principal Component Analysis
In order to differentiate type II microcalcifications occurring in benign and malignant breast
lesions, we employed PCA, described in Chapter IV.B.1 [Geladi and Kowalski 1986].
Although PCA provides little physical information in and of itself; however, it is adept at
isolating spectral trends that correlate with physical information and thereby provides a basis
for development of a diagnostic algorithm. Furthermore, by comparing the lineshapes of the
diagnostic PC spectra with the spectra of pure chemicals, it is possible to ascribe meaning to
them. More importantly, this method of analysis provides a proof of principle that there is
indeed important diagnostic information contained within the Raman spectra of type II
microcalcifications.
We used a singular value decomposition algorithm to determine the principal
components of our data set. The data set was normalized to the 960 cmn' peak height to
remove any possible intensity biases and subsequently mean centered prior to performing
PCA in order to remove features common to all spectra thereby further highlighting spectral
variance. All 60 spectra could be accurately modeled above the noise level using 9 principal
components. The first 6 PCs account for more than 97 % of the total variance in the data.
Next, we used logistic regression, a discriminate analysis technique, to generate a diagnostic
algorithm that was used to classify the breast lesions into benign and malignant categories
[Shama 1996]. Logistic regression correlates the weighting coefficients (scores) of the
principal components calculated for each Raman spectrum with the diagnostic categories.
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Diagnoses were provided by pathologist blinded to the outcome of the spectroscopic
measurements. A leave one out cross-validation analysis was employed in order to obtain a
robust diagnostic algorithm.
VI. E. Diagnostic Algorithm
Fibroadenoma is a benign tumor of a completely different lineage than all other lesions we
have examined [Rosen 1997]. It is most closely related to phylloides tumors, the malignant
counterpart of which is not carcinoma but cystosarcoma phylloides, in which the stroma
rather than the epithelium is malignant. Furthermore, the clinician typically knows that a
breast lesion is in the fibroadenoma/phylloides tumor family based on physical examination
and features other than microcalcification on mammography [Houssami et al. 2001]. As
these lesions must be surgically excised for treatment, physicians would be unlikely to use a
technique like Raman spectroscopy as an adjunct tool for diagnosis of fibroadenoma. For
these reasons, we assessed the performance of the algorithm after excluding samples
diagnosed as fibroadenoma from our analysis.
Using a combination of PCA and logistic regression, we were able to examine Raman
spectral signatures of type II microcalcifications to determine whether or not breast disease
diagnosis could be made on this basis. We obtained good diagnostic accuracy with 3 PC
scores. The significant scores are associated with PC 2, PC 3, and PC5 . PC5 accounts for 1.0%
of the total variance in the data, while PC 2 and PC3 account for 8.8% and 5.2% respectively.
Using these three principal components and a leave one out cross validation method we were
able to predict 14 out of 16 DCIS and 34 out of 39 benign samples correctly. Thus, type II
microcalcifications occurring in benign and malignant breast ducts could be distinguished
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with a sensitivity of 88%
and a specificity of 87%. If
88% with a drop m
A
are only slightly degraded,
maintaining a sensitivity of
we retain all samples, the
sensitivity and specificity
sensitivity to 80%.
graphic representation of
the diagnostic algorithm for
Figure VI.3. Diagnostic algorithm for type nmicrocalcifications
based on the scores of three principal components: benign (triangles),
malignant (circles).
type II microcalcifications is shown in Figure VI.3. In order to condense the algorithm into a
two-dimensional representation, PCs and PC2, which both have higher scores for benign
microcalcifications, were added together to form a single axis. Based on this algorithm, all
of the samples diagnosed as DEH and sclerosing adenosis, the benign conditions most
commonly confused morphologically with carcinoma, were predicted correctly. 4 out of 5
type II stromal calcifications occurring in fibroadenoma were misdiagnosed, as well as 2 of 4
arterial calcifications in Monkeberg's arteriosclerosis and 3 out of 13 ductal calcifications in
fibrocystic disease.
In general, only one microcalcification was studied from each lesihn. However, in
two samples, multiple microcalcifications were studied from the same lesion and no
significant differences were seen in the spectra for each given lesion. When we combine data
acquired from both type I and type II microcalcifications we obtain an overall sensitivity of
88% and a specificity of 93%. This corresponds to a positive predictive value of 74% and a
-210-
negative predictive value of 97%. A
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receiver operating characteristic curve
generated from these results is shown
in Figure VI.4. Based on these in vitro
results in fixed tissue, we believe that
Raman spectroscopy has the potential
0.0 0.2 0.4 0.6 0.8 1.0 to discriminate microcalcifications
1 -Specificity
associated with benign and malignant
Figure VI.4. Receiver operating characteristic (ROC)
curve which illustrates the ability of Raman breast lesions more accurately than
spectroscopy to separate microcalcifications occurring
in benign and malignant breast lesions. A simulated
ROC curve of two indistinguishable populations, mammography. Further studies
represented by the dashed line, is included for
comparison. performed in vitro on fresh tissue and
ultimately in vivo are planned to better evaluate the clinical utility of Raman spectroscopy as
compared to X-ray mammography for the diagnosis of breast cancer.
VI. F. Chemical Analysis
Through examination of the three diagnostic principal component spectra, we can gain
insight into the physical basis responsible for this discrimination. The most diagnostically
significant PC spectrum was PC 5, shown in Figure VI.5a. Examination of this PC spectrum
reveals a broadening of the 960 cm 1 phosphate stretching peak. This broadening is clearly
demonstrated in Figure VI.5b, in which PC 5 is overlaid with the mean spectrum from all type
II microcalcifications. Broadening of this peak has been reported in the literature to result
from the presence of calcium carbonate [Nelson and Williamson 1982; de Mul et al. 1998].
In these studies, the application of Raman spectroscopy to carbonated apatite model systems
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Figure VI.5. a) Principal Component spectrum 5. b) Principal Component spectrum 5 (solid line)
overlaid with the mean spectrum from all type II microcalcifications (dotted line) to illustrate
broadening of the 960 cm-1 peak (arrow).
demonstrated a broadening of the phosphate peak with increased carbonate content. The
introduction of carbonate ions into the apatite structure reduces the symmetry of its' unit cell.
The peak broadening results from a loss of long-range translational order in the apatite
structure as the carbonate content of the sample increases. The study found a linear
relationship between the Full Width at Half Maximum (FWHM) of the 960 cm '1 phosphate
stretching mode and the calcium carbonate content of the sample. Evidence that the
broadening at 960 cm ' in PC5 may result from variations in the calcium carbonate content of
the microcalcifications is manifest in a peak at 1070 cml attributable to the calcium
carbonate VI(CO3) mode. However, the difficulty in interpreting PC spectra conferred by the
inclusion of both positive and negative features necessitates further investigation.
If indeed PC 5 accounts for variations in the amount of calcium carbonate present, then
spectra that have a higher score for PC5 will contain a larger amount of calcium carbonate
than spectra with a lower weighting coefficient. As benign spectra typically have a larger
score for PC5 than malignant spectra, we postulate that type II microcalcifications occurring
in benign lesions of the breast contain a larger amount of calcium carbonate than those
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deposits found in DCIS. To check our hypothesis, the FWHM was calculated for the 960 cm'
I phosphate stretching peak in each Raman spectrum in our study. In accordance with the
theory that type II microcalcifications formed in benign lesions have a larger calcium
carbonate content, we found that type II microcalcifications occurring in benign breast
lesions had an average FWHM of 18.0 0.5 cm l, while deposits in lesions diagnosed as
DCIS had an average FWHM of 17.0 0.5 cm 1. The significance of this difference is
reflected in a p-value of 0.03. This value was calculated based on the Wilcoxon rank sum
test which does not assume a normal distribution of data. Furthermore, if we examine the
FWHM of those samples incorrectly diagnosed, we found the opposite trend. The FWHM of
benign samples incorrectly diagnosed as malignant was 15.8 +0.5 cm 'l while that of
malignant samples incorrectly diagnosed as benign was 17.5 0.5 cm', indicating that the
width of the phosphate stretching mode is a key diagnostic feature. However, although the
peak height of the 1070 cml carbonate stretching mode is on average four times larger in
benign samples, it does not correlate linearly with the FWHM of the 960 cm 1 phosphate
stretching mode. This indicates that additional impurities in the apatite structure contribute
to disruption of the symmetry and thereby the broadening of the 960 cmf peak. These
impurities are manifest in the complex vibrational structure of PCs, but presently have not
been identified. PC5 also contains several features representative of proteins such as the CH2,
CH3 bending mode at 1445 cm ' and the Amide I vibration at 1650 cm 1. Unlike the calcium
carbonate features, which have a positive intensity, the protein features are negatively
directed. This indicates that the protein and carbonate contents are negatively correlated, and
thus that benign samples tend to have a lower protein content than malignant samples.
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and calcium carbonate present in
type II calcifications in benign ,
and malignant lesions is further >
confirmed by examination o
conirmed by examination of VI.6. This
PC2, shown in Figure VI.6. This
spectrum also appears to contain I
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Figure VI.6. Principal Component spectrum 2 exhibiting a
carbonate features, particularly at large, second derivative-like feature around 960 cm-1 (arrow).
1070 cml, as well as negatively directed protein features and contributes more, on average,
to the Raman spectra of microcalcifications formed in benign ducts. Additionally, PC2
exhibits a large, second derivative-like feature around 960 cm 1. This type of structure
accounts for peak broadening in the data and further supports our hypothesis that type II
microcalcifications formed in benign ducts tend to have a larger amount of calcium
carbonate, and thus more broadening of the 960 cm'1 peak, than those formed in malignant
ducts.
PC3 was also found to be diagnostically significant. It is shown in Figure VI.7. PC3,
however, contributes more to Raman spectra acquired from type II calcifications in
malignant ducts. It has positively directed protein features, thus lending further support to
the theory that microcalcifications formed in malignant ducts have a larger amount of protein
than deposits in benign ducts. The amount of protein in microcalcifications in benign and
malignant ducts is confirmed by monitoring the peak height of the Amide I vibration at 1650
cm'1. The intensity of this mode is approximately one and a half times greater in type II
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microcalcifications formed in
malignant lesions. Additionally,
|- - | / >I contributions from phenylalanine, an
2a 9 1 Aamino acid often found in
conjunction with collagen and other
proteins, can be seen in PC 3 at 1004
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Figure VI.7. Principal Component spectrum 3 This feature accounts for a peak shift
exhibiting positively directed protein features such as
the peak at 1445 cm-1, the Amide I vibration at 1650
cm-1, and the phenylalnine feature at 1004 cm- the phosphate stretching mode
which is positively correlated with the protein features. The presence of these protein
features may explain the misdiagnosis of stromal calcifications in fibroadenomas and arterial
calcifications in Monkeberg's arteriosclerosis, which are the result of stromal or arterial
degradation similar to the cellular degradation that occurs in DCIS.
VI. G. Summary and Discussion
This study demonstrated the diagnostic potential of Raman spectroscopy to differentiate
microcalcifications found in benign and malignant breast lesions. Additionally, using PCA
we have discovered subtle differences in the chemical composition of type II
microcalcifications occurring in benign and malignant breast lesions. Based on our results,
we postulate that type II microcalcifications occurring in benign lesions of the breast have
both a lower protein and a higher calcium carbonate chemical content than those formed in
malignant lesions. Although we have identified a few of the chemicals responsible for the
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differences between benign and malignant type II microcalcifications, there are several other
chemical species represented in the rich structural content of the diagnostic PC spectra which
are as yet unidentified. Elucidation of the additional chemical species present in type II
breast microcalcifications may yield further insight into the mechanisms by which they are
formed.
Further studies are needed to identify these chemical species, and fresh breast tissue
may be necessary for these studies. We have found few microcalcifications in the fresh
frozen breast tissue from surgical specimens currently available to us for study because they
are important for medical diagnosis and therefore not usually released for scientific study. It
is for this reason that we used deparaffinized fixed tissue sections for this study. As a result
of the fixation process, the fluorescence occurring as a background on the Raman spectrum
could not be reliably analyzed. However, the development of fiberoptic probes for Raman
spectroscopy may soon allow real time studies of microcalcifications in fresh breast tissue in
the clinical setting prior to pathologic examination. Based on the findings of this study, we
expect type II calcifications occurring in benign and malignant lesions to have distinct
fluorescent properties due to the known fluorescence characteristics of proteins and calcium
carbonate [Fujimoto et al. 1977; Aminzadeh 1997]. Additional differences in the
fluorescence profile of type II microcalcifications formed in benign and malignant lesions
due to as yet unidentified chemical species may also become apparent, once
microcalcifications in unfixed tissue are studied. Thus, the fluorescence of type II
microcalcifications could easily be exploited to increase the diagnostic accuracy of this
methodology. Furthermore, we plan to couple these results with a previously described
Raman spectroscopic model of breast tissue to create a powerful new tool for the diagnosis of
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benign and malignant breast lesions [Shafer-Peltier et al. 2002]. The Raman technique may
be applied first in vitro in breast biopsies in which little tissue is obtained and the lesion may
not be well represented but microcalcifications are present. Ultimately, it may be used as an
in vivo adjunct to mammography to help select those patients with microcalcifications who
need to go on to biopsy.
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Chapter VII. Raman Spectroscopic Breast Cancer Diagnosis: In
Vivo Studies
Previous studies have demonstrated the ability of Raman spectroscopy to diagnose breast
cancer using ex vivo tissues. The final objective of this thesis, the in vivo application of
Raman spectroscopy for diagnosing breast cancer, is described in this chapter. Our in vivo
studies were performed at the Cleveland Clinic Foundation in collaboration with Dr. Joseph
Crowe. Data were collected with our front-viewing Raman optical fiber probes during
lumpectomy and mastectomy surgical procedures. The goals of this study were to
demonstrate our ability to collect in vivo data and make accurate diagnoses using our
previously developed diagnostic algorithm, discussed in Chapter V.A. This study represents
the first demonstration of in vivo collection of Raman spectra of breast tissue. The
culmination of this thesis results in an approach that was employed intra-operatively during
partial mastectomy surgeries to accurately assess margin status.
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VII. A. Introduction
Having established that Raman spectroscopy is a useful technique for evaluating breast
cancer ex vivo, preliminary in vivo investigations are the next step to clinical implementation.
To date, only a handful of in vivo studies using Raman spectroscopy have been undertaken
[Caspers et al. 1998; Bakker Schut et al. 2000; Caspers et al. 2000; Hata et al. 2000;
Utzinger et al. 2001; Shim et al. 2000]. The majority have been targeted towards easily
accessible organs, such as skin, and require relatively long collection times. However, the
recent development of a small diameter high throughput Raman probe provides the ability to
study remote organs with real-time diagnostic capability. In this chapter, the first
demonstration of in vivo collection of Raman spectra of breast tissue is presented. Data were
acquired during mastectomy surgeries. Although we ultimately strive for transdermal needle
probe measurements, for initial investigations, probe positioning and contact can be more
accurately controlled in a surgical environment. However, preliminary results using Raman
spectroscopy for intra-operative margin assessment are promising and may represent a viable
clinical application in addition to transdermal needle probe measurements.
Because we have demonstrated the safety of this technique, we bypassed animal
studies and proceed directly to human investigations [Motz 2003]. Further, animal models,
which would normally be used for initial in vivo studies, are not appropriate for development
of this technology due to species specific variability in the spectra collected.
VII. B. Data Acquisition
The experimental system and optical fiber Raman probes used for these procedures are
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described in detail in section III.E.3. All room and surgical lights were turned off during
each measurement. The spectrally examined tissue was then excised by the surgeon and
underwent conventional pathological examination. Spectra were collected for a total of 1 s.
A range of powers, 82-125 mW, were used depending on the probe employed.
Following each procedure, calibration data were collected for spectral corrections.
Wavenumber calibration was established with a spectrum of 4-acetamidophenol. Chromatic
intensity variations were corrected by collecting the spectrum of a tungsten white light source
diffusely scatted by a reflectance standard (BaSO4). The remaining probe background
generated in the optical fibers was characterized by collecting the scattered excitation light
off of a roughened aluminum surface. This background was optimally subtracted from the
data in an iterative loop by using a scaling factor related to the tissue's optical properties
[Motz et al. 2003]. The tissue fluorescence background was modeled with a sixth-order
polynomial. Finally, the data was fit via non-negativity constrained least-squares
minimization with our spectral model of breast tissue, described in section IV.C. In order to
accurately model the in vivo data, spectra of probe components, epoxy and sapphire, were
included in the model. In accordance with our initial diagnostic study, the fit coefficients of
fat, collagen, cell nucleus, epithelial cell cytoplasm, and cholesterol-like were normalized to
sum to a total contribution of one. In the present study, the two types of microcalcifications,
calcium hydroxyapatite and calcium oxalate dihydrate, were excluded from this
normalization as these species were not present in the tissue samples used for the diagnostic
algorithm development. We also observed increased contributions from It-carotene in our in
vivo data and thus this component was excluded from normalization.
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VII. B. 1. Raman Optical Fiber Probes
Four different probes were used in the in Probe Laser Power
vivo clinical studies presented in this
D (15 collection fibers) 161.9 mW
chapter. Probes D and F have 15
F (15 collection fibers) 118.2 mW
collection fibers and a diameter of 2.5
G (9 collection fibers) 109.1 mW
mm. Probes G and H have 9 collection
H (9 collection fibers) 78.5 mW
fibers and a smaller diameter of 2.0 mm.
Table VII.1. The throughput of the probes used in the in
The throughput of each probe, assessed vivo studies.
as the laser power emerging from the distal tip, is give in Table VII.1. These values were
obtained with 1260 mV, the maximum laser output.
The day prior to each clinical procedure, the experimental system was aligned and the
probes submitted for cold-gas ethylene oxide sterilization. Just before surgery, the proximal
ends of the sterilized Raman probe were coupled to the experimental system. The distal end
of the probe was kept sterile and placed in gentle contact with the tissue while spectra were
acquired. In the studies of atherosclerosis by Motz and coworkers, a single procedure was
performed per day [Motz et al. submitted]. This allowed alignment of the specific probe to
be used and the experimental system the day prior to intra-operative data collection. The
probe was then submitted for ethylene oxide cold gas sterilization and the instrumental
system aligned for precise coupling of the laser and the sterilized probe. To maximize the
data collection in the mastectomy studies, spectra were acquired during as many as 4
surgeries in a single day. Because it is difficult to align the system while ensuring probe
sterility, the instrument was aligned for best laser coupling with all 4 probes prior to
sterilization. To assess how to optimally align the system for all 4 probes, each probe was
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aligned and the throughput of the other 3 probes measured at this alignment. Results are
shown in Table VII.2. Based on these results, the system was aligned for either probe H or
probe G depending on the number of surgeries scheduled during the next day of data
collection.
The linear array of
Probe Optimally Aligned Other Probe Throughputs
collection fibers are
Probe F 73.7 mW
Probe D Probe G 91.5 mWterminated with a
Probe H 66.6 mW modified BNC connector
Probe D 169.5 mW
and coupled to the
Probe H Probe F 91.4 mW
spectrograph with a
Probe G 99.1 mW
Probe D 125.9 mW customized adaptor plate
Probe G Probe F 94 mW that was built in house.
Probe H 73.5 mW The BNC connector
Table VII.2. Probe throughputs with different laser coupling snaps into place on the
alignments.
adaptor plate, however,
the coupling does not ensure precise alignment of the linear array with the spectrograph slit
Vertical alignment of the linear array is necessary to assure adequate spectral resolution and
thus alignment must be checked in the surgical suite prior to data collection. Perpendicular
alignment of the linear area of collection fibers can usually be achieved with OR lights.
However, OR lights are bright and can saturate the detector. Further, the BNC connector is
the portion of the clinical instrumentation that allows the majority of light to enter the
system. Each probe also has a different focal plane within the spectrograph. Thus, prior to
each procedure the spectrograph must be focused in the OR. Again this can typically be
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done using the OR lights. Precision refining of the collection fiber/ spectrograph coupling
will result in less instrumental adjustments in the OR and easier clinical implementation.
VII. C. Margins
VII. C. 1. Introduction
Breast cancer is the most common female cancer in the United States, the second most
common cause of cancer death in women (after lung cancer), and the main cause of death in
women ages 45 to 55 [Jemal at al. 2004]. Breast cancer surgery has changed dramatically
over the past several decades, and continues to evolve. With the emergence of the partial
mastectomy, women may now preserve their breast without sacrificing oncologic outcome.
Partial mastectomy is the surgical removal of the tumor, also known as breast conservation
surgery or lumpectomy, followed by radiation therapy to eradicate any residual disease.
Several clinical trials directly comparing partial mastectomy with traditional mastectomy,
removal of the entire breast, have shown equivalent survival rates between the two treatment
approaches [Early Breast Cancer Trialists' Collaborative Group 1995]. The goals of partial
mastectomy are to provide a low rate of cancer recurrence in the treated breast while
maintaining a cosmetically acceptable breast.
Complete surgical excision of the primary tumor is key to reducing the risk of local
recurrence in women undergoing partial mastectomy procedures while minimizing the
amount of breast tissue removed is the main factor in preserving cosmetic appearance. Thus,
in successful partial mastectomy surgeries, complete resection of the cancer must be
balanced with tissue conservation. To ensure that all malignant tissue is removed, a small
margin of normal breast tissue surrounding the lesion is also excised. After surgery, a
pathologist checks to make sure the surgeon has removed the entire cancerous lesion by
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histologic assessment of the tissue margins. Margin status is gauged by pathological
examination of the border of the excised lesion. Additionally, six small tissue samples are
often taken from locations within the surgical cavity and examined for the presence of
malignancy. Negative resection margins, typically defined as the absence of either invasive
or intraductal carcinoma, have lower associated rates of local recurrence following partial
mastectomy than do positive resection margins [Gage et al. 1996; Park et al. 2000; Smitt et
al. 1995; Anscher et al. 1993; Borger et al. 1994]. Positive or unknown histologic margins
usually prompt re-excision of the initial surgical site, since such patients are at higher risk for
local recurrence even when radiation therapy is administered. In clinical practice, as many as
20%-55% of patients undergoing partial mastectomy will require a second surgical procedure
due to positive margins indicative of incomplete cancer excision [Walls et al. 1995;
Klimberg et al. 1998].
As a consequence of the large number of re-excision surgeries performed, there are
numerous approaches under investigation to enhance intra-operative margin assessment.
Gross inspection of the specimen in the operating room, with or without frozen section
analysis, may permit identification of positive or close margins and immediate re-excision.
However, routine frozen section analysis is time consuming and can lead to inadequate
assessment of tumor margins in large specimens, and loss of diagnostic material in small
specimens [Ferreiro et al. 1995; Johnson et al. 2001; Rubio et al. 1998]. Time intensive
techniques, such as frozen section analysis, also have the disadvantage of prolonging the
surgical procedure, thereby increasing the time the patient remains anesthetized. Therefore,
many intra-operative techniques, which can provide real-time feedback, are under
investigation. Intra-operative ultrasound may assist in assuring negative margins, although it
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is generally of low resolution and thus its use does not preclude the presence of microscopic
tumor on permanent sections [Klimberg et al. 1999]. Sehgal and coworkers used tissue
echogenicity, the angular variance in echogenicity around the circumference of the lesion,
and the patients age to obtain a sensitivity and specificity of 95% and 63%, respectively
[Sehgal et al. 2004]. Optical techniques are also capable of providing immediate diagnosis
and thus can assist in tumor resection during partial mastectomy surgeries. Currently, a
variety of optical imaging and spectroscopic techniques are being explored to improve breast
cancer diagnosis. These techniques employ visible or near-infrared light, are of high
resolution when compared with ultrasound, and provide chemical information about the
tissue being studied. Preliminary in vivo investigations have examined the efficacy of diffuse
reflectance spectroscopy in the diagnosis of breast lesions, as well as in the assessment of
tumor margins [Bown et al. 2000]. Diffuse reflectance spectroscopy monitors changes in
the absorption and reduced scattering coefficients among tissues with different pathologies.
It yielded a sensitivity and specificity of 67% and 79%, respectively.
In this study, we present the first demonstration of in vivo collection of Raman
spectra of breast tissue. Data were collected during partial mastectomy surgeries to
demonstrate the feasibility of in vivo Raman spectroscopy for intra-operative margin
assessment and diagnosis of breast cancer. The research serves to extend and confirm the
results of our ex vivo studies. The results of this study indicate that Raman spectroscopy has
the potential to aid in intra-operative tumor resection. Accurate in vivo margin assessment
techniques will allow numerous re-excision surgeries to be avoided. They may also extend
partial mastectomy procedures to those women who do not harbor sufficiently small or
localized breast cancers to qualify by current standards.
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VII. C. 2. Sample Preparation
The clinical protocol has been approved by both the MIT Committee on the Use Of Humans
as Experimental Subjects and the Institutional Review Board of the Cleveland Clinic
Foundation. Informed consent was obtained from all subjects prior to the surgical
procedures.
This study utilizes partial mastectomy surgery to demonstrate the feasibility of in vivo
Raman spectroscopy. The standard of care at the Cleveland Clinic Foundation involves the
excision of 6 margin specimens from the surgical cavity. Raman spectra were collected from
several of these margins prior to excision and thus only tissue that would normally be excised
during the procedure was removed. A total of 30 Raman spectra were collected from 9
patients, 29 from margins subsequently found to be negative on pathology examination and 1
spectrum from a margin subsequently found to be positive on pathology examination. Of
the 29 negative margins, 21 were comprised of normal breast tissue and 8 contained tissue
diagnosed as fibrocystic change. The 1 positive margin was diagnosed as high-grade ductal
carcinoma in situ (DCIS). We are able to accurately fit all 30 spectra with our previously
developed spectral model of breast [Shafer-Peltier et al. 2002].
Two spectra were excluded from the present analysis. The first, a benign papilloma,
is a pathology not encountered in our previous studies and thus our diagnostic algorithm does
not encompass this type of tissue. The second is a margin noted by the pathologist to harbor
significant cautery effects resulting from the surgical procedure. This was the only specimen
where cautery of this degree was seen.
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VII. C. 3. Model Fits
Model fits to in vivo Raman spectra acquired from normal, benign, and malignant breast
tissues are shown in Figure VII. 1. The difference between the measured spectrum and the
model fit, the residual, is shown below each spectrum. The lack of significant structure in
the residuals demonstrates that the model accounts for the majority of the spectroscopic
features observed and describes the data well. The fit coefficients, also displayed in Figure
VII.I, represent the amount that each model basis spectrum must be weighted in order to
recreate the tissue spectrum, thereby providing insight into the chemical/morphological
makeup of the tissue.
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Figure VII.1. Normalized Raman spectra (solid line), model fit (dotted line), residual (shown below),
and fit coefficients representative of a) normal breast tissue, b) fibrocystic change, and c) ductal
carcinoma in situ.
Fit coefficients are a function of both the concentration of a particular model
component and its Raman scattering cross-section (which indicates the strength of the signal
-229-
>,
.c
-
at unit concentration). The fit coefficients of normal breast tissue exhibit a large contribution
from fat. This is because normal breast tissue is predominately comprised of adipocytes,
cells containing large amounts of cytoplasmic fat, and also because relative to most other
model components, fat has a large Raman scattering cross-section. This explains the
excellent signal to noise ratio evident in the spectrum acquired from normal breast tissue,
Figure VII. 1 a. Although there is more noise evident in spectra acquired from diseased tissue,
data analysis still yielded excellent model fits.
Fibrocystic change is a benign condition that can manifest itself as fibrosis (a scarring
process characterized by an increased stromal component, and thus by accumulation of
collagen), adenosis (increase in the number of ductules) or cyst formation (dilation of ducts
and lobules with fluid). The margin which harbors fibrocystic change shows an increase in
the fit coefficients of collagen due to fibrosis and epithelial cell cytoplasm as a consequence
of adenosis. The fit coefficients of the positive margin, diagnosed as high-grade ductal
carcinoma in situ (DCIS), also display an increase in the amount of epithelial cell cytoplasm.
However, a signature of carcinoma is enlargement of cell nuclei, and thus a higher nuclear to
cytoplasm (N/C) ratio than in benign conditions. Nuclear enlargement and atypia are
hallmarks of cancer. Thus, the N/C ratio is a diagnostic criterion routinely used by
pathologists [Elston and Ellis 1991; Hoda and Rosen 2002]. In our studies, the spectroscopic
parameter characterizing the N/C ratio, obtained by dividing the fit coefficient of the cell
nucleus basis spectrum by the fit coefficient of the epithelial cell cytoplasm basis spectrum,
is much larger for the cancerous specimen, shown in Figure VII.lc, than for any of the
fibrocystic lesions encountered in this study.
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Table VII1.3 displays the fit coefficient error associated with each model component.
The method used for calculating prediction error is presented in section IV.F. Errors are
broken down by diagnosis, as spectra corresponding to different pathologies contained
dissimilar amounts of noise. The amount of noise was extremely variable even within
pathologies due to collection with different Raman probes as well as day to day variations in
laser coupling.
Table VII.3. Fit coefficient errors for the in vivo data.
VII. C. 4. Diagnostic Algorithm
Figure VII.2 displays a scatter plot of the fit coefficients for collagen and fat,
FC(Coll) and FC(Fat), respectively, for all data acquired in this study. Also shown are the
decision lines that separate samples according to diagnoses. The diagnostic algorithm shown
in Figure VII.2 was developed previously using 126 spectra from 58 patients and is used in a
prospective manner in this study [Haka et al. submitted]. Table VII.4 compares the
pathologic diagnosis with that of the Raman diagnostic algorithm for our data set. The
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Calcium Oxalate Dihydrate 2.68 0.96 0.02 0.04 0.07
Calcium Hydroxyapatite 2.85 0.93 0.02 0.03 0.07
Cholesterol-like 4.48 0.28 0.04 0.07 0.15
Water 7.04 0.64 0.01 0.02 0.04
O-Carotene 3.67 0.84 0.01 0.03 0.06
Fat 4.97 0.40 0.02 0.05 0.09
Collagen 8.12 0.45 0.01 0.03 0.05
Cell Nucleus 5.96 0.69 0.01 0.02 0.04
Epithelial Cell Cytoplasm 6.32 0.31 0.02 0.05 0.09
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Figure VI.2. Scatter plot displaying the fat and collagen content for the in vivo Raman spectra
acquired margin specimens. Normal (stars), Fibrocystic Change (diamonds), Ductal Carcinoma In
Situ (square).
algorithm results in a sensitivity for detecting carcinoma of 100%, a specificity of 100%, and
an overall accuracy of 93% (28/30). We note, that although there is only one malignant
sample in the present data set, this algorithm has been previously validated with 31 cancerous
specimens. The high grade DCIS correctly identified by Raman spectroscopy was grossly
invisible. Upon pathologic review, the finding that this margin was positive necessitated that
the patient undergo a second surgery to excise the remaining cancerous cells. Had Raman
spectroscopy been employed in a real-time fashion to guide excision during the initial
surgery, the additional procedure could have been avoided.
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Pathology Normal Fibrocystic Cancer
Diagnosis Change
Raman
Diagnosis (21 spectra) (8 spectra) (1 spectrum)
Normal 21 2 0
Fibrocystic Change 0 6 0
Cancer 0 0 1
Table VII.4. Comparison of pathologic diagnosis with that of the Raman diagnostic algorithm for
margin specimens. The Raman diagnostic algorithm results in an overall accuracy of 93% (28/30).
VII. C. 5. Discussion
This pilot study is the first use of Raman spectroscopy to examine breast cancer in vivo. It
clearly demonstrates the feasibility of Raman spectroscopy as a clinical technique for breast
cancer diagnosis. The data exhibit good agreement with our previously developed spectral
model and diagnostic algorithm. Studies with a larger patient pool are currently underway to
further expand and validate our diagnostic algorithm. Further, we have developed and
demonstrated real-time Raman diagnosis with our clinical instrumentation thus allowing its
implementation in upcoming studies [Motz et al. in press]. These excellent results indicate
that Raman spectroscopy has the potential to provide real-time margin assessment thereby
reducing the recurrence rate of breast cancer following partial mastectomy surgeries.
As the first in vivo demonstration of Raman spectroscopy of breast tissue, this study
has implications beyond margin assessment. There are several areas where Raman
spectroscopy may aid in breast cancer diagnosis and treatment. In particular, optical
techniques are less invasive than current diagnostic procedures. The results of this study
illustrate the potential for transdermal needle measurements to provide breast cancer
diagnosis. As opposed to standard biopsy, a spectroscopic transdermal needle measurement
would have the advantage of providing immediate diagnosis. As a result, Raman
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spectroscopy has the potential to reduce both the likelihood of a non-diagnostic biopsy that
would require repeat needle or surgical biopsy, and patient anxiety by eliminating the
currently unavoidable wait for a traditional histopathology diagnosis. Furthermore, with the
development of minimally invasive breast cancer therapies, such as radio frequency ablation,
which relies on insertion of a thin metal probe into the breast, there is the potential that
diagnosis and treatment could be performed in a single procedure [Fornage et al. 2004].
VII. D. Mastectomies
VII. D. 1. Sample Preparation
The clinical protocol has been approved by both the MIT Committee on the Use Of Humans
as Experimental Subjects and the Institutional Review Board of the Cleveland Clinic
Foundation. Informed consent was obtained from all subjects prior to the surgical
procedures.
This study utilizes mastectomy surgenes to
demonstrate the feasibility of in vivo Raman
spectroscopy. Spectra were acquired from the
mastectomy specimen prior to removal of the breast.
Locations of data acquisition were selected by the
Figure VII.3. Schematic of a
mastectomy surgery.
surgeon. Small samples of tissue were taken from the spectrally examined region of the
breast. As the entire breast is excised during a mastectomy procedure, only tissue that would
normally be excised during the surgery was removed. A total of 32 Raman spectra from 9
patients was collected, 24 spectra from normal breast tissue, 6 from tissue diagnosed as
fibrocystic change, and 2 spectra from cancerous lesions. The malignant tissue was
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diagnosed as intermediate-grade DCIS. We are able to accurately fit all 32 spectra with our
previously developed spectral model of breast [Shafer-Peltier et al. 2002]. In the mastectomy
procedures, spectra were acquired from more peripheral tissue sites than in the margin
specimens. The surgical procedure, diagramed in Figure VII.3, illustrates the area of data
collection from deep within the breast, closer to the chest wall.
Seven spectra were excluded from the present analysis. The first, a lesion diagnosed
ik0Ca,E
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Figure VII.4. a) A Raman spectrum contaminated with light. Also shown are the model fit (dotted line)
and residual (below). b) A spectrum obtained by shining light onto the probe/ spectrograph connection.
c) Raman spectrum shown in a. The light spectrum, shown in b, is included in the model resulting in
the fit (dotted line) and residual (below) shown in c.
as granulomatous response, is a pathology not encountered in our previous studies and thus
our diagnostic algorithm does not encompass this type of tissue. Six spectra, all from a
single patient, were excluded due to distortions from light contamination. Figure VII.4
shows a Raman spectrum contaminated with light. Although the OR lights were turned off
during data acquisition, it did not result in complete darkness due to windows in the surgical
suite and computer monitors. The light was found to enter through the probe spectrograph
BNC connection. Only probe D exhibited this type of light contamination. In latter data
collection, the BNC connection was covered with a black cloth. A spectrum of the light
entering probe D is shown in Figure VII.4b. When this light spectrum was included in the
model, fits were improved as seen in Figure VlI.4c. However, all 6 spectra were still
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incorrectly diagnosed and thus excluded from the analysis. Refinement of the light spectrum
shown in Figure VII.4b may further improve the accuracy of the model fit.
VII. D. 2. Model Fits
Model fits to in vivo Raman spectra acquired from normal, benign, and malignant breast
Cu
:tl
tor_C
.,
NORMAL
Cholesterol-like 0.19
Fat 0.79
Collagen 0.01
Cell Nucleus 0.00
Cell Cytoplasm 0.01
FIBROCYSTIC CHANGE
Cholesterol-like 0.12
Fat 0.73
Collagen 0.04
Cell Nucleus 0.00
v-- ,_. <I - Cell Cytoplasm 0.11
800 1000 1200 1400 1600 1800
DUCTAL CARINOMA IN SITU
Cholesterol-like 0.14
Fat 0.81
Collagen 0.00
= ~nn--VJ-·. Cell Nucleus 0.00
600 800 1000 1200 1400 1600 1800 Cell Cytoplasm 0.05
Raman Shift (cm-' )
Figure VII.5. Normalized Raman spectra (solid line), model fit (dotted line), residual (shown below),
and fit coefficients representative of a) normal breast tissue, b) fibrocystic change, and c) ductal
carcinoma in situ.
tissue are shown in Figure VII.5. The difference between the measured spectrum and the
model fit, the residual, is shown below each spectrum. All 3 spectra were acquired from the
same patient. Some structure is visible in the residuals. Much of the structure in the
residuals results from spectral broadening as a consequence of incomplete vertical alignment
of the probe fibers and the detector. The BNC connectors on some probes prevent vertical
alignment. However, the model still accounts for the majority of the spectroscopic features
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observed and describes the data well. It is notable that all 3 spectra, regardless of diagnosis,
are predominately composed of fat. Because most spectra acquired in the mastectomy
studies contain large signals from fat, the noise in the data is similar regardless of the
corresponding diagnosis. Thus, the fit coefficient error for all data, regardless of pathology,
is similar to the error shown for normal samples in Table VII.3.
VII. D. 3. Diagnostic Algorithm
Figure VII.6 displays a scatter plot of
acquired from mastectomy specimens.
samples according to diagnoses. Table
the Raman diagnostic
algorithm for our data set. The 0.7
0.6
algorithm results in a
sensitivity of 0%, a specificity 04
UO 0.3
of 100%, and an overall
0.2
accuracy of 81% (26/32). 0.1
Clearly, the results from the
the fit coefficients for collagen and fat for the data
Also shown are the decision lines that separate
VII.5 compares the pathologic diagnosis with that of
0
Fibrocystic Change
+
+
FC(Fat)
mastectomy specimens are Figure VII.6. Scatter plot displaying the fat and collagen content
for the in vivo Raman spectra acquired during mastectomydifferent than those firom the surgeries. Normal (stars), Fibrocystic Change (diamonds), Ductal
Carcinoma In Situ (squares).
margin tissues. In particular all
of the mastectomy data, regardless of pathology, exhibits large contributions from fat. We
are currently investigating the reason for the difference between the in vivo Raman spectra
acquired from mastectomy and margin specimens.
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Pathology Normal Fibrocystic Cancer
Diagnosis Change
Raman
Diagnosis (24 spectra) (6 spectra) (2 spectra)
Normal 22 2 2
Fibrocystic Change 2 4 0
Cancer 0 0 0
Table VII.S. Comparison of pathologic diagnosis with that of the Raman diagnostic algorithm for
mastectomy specimens. The Raman diagnostic algorithm results in an overall accuracy of 81% (26/32).
One possibility is that the tissue examined in the mastectomy surgeries was more
peripheral than the specimens in the lumpectomies. This peripheral tissue is further from the
core area of the breast, which contains the ductal system, and thus may have a higher fat
content, as shown in Figure VII.7. Future studies of Raman spectra at different locations
with in the breast can be used to examine the effect of anatomical position on spectrally
extracted composition. Misdiagnoses may also arise from the fact that in the 2 cancerous
mastectomy specimens malignant cells
only occupied 10% and 20% of the
volume of tissue spectrally examined.
It is possible that this level of
cellularity provides insight into our
lower detection limits. Future studies,
aimed at obtaining quantitative fit
coefficients, will elucidate lower
detection limits as well as Raman
Figure VII.7. Schematic of the breast illustrating the
distribution of the ductal system.
oADAM.
scattering cross-sections of our model cOmPOnents. However, it is also possible that there
was a slight registration error between the excised tissue and the spectroscopic data. Such
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registration errors have presented problems in many of our studies, including our in vivo
examination of atherosclerosis [Motz et al. submitted].
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Chapter VIII. Other Applications of Raman and Fluorescence
Spectroscopies
Although there are many advantages to Raman spectroscopy, other optical techniques may
also play a role in breast cancer diagnosis. Preliminary investigations have examined the
diagnostic potential of fluorescence and reflectance spectroscopies. Studies have also been
conducted on spectroscopic techniques that have only recently been applied to tissue, such as
surface enhanced Raman spectroscopy and fluorescence lifetime measurements. Finally,
Raman and fluorescence spectroscopies are used in a synergistic manner to elucidate the
mechanism of ceroid formation in situ. Ceroid is an insoluble lipid-protein complex
characteristic of atherosclerotic plaques. The mechanism of ceroid formation has been
extensively studied but despite intensive research, ceroid is only defined empirically through
its fluorescence properties and its behavior during various staining processes. The synergy of
these two types of spectroscopy allows for the identification of ceroid via its fluorescence
signature and the subsequent elucidation of its chemical composition through the acquisition
of a Raman spectrum. A better understanding of the mechanism of ceroid formation may
suggest avenues to induce regression or prevent progression of atherosclerotic plaques with
medical therapy
-242-
VIII. A. Fluorescence and Reflectance of Breast
Although there are many advantages to Raman spectroscopy, other optical techniques may
also play a role in breast cancer diagnosis. In particular, several studies examining
fluorescence spectroscopy for the diagnosis of cancer have shown promising results,
particularly for the detection of precancerous changes. Because fluorescence spectroscopy is
fast, easily implemented, and has relatively strong signals, many researchers have employed
it for tissue diagnosis. As such, we are investigating the diagnostic role of fluorescence and
reflectance spectroscopies in breast cancer. The techniques may provide complementary
information to that obtained with Raman spectroscopy. To assess this, each fluorescence and
reflectance data set acquired in this study corresponds to a Raman spectrum obtained from
the same region of tissue. Preliminary results of the corresponding Raman spectral data set
are presented in Chapter V.B. In combination, these techniques may provide a more
complete understanding of the biochemical and/or morphological changes that take place
during the progression of breast disease. Ultimately all three modalities may be combined
into a single spectroscopic technique for the diagnosis of breast cancer. The overall goal of
this research project is to develop fluorescence and reflectance spectroscopies as a diagnostic
tool for the detection and differentiation of various breast diseases. We have collected a
large pool of data from a wide range of samples in order to further our understanding of
breast disease progression. Using this data we shall determine the key diagnostic features
contained within the fluorescence and reflectance spectra and utilize them in the development
of a diagnostic algorithm for the differentiation of normal, benign and malignant breast
tissue.
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VIII. A. 1. Introduction
The energy of visible and UV light can elevate the electrons in molecules and atoms to
excited energy states. These energy states exist as discrete levels, and can be excited only by
photons of a frequency that corresponds to the energy difference between level. The
structure of the molecule determines which incident frequencies will be absorbed. In many
cases light absorbed by a molecule is converted into heat; however, an absorbed photon can
also be re-emitted as fluorescence. Fluorescence emission typically occurs at a lower energy
than the absorption energy of the incident photons.
Fluorescence spectra in tissue can be used to identify fluorophores and monitor their
concentrations. Various tissue fluorophores include metabolic substances such as NADH
and flavins, aromatic amino acids such as tryptophan, tyrosine and phenylalanine, structural
proteins such as collagen and elastin, several porphyrins, and lipids such as ceroid and
lipofuscin. Each of these fluorophores has specific wavelengths for excitation and emission.
The fluorescence emitted by a molecule in tissue depends on the energy level difference
between the electronic ground state and excited state and the distribution of vibrational and
rotational levels within these states. These energy states can shift in the presence of different
local environmental factors, such as pH, temperature and oxygenation. In the progression of
disease the local environment in which the fluorophores are embedded changes, as well as
their relative concentrations, thus leading to changes in the observed fluorescence intensity
and lineshape.
The measured reflectance spectrum contains both diffuse reflectance (multiply
scattered) and singly backscattered light. The penetration depth of the diffusive component
is 0.5 mm to 1.5 mm, and therefore, diffuse reflectance spectroscopy (DRS) predominately
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provides information about the morphology and absorption of the tissue stroma. The
absorption spectrum of tissue depends on the type of predominant absorbing molecules or
chromophores and therefore, provides information about its chemical composition. Water is
a strong tissue absorber in both the UV and IR regions. DNA and proteins absorb in the UV
region, while hemoglobin, melanin and [l-carotene absorb in the visible region. Other tissue
chromophores include porphyrin-like structures such as bilirubin, myoglobin, cytochrome c
oxidase and protoporphyrin. For breast tissues, the diffuse reflectance spectra can be
analyzed using a mathematical model based on the diffusion approximation to extract the
hemoglobin and -carotene concentrations, oxygen saturation, average diameter and density
of scatterers [Zonias et al. 1999].
Extraction of the singly backscattered spectrum, which comprises a small fraction
(2% to 5%) of the entire reflectance spectrum, can be achieved by subtracting the diffuse
reflectance fit from the measured reflectance spectrum [Perelman et al. 1998]. The resulting
singly backscattered spectrum, referred to as light scattering spectroscopy (LSS), exhibits an
oscillatory behavior in wavelength. When arising from epithelium, the frequency of these
oscillations corresponds to the nuclear size distribution within the epithelial cells [Perelman
et al. 1998]. In breast, where the architecture of the tissue examined does not consist of a
layer of epithelial cells overlying the stroma, it is not clear what type of information LSS will
provide.
Fluorescence photons are scattered and absorbed during their path to the tissue
surface where they are collected. Therefore, the spectral features of the collected
fluorescence can be significantly distorted, making the extraction of the biochemical
composition of the tissue from the measured signal difficult. This is a particular problem in
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the presence of strong tissue absorbers such as hemoglobin. Intrinsic fluorescence
spectroscopy (IFS) is a technique that extracts the fluorescence of molecules unaffected by
absorption and scattering events [Zhang et al. 2000; Muller et al. 2001]. Because diffuse
reflectance undergoes similar absorption and scattering events as fluorescence, information
contained within the reflectance spectra can be used to extract the intrinsic fluorescence from
the measured fluorescence spectra. An example of measured fluorescence and reflectance
data and the corresponding intrinsic fluorescence spectrum is shown in Figure VIII.1. A
large dip, due to hemoglobin absorption, 10
0.8
can be seen at 420 nm in both the 8 337 n
O0.4
measured reflectance and fluorescence U. 0.2
00
300 400 500 600 700 800
spectra. This feature is not present in the Wavelength (nm)
0.40
intrinsic fluorescence because effects due 8
0.30
to tissue scattering and absorption have 0.20
been removed. The three techniques, IFS, 0.103 400 500 00 700 800
Wavelength (nm)
DRS and LSS, can be combined into a Figure VIII.l. Measured tissue fluorescence (dashed
line) and reflectance (solid line below) used to extract
single spectroscopic modality. This the intrinsic fluorescence spectrum (solid line above).
technique, known as tri-modal spectroscopy (TMS), provides biochemical, structural, and
morphological information simultaneously [Georgakoudi et al. 2001, 2002; Muller et al.
2002].
Several studies have fueled our interest in the use of fluorescence spectroscopy as a
diagnostic tool for the detection of breast disease [Yang et al. 1996, 1998; Gupta et al. 1997;
Majumder et al. 1998]. Previous research has demonstrated the ability of fluorescence
spectroscopy to differentiate benign and malignant tumors at certain key excitation
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wavelengths. owever, tnere are
several questions that these
studies have left unanswered.
First, their data was acquired at
least 4 hours after the tissue was
excised, well after key
fluorophores, such as NADH,
have decayed. This results in
diagnostic schemes that may not
Figure VIII.2. Schematic layout of the FastEEM clinical
spectrophotometer. LI, L2, L3, LA are lenses. M1 and M2 are be applicable to in vivo studies.
mirrors.
Second, previous studies have
only explored a limited number of excitation wavelengths. Third, the groups' results are not
consistent, raising questions regarding reproducibility of the data. Our experience in
fluorescence spectroscopy of human tissues places us in a good position to take this research
a step further. We have optical fiber fluorescence probes, as well as a special instrument, the
FastEEM (excitation-emission matrix), shown in Figure VIII.2, for collecting fluorescence
and reflectance data [Muller et al. 2002]. This instrument provides a broader range of
excitation wavelengths than was available in previous studies. Not only can we verify prior
published results, but it is possible that we can achieve superior diagnostic information by
employing a wider range of excitation wavelengths.
Additionally, a recent publication has indicated the utility of diffuse reflectance
spectroscopy for breast cancer diagnosis [Bown et al. 2000]. Our FastEEM instrument also
allows for the collection of reflectance data. A diagnostic algorithm that combines both
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fluorescence and reflectance data could result in significantly more accurate diagnoses. Our
current protocol for examining fluorescence spectra allows for the removal of artifacts
resulting from tissue absorption and scattering, factors which were not taken into account in
previous studies. Removal of features resulting from scattering and absorption is crucial for
both an in depth understanding of the origins of tissue fluorescence and for obtaining
reproducible data. Further, we have the ability to examine the tissue within minutes of
excision. Our capability to examine a wide range of excitation wavelengths, our previous
experience with fluorescence and reflectance data processing protocols, and the collection of
data immediately following tissue excision should result in more accurate diagnoses and a
deeper understanding of the chemical and physical changes accompanying the onset of breast
cancer.
vmI. A. 2. -Carotene Absorption
Analysis of the FastEEM data of breast tissue revealed contributions from -carotene, a
moiety not encountered in previous studies. We were unable to fit the reflectance data of
breast tissue using an absorption spectrum of -carotene dissolved in hexane
[http://omlc.ogi.edu/spectra/photochemCAD/html/beta-carotene.html]. This is because the
absorbance properties of carotenoids are highly dependent on their chemical environment
[Zang et al. 1997]. fl-carotene is extremely lipophillic and not soluble in water. In
physiologically relevant environments l-carotene is typically dissolved in adipose tissue, and
thus it is difficult to select an appropriate solvent for its' examination. For this reason, we
employed an absorption spectrum that was obtained by manipulating a diffuse reflectance
spectrum of a sample of breast tissue known to contain high concentrations of f-carotene.
This reflectance spectrum was inverted, smoothed using a five point adjacent averaging
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algorithm, and scaled to encompass a
similar intensity range as an absorption
spectrum of known [-carotene
concentration in hexane. The
manipulated reflectance spectrum was
subsequently averaged with the
absorption spectrum of -carotene
dissolved in hexane. Figure VIII.3
shows the absorption spectrum of 3-
carotene in hexane, the diffuse
reflectance spectrum used in this analysis
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Figure VIII.3. Absorption spectrum of b-carotene in
hexane (dashed line), inverted reflectance spectrum
(dotted line) manipulated to generate the 'b-carotene'
absorption spectrum used for fitting diffuse reflectance
of breast and artery (solid line).
and the resultant absorption
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Figure VIII.4. Reflectance data (solid lines) model fits (dotted lines) using the
absorption spectrum of b-carotene in hexane (left) and the mathematically
derived 'b-carotene' absorption spectrum (right).
spectrum used to fit
our diffuse
reflectance data.
This absorption
spectrum provides
superior reflectance
fits as it more
closely mimics the
properties of P-
carotene in its
natural
environment.
Reflectance fits
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using the absorption spectrum of -carotene in hexane and the mathematically derived
absorption spectrum are shown in Figure VIII.4. Using an integrating sphere, it should be
possible to obtain a more accurate absorption spectrum of -carotene in its natural
environment, tissue.
VIII. A. 3. Data Acquired at the Cleveland Clinic Foundation
This study was carried out in collaboration with Drs. Crowe and Dawson at the Cleveland
Clinic Foundation. All studies involving human tissue were approved by the Cleveland
Clinic Foundation Institutional Review Board and the Massachusetts Institute of Technology
Committee On the Use of Humans as Experimental Subjects. Informed consent was obtained
from all subjects prior to the surgical procedures.
VIII. A. 3. a) Sample Preparation and Data Acquisition
Breast tissue was obtained from patients immediately following surgical lumpectomy or
mastectomy procedures. Upon removal, the samples were sectioned per the normal
pathology protocol and spectral data acquired in the pathology suite at CCF. Locations for
data acquisition were chosen by the pathologist. Several sites were studied per patient (-3 to
4 depending on the size of the sample). Following spectral acquisition, specimens were
marked with India ink to indicate the region sampled, and fixed in formalin. The fixed tissue
samples were routinely processed, paraffin embedded, cut through the marked locations in 5
gm thick sections, and stained with H&E. The histological slides were examined by an
experienced breast pathologist who was blinded to the outcome of the spectroscopy analysis.
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Thirteen patients were examined corresponding to 6 FastEEM data sets from normal tissues,
11 from benign and 6 from malignant samples.
Reflectance and fluorescence spectra were obtained with an old version of FastEEM
instrumentation [Zangaro et al. 1996]. A xenon flash lamp (EG&G Optoelectronics, FX-139,
Salem, Massachusetts) was used as a white-light source to acquire reflectance spectra in the
360-700 nm range. Excitation light sources for fluorescence measurements were provided by
a 337 nm wavelength nitrogen laser (Laser Science, Inc., Franklin, Massachusetts) and 10
different dye lasers (358 nm to 610 nm), sequentially pumped by the nitrogen laser. The dye
cuvettes were mounted on a rotating wheel driven by a stepper motor. Light was delivered to
the tissue and collected by means of a probe containing seven optical fibers (200 Im core
diameter, 1 fiber used for light delivery and 6 for collection). At the distal tip the collection
fibers surrounded the delivery fiber and were fused together, creating a quartz shield
approximately 1.5 mm in diameter, which was beveled and then polished at a 170 angle to
reduce internal reflections at the boundary between glass and tissue. During a measurement,
the probe tip was brought into contact with the sample under investigation, thus providing a
fixed light delivery collection geometry. A wheel of long-pass filters was used to prevent
reflected laser excitation light from reaching the spectrograph (CP 200, Jobin Yvon SA,
Edison, New Jersey) and the intensified diode array detector (EG&G Princeton Applied
Research, Trenton, New Jersey). Fluorescence spectra at 11 excitation wavelengths and a
reflectance spectrum were collected in less than 5 s. The incident laser light was sufficiently
low in energy, -400 mJ/cm2, that no tissue damage was observed. The wavelength scale was
calibrated with a mercury lamp. A concentrated barium sulfate suspension (concentration
>20%) was used for reflectance calibration.
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Figure VIII.5. Diffuse reflectance spectra of breast
can be seen in the intrinsic fluorescence tissue.
spectra. Normalized intrinsic fluorescence spectra, averaged by pathology, are shown in
Figure VIII.6b. The cancerous samples have the smallest FWHM and the normal samples
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Figure VIII.6. a) Raw fluorescence spectra and b) normalized intrinsic fluorescence spectra of breast
tissues at 342 nm excitation. Cancer (solid lines), Fibrocystic Change (dashed lines), Normal (dotted
lines).
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the largest. This is not consistent with previous fluorescence studies in our laboratory. In
these studies, cancerous sample typically have the largest FWHM due to increased
contributions from NADH. The discrepancy between previous studies and the fluorescence
observed in breast is not surprising. Prior work using fluorescence to diagnose cancer has
mainly examined dysplasia in epithelial tissues. NADH is observed in higher concentrations
in dysplastic tissues, possibly as a result of an increase in epithelial thickness and/ or higher
metabolic activity of the cells. In contrast to breast, studies of dysplastic tissues provide a
well defined tissue architecture consisting of epithelial tissue overlaying stroma. Although
tissue changes occur during dysplasia, the overall tissue architecture, epithelial cells
overlying stroma, remains largely unchanged. This is in contrast to breast where samples
may be composed of fat, collagen, a cellular tumor, or any combination of features.
vm. A. 4. Data Acquired at University Hospitals of Cleveland
This study was carried out in collaboration with Drs. Fitzmaurice, Shenk, and Wang at
University Hospitals of Cleveland and Case Western Reserve University. All studies
involving human tissue were approved by the University Hospitals of Cleveland and Case
Western Reserve University Institutional Review Board and the Massachusetts Institute of
Technology Committee On the Use of Humans as Experimental Subjects. Informed consent
was obtained from all subjects prior to the surgical procedures.
VIII. A. 4. a) Sample Preparation and Data Acquisition
Breast tissue was obtained from patients immediately following surgical lumpectomy, re-
excision or mastectomy procedures. Tissue was examined as detailed in section VIII.A.3a.
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However, in this study a newer version of the FastEEM instrumentation was employed
[Tunnell et al. 2003]. Further, two identical FastEEM data sets were acquired from each
tissue location to assess measurement error. Raman spectra were also obtained from the
same location as the fluorescence and reflectance data.
VIII. 4. b) Results
Preliminary data analysis is promising, indicating that fluorescence and diffuse reflectance
not only contain diagnostic information, but may also be most accurate in differentiating
pathologies where Raman is least accurate. Figure VIII.7a shows average IFS data from the
pathologies encountered in this study. The trend in intensity seen in the CCF data is not
recapitulated and no clear trend in intensity is observed. However, lineshape trends, as can
be seen in Figure VIII.7b, are similar to those observed in the CCF data with normal samples
having a larger FWHM than benign or IDC samples. DCIS, a pathology not encountered in
the CCF studies, has the largest FWHM, potentially indicating an increase in NADH. The
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Figure VIII.7. a) Raw fluorescence spectra and b) normalized intrinsic fluorescence spectra of breast
tissues at 342 nm excitation. IDC (solid black lines), DCIS (solid gray lines), Fibrocystic Change
(dashed black lines), Fibroadenoma (dashed gray lines), Normal (dotted lines).
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reason for these lineshape trends is currently not well understood.
The basis spectra, used to model the IFS data, were extracted using multiple curve
resolution (MCR), an iterative statistical technique [Tauler et al. 1994]. The basis spectra
obtained using MCR are though to represent NADH and collagen because they have similar,
but not identical, lineshapes to spectra of commercially available NADH and collagen. The
basis spectra extracted at 340 nm excitation are shown in Figure VIII.8. Also shown for
comnarison is a snectrum acauired from
breast tissue. However, MCR provides no
information as to the source of the basis
spectra fluorescence. Further, MCR can "
generate erroneous results if the number of
fluorophores present in the tissue, an input
350 400 450 500 550 600
parameter, is guessed incorrectly. It is also Wavelength (nm)
Figure VIIL8. Emission spectra of NADH (dashes)
possible that the basis spectra do indeed and collagen (dots) at 340 nm excitation. Also
shown for comparison is a spectrum acquired from
represent NADH and collagen and that the breast tissue (solid).
amount of NADH seen in normal samples is a consequence of large numbers of adipocytes.
The literature should be examined to determine the relative amounts of NADH contained in
adipocytes and epithelial cells in order to explore this possibility. Whether the trends
observed for the tissue fluorophores are the result of inaccurate basis spectra, additional
tissue fluorophores, or unexpected pathology requires further investigation.
Figure VIII.9 displays the excellent separation obtained between fibroadenoma and
cancerous specimens. The separation is based on a single parameter. The diagnostic
parameter, A, is extracted from the diffuse reflectance fit. It represents the density of
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scatterers in the stroma. Two
identical FastEEM data sets were
acquired of each sample to assess
measurement reproducibility. The
parameters corresponding to both
data sets are shown in Figure
VIII.9 to provide insight into the
0.7 0.8 0.9 1 1.1 1.2 1.3 1.4
A error of the measurements. These
Figure VIII.9. Diagnostic plot showing the difference between
benign and cancerous tissues. Fibroadenoma (triangles), IDC diagnostic categories, cancer and
(squares) and DCIS (circles).
fibroadenoma, pertain to the lowest sensitivities and specificities obtained with Raman
spectroscopy. Sensitivities and specificities for distinguishing individual pathological
categories using intrinsic fluorescence and diffuse reflectance data are displayed in Table
VIII. 1.
Normal Normal Fibrocystic Fibroadenoma DCIS
Change
Fibrocystic A/N-Carotene
Change Se=100%
Sp=75%
Fibroadenoma NADH/p-Carotene A/Collagen
Se=100% Se=94%
Sp=100% Sp=87%
DCIS A/Collagen A/Hb A/Collagen
Se=100% Se=100% Se=100%
Sp=100% Sp=100% Sp=100%
IDC A/Collagen A/Hb A/Collagen AINADH
Se=100% Se=100% Se=100% Se=100%
Sp=100% Sp=100% Sp=100% Sp=100%
Table VIII.1. Sensitivities and specificities for distinguishing individual pathological categories
using IFS and DRS.
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VIII. A. 5. Future Directions
Preliminary results are very promising and convey that fluorescence and reflectance
spectroscopies do contain diagnostic information. However, a significant amount of data
analysis still remains. Additional cancerous samples must be examined as the algorithms
currently only contain 5 malignant data points, 2 IDC and 3 DCIS. A comprehensive
diagnostic algorithm must be developed which examines all data simultaneously. Further,
there is currently little comprehension of the correlation between the tissue pathology and
spectroscopic parameters. The tissue fluorophores and scatterers responsible for
differentiation must be identified. Future analysis will also focus on correlating information
obtained from FastEEM data and Raman spectroscopy. As a starting point, species that both
approaches are sensitive too, such as collagen and p-carotene, can be compared. Ultimately,
if the results warrant it, all three modalities (fluorescence, reflectance and Raman) may be
combined into a single spectroscopic technique for the diagnosis of breast cancer.
VIII. B. Effects of Tissue Freeze-Thaw on Fluorescence and Reflectance
In developing spectroscopic modalities for the in vivo detection of disease, it is often
necessary to perform preliminary studies on excised tissue. However, unlike Raman
spectroscopy, fluorescence and reflectance spectroscopies are very sensitive to the process of
tissue excision and freezing. These processes can have profound effects on the spectroscopic
properties of the tissue resulting in significant changes in intensity and lineshape relative to
in vivo data. Given the frequent necessity of ex vivo measurements, it is crucial to understand
the effects of tissue removal and freeze-thaw on fluorescence and reflectance data. Although
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studies have been conducted which examine these effects, they did not account for distortions
of the fluorescence spectra caused by tissue scattering and absorption [Palmer et al. 2002].
Accounting for absorption was particularly important in prior studies as they observed
increased hemoglobin absorption in freeze-thaw tissues, possibly due to red blood cell lysis.
Increased tissue absorption will concomitantly reduce the tissue fluorescence. Indeed less
fluorescence was observed in the freeze-thaw samples. However, without correcting the
fluorescence data for the effects of scattering and absorption, it is difficult to relate the
observed changes to specific parameters. In other words, it is not clear if the decrease in
fluorescence intensity resulted solely from increased absorption or if changes in intrinsic
tissue fluorescence were also present. Our study examines normal rat esophagus and
esophageal papillomas. Further, our analysis allows for disentangling the effects of
scattering and absorption from tissue fluorescence.
VIII. B. 1. Sample Preparation and Data Acquisition
In an effort to examine the effect of tissue removal and the freeze-thaw process on spectral
features, a number of rat esophagi were examined as a function of time following tissue
removal and pre- and post- tissue freezing. Data was collected with the FastEEM
instrumentation described in section VIII.A.4 from both normal esophageal tissue and
papillomas. After the removal of the esophagus, the tissue was examined in two ways. To
assess the effect of excision, a spectrum was taken immediately following tissue removal,
with periodic sampling every 10 min. for a total of 30 min. After 30 min. the intervals were
lengthened to every half hour with a total monitoring period of 2 hours. To assess the effect
of freeze-thaw, the esophagus was sampled immediately after removal and then snap-frozen
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in liquid isopentane for a period of 20 min. after which the tissue sample was thawed and a
second spectrum taken.
A rat model for human esophageal squamous cell carcinoma was investigated using
DRS and IFS as an opportunity to examine the freeze-thaw process. Fisher 344 rats were
injected with the carcinogen N-nitrosomethylbenzylamine (NMBA). Within 15-20 weeks
visible polypoid tumors ("papillomas") developed, after proceeding through dysplastic stages
characterized by cellular proliferation and keratinization.
VIIL. B. 2. Preliminary Results
A decrease in fluorescence intensity was
·E_ _ _ ~ ._ . / .. / a. · .-
observed as a unctlon or time ollowing tissue
excision at all excitation wavelengths. Figure
VIII.10 shows an example of the decrease
observed at 337 nm excitation for a sample of
300 400 500 600 700 800
Wavelength (nm) normal rat esophagus. The magnitude of the
Figure VIII.10. Changes in intrinsic
fluorescence of normal rat esophagus at 337 nm intensity decrease varied between samples. No
excitation 20 min. (solid line), 40 min. (dotted
line), 60 min.(dashed line), and 80 min.(lower
dotted line), following tissue excision.
time. The freeze-thaw process was found to cause both intensity and lineshape changes.
Figure VIII. 11 demonstrates a decrease in the fluorescence intensity at 337 nm excitation,
resulting from the freeze-thaw process. Such a decrease was witnessed for all samples.
Lineshape changes can also be seen in Figure VIII. 11. These lineshape changes were
particularly pronounced for esophageal papillomas. A large increase in porphyrin
fluorescence was observed in fresh-frozen papillomas compared to that seen in the freshly
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Figure VIII.II. Intrinsic fluorescence spectra at 337 nm excitation showing intensity and lineshape
changes resulting from the freeze-thaw process in a &b) normal esophagus and c &d) an esophageal
papilloma. Fresh tissue (solid line) Fresh-frozen tissue (dotted line)
excised tissue. An example of the increase in porphyrin fluorescence is shown in Figure
VIII. 12.
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Figure VIII.l2. Intrinsic fluorescence spectra at 412 nm excitation showing differing effects of the
freeze-thaw process on porphyrin fluorescence in a) normal esophagus and b) an esophageal papilloma.
Fresh tissue (solid line) Fresh-frozen tissue (dotted line).
The reflectance spectra also exhibited differences between fresh and fresh-frozen
tissues. An increase in the oxygen saturation parameter is observed in the fresh-frozen
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tissues. Absorption techniques are widely used for the purpose of evaluating tissue
oxygenation and are the basis of pulse oxymetry [Takatani and Ling 1994]. The
measurement relies on the slight change in the hemoglobin absorption spectrum with
oxygenation. Oxy-hemoglobin has a strong absorption peak in the blue region at 415 nm and
a smaller double peak at 542 nm and 577 nm, while deoxy-hemoglobin has a strong peak at
430 nm and a single smaller peak at 560 nm. The absorption spectra of oxy- and deoxy-
hemoglobin are shown in Figure VIII.13a. Also shown are representative reflectance spectra
and model fits of fresh and fresh-frozen tissue. Changes in the hemoglobin oxygen
saturation for several different samples are included in Figure VIII.13 as a table. No
significant increase in the amount of hemoglobin was observed following the freeze-thaw
process, indicating that red blood cell lysis was minimal.
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Figure VIII.13. Changes in the hemoglobin oxygen saturation induced by the freeze-thaw process.
a) Absorption spectra of oxy- (solid line) and deoxy- (dotted line) hemoglobin. b) Diffuse
reflectance spectrum (solid line) and model fit (dotted line) of freshly excised tissue and c) fresh-
frozen tissue. Also shown are the changes in the hemoglobin oxygen saturation for several
different samples.
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Hemoglobin Oxygen Saturation Parameter
Ex vivo Freeze/Thaw
Sample 1 0.55 0.83
Sample 2 0.53 0.50
Sample 3 0.70 0.85
Sample 4 0.48 0.70
Sample 5 0.53 0.72
'I -11~
From these studies, we can conclude that the effects of tissue removal are minimal
within a time period of 1.5 hrs. Although changes in intensity occur with tissue excision, we
do not observe changes in lineshape or reflectance. However, the freeze-thaw process results
in significant differences in both the diffuse reflectance and the intrinsic fluorescence.
Consequently, data acquired shortly after tissue excision should accurately mimic an in vivo
environment while studies on fresh-frozen tissues are not appropriate for extension to clinical
data.
VIII. C. Fluorescence Lifetime Measurements
Most in vivo fluorescence spectroscopy studies to date have focused on monitoring the
steady-state intensity of fluorescence emitted at one or more wavelengths (i.e. the
fluorescence induced by constant excitation light). An alternative approach measures the
time-resolved fluorescence (the time-decay of the fluorescence excited by a short pulse).
Typically, this time-decay is typically on the order of nanoseconds. The method is
technically more demanding than steady-state measurements, as it requires the use of a very
short excitation pulse and special detectors. However, the time dependence of fluorescence
emission can be very sensitive to changes in the environment of the fluorescent species.
Furthermore, as time-resolved measurements are unaffected by tissue elastic scattering and
absorption, they can provide diagnostic information that might otherwise be convoluted when
measured with steady-state fluorescence.
VIII. C. 1. Sample Preparation and Data Acquisition
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Picosecond fluorescence
spectra were obtained
with the laser system,
shown in Figure VIII.14.
Excitation wavelengths
from 250 nm to 360 nm
and 450 nm to 750 nm
Figure IIIV.14. Laser System for Picosecond Spectroscopy
were available. Most
studies presented here employed 330 nm excitation light. The pulse length was 150 fs
FWHM however the temporal resolution was limited by the streak camera detection limit of
10 ps. A spot size of 5 mm was used with an average pulse power of <1 mJ per pulse and a
repetition rate of I KHz. No photobleaching was observed on the samples examined.
Average data acquisition times were on the order of 15 min.
VIII. C. 2. Preliminary Results
103
102
101
a, In
C
4.
0-4
-4 -
- - __ I - T I , I - I
500 1000 1500 2000 2500 3000 3500
Time (ps)
Figure IIIV.15. Fluorescence Decay of NADH in PBS: T'
Component Fit and Residual
To begin our studies we
examined the time-decay
spectra of two biological
moieties often encountered in
our steady-state fluorescence
work, NADH and collagen.
Data were acquired from
wo NADH in solution. NADH has
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two decay times, resulting from different conformations, 240 ps and 550 ps [Couprie et al.
1994]. Our data, shown in Figure VIII.15, exhibits excellent agreement with the literature
values. We extracted lifetimes of 243 ps and 547 ps. This two component fit corresponded
to a 2 value of 1.08. We also examined the
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decay properties of collagen. Commercially
available collagen is powdered while collagen is
present in the body in a hydrated form. We
0o.o0I . exammeeu type collagen in otM poweredu orm
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Wavenumber (nm) and as a hydrated collagen gel. A three
Figure VIII.16. Fluorescence time-decay
data of cervical tissue. a) Fluorescence component fit was necessary to. describe the
lineshape variations as a function of decay
time. 100 ps (solid line) 5.7 ns (dotted line). data. Differences in lifetimes were found as a
The steady state spectra of collagen and
NADH are included for comparison (dashed
lines). Also shown are decay rates and their function of environment. Powdered collagen
relative amplitudes in spectral regions
corresponding to b) collagen and c) NADH. had
decay times of 798 ps, 3.54 ns and 10.03 ns, while
the collagen get had shorter lifetimes of 442 ps,
2.06 ns and 6.57 ns. 2 values were slightly higher
for the data acquired from collagen, 1.1 to 1.2, but
still good. . . . .0 10 20 30 40 50
fVII1.16c Time (ns)
We also examined the fluorescence time-
decay properties of cervical tissue. Fluorescence -
lineshape changes were observed as a function of
. Tl
time. These lineshape changes, shown in Figure t
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VIII. 16a, are consistent with a faster decay for , . . . . .0 10 20 30 40 50
Time (ns)
-264-
.
NADH. Decays from two different spectral regions, known to correspond predominately to
NADH and collagen fluorescence, were examined. The decay with dominant contributions
from collagen fluorescence was obtained by averaging the spectral range from 400 nm to 415
nm and is shown in Figure VIII. 16b. Lifetimes found in this spectral region were 997 ps and
5.57 ns with a relative amplitude ratio of 477. In the spectral region from 450 nm to 465 nm,
indicative of NADH, comparable lifetimes of 881 ps and 5.87 ns were obtained. However, in
this spectral region, shown in Figure VIII. 16c, the relative amplitude ratio was 1361. This is
indicates a larger contribution from the shorter lifetime decay in the spectral region
dominated by NADH fluorescence. The lineshape changes and decay analysis of different
spectral ranges are consistent and allow us to conclude that NADH has the faster decay rate
and collagen the slower. It is notable that extension of the results from pure component
chemicals to tissue was not straightforward. Further studies are necessary to confirm these
findings. Also, lifetime variations between tissue types must be examined within a single
tissue type and between normal and diseased tissues.
VIII. D. Surface Enhanced Raman Scattering
A great disadvantage of Raman spectroscopy results from the extremely small scattering
cross-section of the Raman process. Surface enhanced Raman scattering (SERS) is a
spectroscopic technique that results in strongly increased Raman signals when molecules are
attached to nanometer-sized gold or silver structures. The effect provides the structural
information content of Raman spectroscopy together with ultrasensitive detection limits.
Further, since SERS occurs in the local fields of metallic nanostructures, the lateral
resolution is determined by the confinement of the local fields and can be orders of
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magnitude better than the diffraction limit. Another advantage of SERS is that the
fluorescence background, which often complicates the accurate analysis of Raman spectra, is
quenched by nonradiative decay channels provided by the metallic nanostructure. For theses
reasons, SERS has the possibility to greatly advance biomedical Raman spectroscopy. To
this end, we have begun an investigation of SERS of both cells and tissues.
VIII. D. 1. SERS Cell Studies
Within the recent decade, Raman spectroscopy was successfully applied to living cells
[Puppels et al. 1990; Peticolas et al. 1996; Otto et al. 1997; Sijtesema et al. 1998, 2000;
Feofanov et al. 2000; Shafer-Peltier et al. 2002]. Measurements on cell monolayers using
confocal Raman systems show clear differences in the Raman spectra of the cell nucleus and
the cell cytoplasm. Excellent Raman spectra of DNA in the nucleus of a living cell can be
obtained using a laser Raman microscope, where the sample is inside the laser cavity
[Patapoff et al. 1988; Peticolas et al. 1990].
Raman scattering is an inefficient effect, with typical non-resonant Raman scattering
cross-sections on the order of 10-30 cm2 per molecule. Typical collection times for a
spontaneous Raman spectrum of a living cell (using 5-10 mW laser excitation and a confocal
Raman system) can be hundreds of seconds. This results in very long data acquisition times
to generate a "Raman map" of a cell [Shafter-Peltier et al. 2002], Further, many chemicals
are present in a cell at very low concentrations and the excitation laser intensity is limited by
effects of cell degeneration, the Raman signal observed from a single cell is extremely weak.
Thus it is difficult to study viable cell lines.
In SERS, Raman signals can be enhanced by many orders of magnitude. SERS
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occurs when the probed molecules are attached to metallic nanostructures. Raman scattering
takes place in the high local optical fields of these nanostructures [Otto et al. 1984;
Moskovits 1985; Campion and Kambhampati 1998; Kneipp et al. 1999]. Areas of enhanced
local optical fields occur due to resonances of the applied optical fields with the surface
plasmon oscillations of the metallic nanostructures. In addition to this "electromagnetic field
enhancement," the electronic interaction between the Raman molecule and the metal can
result in an increase of the Raman scattering cross-section itself, called "chemical or
electronic enhancement". In the visible and NIR frequency range, silver and gold colloidal
clusters or island films of these materials can result in electromagnetic SERS enhancement
factors up to 10 to 12 orders of magnitude [Kneipp et al. 1995, 1997, 1998].
The field enhancement effect is also operative in fluorescence. Although the effect of
surface-enhanced fluorescence has been observed for a few molecules, in many cases, the
metal provides strong nonradiative decay channels [Weitz et al. 1983; Sokolov et al. 1998].
This fluorescence quenching effect can compensate for the field enhancement, resulting in a
net fluorescence signal much smaller than that measured without the metal. That explains
why in many experiments the surface enhanced resonance Raman (SERRS) spectrum does
not show the expected fluorescence background [Bachackashvilli et al. 1983, 1984; Kneipp
et al. 1983; Pettinger 1984].
SERS studies have also been performed on living cells [Manfait et al. 1990, 1992;
Nabiev et al. 1991; Morjani et al. 1993]. In these experiments, colloidal silver particles were
incorporated inside the cells and SERS was applied to monitor the intracellular distribution
of drugs. Surprisingly, these experiments show SERS spectra of the drug but no SERS
spectra of the native cell constituents themselves were detected.
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In general, due to its chemical inactivity, gold is the more suitable metal for
incorporation inside living cells. It has been shown that gold colloidal clusters have SERS
enhancement factors comparable to silver clusters when NIR excitation is applied [Kneipp et
al. 1993]. Moreover, NIR is the desired excitation range for Raman measurements of cells
since the lower energy photons reduce the fluorescence background in biological samples
and also the risk of cell damage [Hanlon et al. 2000; Shafter-Peltier et al. 2002].
In this study we report NIR SERS studies of living cells using colloidal gold as the
SERS active substrate [Kneipp et al. 2002]. In contrast to previous SERS studies using
colloidal silver, we measure strong SERS signals from the native chemical constituents of the
cell. Thus, this work provides a tool for the sensitive detection of native chemicals inside a
cell as well as their intracellular distribution, suggesting many applications in biomedical
research.
VIII. D. 1. a) Cell Preparation
Differentiated intestinal epithelial cells HT29 (gift of the Harvard Digestive Diseases Center)
were grown on 25 mm round coverglasses for SERS measurements and on formvar-carbon
coated grids for electron microscopy studies. Cells were grown with Dulbecco's high-
glucose modified Eagle medium (DMEM) supplemented with 10% fetal calf serum, 100
units/ml penicillin and 100 g/ml streptomycin (Gibco BRL, Life Technologies, Grand
Island, NY). Cells were grown to confluency at 370 C in a humidified atmosphere of 5%
CO2 in air. Monolayers were loaded with colloidal gold by fluid-phase uptake.
Approximately 24 hours prior to data collection, the culture medium was supplemented with
the colloidal gold suspension either at either -3,300 particles/cell or -330 particles/cell.
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Immediately before the experiments, free gold was removed by rinsing the monolayers in
Hank's Balanced Salt Solution (HBSS) without sodium bicarbonate or phenol red, buffered at
pH 7.4 with 10 mM HEPES (Sigma, St. Louis, MO). Cells remained in the same buffer
throughout the measurements. The salts in the buffer solution induce the formation of small
colloidal aggregates with sizes of a few hundred nanometers. Cluster-cluster aggregation
inside the cell results in the formation of larger gold colloidal clusters, discussed further
below.
VIII. D. 1. b) SERS Measurements and Data Processing
Raman measurements were carried out on single cells using the confocal microscope,
discussed in Chapter III. 830 nm excitation and a spot size of -1 gm were employed.
Application of 2 to 5 mW NIR excitation did not
result in any cell damage. Good SNR SERS
spectra were measured with a 1 s. collection time.
For mapping experiments, the cell monolayer was
moved in 1 gm steps under the laser focus,
covering a total area of 30 x 30 gm.
VIII. D. 1. c) Results
Figure VIII. 17 shows examples of unprocessed
SERS spectra measured at different places on the
cell monolayer incubated with colloidal gold. The
Figure VIII.17. Typical unprocessed
spectra acquired in 1 s. show a very good SNR surface enhanced Raman spectra.
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allowing for the possibility of much shorter collection times. The SERS signal appears on
the order of thousands of counts per second compared to signals of counts per second
measured in "normal" Raman spectroscopy of single cells.
In general, all 900 spectra measured at different locations within the cells are distinct.
The variety of lineshapes, relative Raman amplitudes and Raman line widths observed
indicate a sensitive means to measure the inhomogenity of a cell. The Raman lines can be
assigned to native chemical constituents in the cell nucleus and cytoplasm, such as DNA,
RNA, phenylalanine, and tyrosine. The 1120 cm 1 line is characteristic of an O-P-O DNA
backbone vibration [Puppels et al. 1990; Peticolas et al. 1996]. Raman lines around 1300
cm-' are related to adenine and guanine vibrations, however, RNA also has strong SERS
bands in this frequency region [Kneipp et al. 1991]. The spectral region around 1000 cm 1
may result from phenylalaline at 1004 cm-' and a C-O DNA backbone vibration at 980 cm'.
The bands at about 830 cm' l are likely due to a sugar-phosphate backbone vibration. The
frequency of these bands is slightly different for B- and A-forms of DNA [Peticolas et al.
1996]. The absence of a strong SERS line at 735 cm', which arises from the adenine ring
breathing mode, indicates that native, and not denatured, DNA contributes to the spectra
[Kneipp and Flemming 1986; Chumanov and Cotton 1999]. SERS spectra also show the
conformationally sensitive guanine lines around 650 and 670 cmri [Peticolas et al. 1996].
The spectrum in Figure VIII. 17a exhibits a strong SERS line at 650 cm'l. This peak
is likely a guanine vibration superposed with a strong tyrosine vibration and thus also not
indicative of DNA denaturation [Peticolas et al. 1996]. In contrast to "normal" Raman
spectra of living cells, where strong Raman bands appear around 1450 cm-' (protein CH
deformation vibration) and at 1650 cm 'l (Amide I), in the SERS spectra these bands exhibit
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almost no enhancement. In a few spectra, a very weak SERS band appears at about 1450
Figure VIII.18 displays
200 run
electron micrographs showing the
distribution of colloidal gold particles
inside a cell monolayer. The colloidal
particles form small colloidal clusters
between 100 nm and a few microns in
stze. The largest clusters can also be
Figure VIII. IS. Electron micrographs of colloidal gold
particles inside a cell monolayer.
seen in the phase contrast microscope
views in Figure VIII.19. The higher magnification image, shown in Figure V1I1.18b,
demonstrates that the gold clusters are made of 60 nm colloidal gold spheres. Extension from
NIR SERS experiments performed on DNA attached to similar gold colloidal cluster, allows
us to infer a minimum enhancement factors of 103 - IU" for DNA IKneipp and Remming
19861. This estimate is based on the assumption that all DNA molecules contribute to the
SERS signal.
Figure VIII.19
acquired from these cells.
4 and the Raman map
3
image of two living cells
shows a phase contrast
9
8
7
6
a) 10 JlIll b) 10~ The image was created by
Figure VIII.I9. a) Phase contrast image of two living cells and b) the
image of the total SERS signal.
summing the total Raman
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signal obtained at each location. The image shows that the SERS signal does not appear over
the entire cell and that parts of the cell show no Raman signal. Since it is unlikely that there
are regions of the cell that do not contain Raman scatterers, it follows that the lack of a SERS
signal results from the absence of a colloidal gold particle. Variations in the signal strength
in the "SERS-active" or gold occupied cell regions may be due to a non uniform
electromagnetic SERS enhancement factor within the cell or may retlect a very
inhomogeneous distribution of the scattering substance inside the cell.
In order to image the distribution of a particular substance using SERS, the signal of a
Raman line resulting from that substance must be normalized to the SERS enhancement
factor operative at each location. The SERS features appear on a broad background, which
we ascribe to surface-enhanced fluorescence signals from the cell. The lateral distribution of
the broad surface-enhanced fluorescence
signal (with contributions from many
tluorophores) should roughly monitor
the distribution of the field enhancement.
Therefore. the signals are normalized to
the average fluorescence signal between
400 and 1700 cm-I.
Example of SERS mappmg,
Figures VII1.20a and V1I1.20b, show the
distribution of phenylalanine and DNA
"
a) b)
•••",
... 1
2over a 30x30 Jlm cell monolayer based
on the areas of the 1004 cm-1 Phe- and
Figure VIII.20. Distribution of a) phenylalanine and b)
DNA over a 30x30}im2 cell monolayer. SERS spectra
represent locations of the maximum signals of the two
modes used to generate the Raman maps.
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1120 c' O-P-O DNA backbone peaks, respectively. Also shown in Figure VIII.20 are
SERS spectra taken from regions of high intensity in each map. In general, the cell nucleus
should contain a larger amount of DNA, whereas phenylalanin should be present mainly in
the cytoplasm [Pupples et al. 1990; Shafter-Peltier et al. 2002].
Figure VIII.20 demonstrates the feasibility of using SERS for generating Raman
images. The strongly enhanced Raman signals allow one to generate a surface-enhanced
Raman map of a cell (approximately 15x15 #,m) with 1 #.m lateral resolution in about 5
minutes (1 s. per mapping point) using 2 to 5 mW NIR excitation. It should be noted, that
these first SERS images are "qualitative". The Raman signal appears as a superposition of
the concentration of the Raman molecule and SERS enhancement factor. At present, the
normalization scheme accounts for the electromagnetic SERS enhancement. For further
development of this technique, nanotechnologies should be explored which generate a
uniform distribution of the SERS-active nanostructures over the cell and show only a weak
substance-specific chemical SERS enhancement.
To summarize, we have demonstrated the feasibility of measuring SERS spectra of
native constituents within a single viable cell and generating a SERS map showing the
distribution of specific chemicals within the cell. A SERS spectrum provides rich chemical
information about the cell and allows observation of small structural modifications.
Moreover, the strong Raman signals allow Raman mapping over single cells in very short
times compared to normal Raman measurements. Ultrasensitive Raman spectroscopy inside
living cells opens up exciting opportunities for the diagnosis of diseases at a very early stage.
It may allow the detection of subcellular chemical changes that are the precursors of larger
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morphological changes. In this way, exciting opportunities are opened up for the diagnosis
of diseases to be made at very earlier stages.
VIII. D. 2. SERS Tissue Studies
We have also conducted reliminarv 1400r
investigations of SERS with tissue. 1200
Both homogenized and thin slices of 1000
C
tissue were examined using the (
600
confocal Raman microscope. Figure
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obtained from a sample of Raman Shift (cm- 1)
homogenized breasttissue. Sampl s Figure VIII.21. SERS spectrum of homogenized breasthomogenized breast tissue. Samples tissue.
were prepared by spreading homogenized tissue mixed with nanoparticle solution onto an
MgF2 flat for microscopy. The spectrum, displayed in Figure VIII.21, was collected in 1 s.
with very low levels of laser power (>5 mW). It exhibits a large number of sharp Raman
peaks indicating high information content. SERS opens the possibility to examine chemicals
present in very low concentrations in the tissue. However, identification of the species
responsible for these peaks is challenging.
The distribution of chemicals within a tissue can rapidly be probed using SERS.
Figure VIII.22 is a SERS map of a thin section of breast tissue. Nanoparticles were applied
to the sample by allowing the colloid solution to evaporate from the tissue surface. The
nanoparticles form small colloidal clusters, which can be seen in the phase contrast image
shown in Figure VIII.22a. The SERS map, displayed in Figure VIII.22b, was generating by
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plotting the area under the Raman spectrum acquired at each location. Regions of high SERS
intensities correlate well with the colloidal clusters seen in the phase contrast image. SERS
spectra obtained from regions of high intensity on the map are shown in Figure VIII.22c. By
500 1000 1500
Wavenumber (em-)
VII1.22c
10000
12000
"" 8000
C~
8 6000
4000 l
Mi"A;......... ~ ,.............. 2'000. l
Figure VIII.22. SERS map of breast tissue.
utilizing nanotechnology techniques, such as period particle arrays, a uniform distribution of
nanoparticles can be achieved thereby providing chemical inforrnation at regular intervals
across the tissue sample.
During our preliminary investigations into SERS of tissue, we noted unusual spectral
behavior. Occasionally, while focusing the microscope to obtain maximum signal, the
spectral lineshape would exhibit time dependent fluctuations. An example of such behavior
can be seen in SERS spectra of carotid artery. Each of the 4 spectra in Figure VIII.23 was
integrated for I s. and the spectra were collected sequentially with no change in focus.
-275-
Raman peaks grow in size, appear and disappear
dependant fluctuations is not known. It may be
suggestive of single molecule dynamics as moieties
move in and out of the nanoparticle zone of
enhancement. Such time dependent fluctuations
were also observed in the SERS cells study
discussed above.
with time. The cause of these time
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Combination of Raman and Fluorescence
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complex, ceroid, is a characteristic of Wavenumber (cm-')
atherosclerotic plaques. The mechanism of ceroid Figure V1i.23. SERS spectra of crotid
artery exhibiting time dependent
fl Ictilationls.
formation has been extensively studied as the
complex is postulated to cause cell injury and necrosis ultimately resulting in plaque
irreversibility. Despite intensive research, ceroid is only defined empirically through its
fluorescence properties and its behavior during various staining processes, while its precise
chemical composition remains unknown. By using our combined Raman and fluorescence
microscopy system we have examined the chemical composition of ceroid deposits in situ in
aorta and coronary artery atherosclerosis. 'The synergy of these two types of spectroscopy
allows for the identification of ceroid via its fluorescence signature and the subsequent
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elucidation of its chemical composition through the acquisition of a Raman spectrum.
Analysis of the Raman spectra from numerous ceroid deposits demonstrates that several
different mechanisms contribute to its formation in vivo. Data indicate that the primary mode
of lipid peroxidation resulting in the production of ceroid occurs through a Fenton reaction
while the principal method of protein modification is direct oxidation of amino acids.
Furthermore, we compare the chemical composition of intracellular and extracellular ceroid
deposits thereby providing a timeframe for the order of chemical reactions which ultimately
result in ceroid deposition within atherosclerotic plaques.
VIII. E. 1. Introduction
It has been suggested that the progression of a fatty streak to an advanced atherosclerotic
lesion with necrosis results from toxic products of lipid oxidation produced by macrophages.
Incubation of macrophages with oxidized low density lipoprotein (oxLDL) has been shown
to induce lipid loading [Steinbrecher et al. 1990; Witztum and Steinberg 1991]. Ultimately,
most of this lipid is contained within the macropahge lysosomes, primarily in the form of the
lipid-protein complex called ceroid [Ball et al. 1986]. Ceroid is thought to have detergent
properties, which dissolve the foam cell membrane leading to extravasation of the complex
into the extracellular space and eventually permanent tissue damage. Ceroid is described as a
golden yellow, granular or globular, lipoid pigment. It is histochemically identified by
insolubility in a variety of lipid solvents and stainability with lipid dyes [Hartroft and Porta
1965; Porta and Hartroft 1969; Wolman 1980; Pearse 1985]. In addition, ceroid is
characterized by the emission of intense yellow autofluorescence when it is excited with
ultraviolet (UV) light [Mitchinson et al. 1985; Fitzmaurice et al. 1989; Verbunt et al. 1992].
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This definition, however, provides no information as to the origin or definitive chemical
nature of ceroid.
Pappenheimer and Victor were the first to report the presence of ceroid in
atherosclerotic plaques [Pappenheimer and Victor 1946]. Since then, several reports have
described its prevalence in the full spectrum of atherosclerotic lesions [Burt 1952; Hartroft
1953; Slater and Smith 1972; Mitchinson 1982]. Ceroid is not found in normal vessels or
thrombi. In small uncomplicated plaques, it initially appears within the cytoplasm of
superficial macrophage-like foam cells and is rarely associated with smooth-muscle cells or
endothelial cells. It has therefore been suggested that macrophages might be responsible for
ceroid accumulation in the plaque, with potentially damaging consequences, such as cell
injury, necrosis, and the release of insoluble material into the extracellular space, ultimately
causing the plaque to become irreversible. In accordance with this theory, most of the ceroid
in advanced plaques is extracellular appearing as solid granules or ring structures in the
necrotic base.
Detection of ceroid has proven to be diagnostic of atherosclerotic disease using both
standard histopathology and fluorescence spectroscopy. Additionally, several reports suggest
that there is a correlation between the amount of ceroid present and the severity of an
atherosclerotic lesion [Burt 1952; Slater and Smith 1972]. However, relatively little is
known of the chemical composition of ceroid deposits and their role in the progression of
atherosclerosis. This is primarily because ceroid is insoluble in organic solvents and cannot
be extracted from the plaques and purified for chemical analysis.
Although the definitive mechanisms leading to the production of ceroid are unknown,
several routes of formation have been proposed based on biochemical studies, in vitro cell
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culture experiments, and animal models. These investigations have established that
modification of proteins during lipid peroxidation produces fluorescence similar to that
observed in situ in atherosclerotic lesions and attributed to the presence of ceroid [Kikugawa
and Beppu 1987]. Further, experiments in which homogenized tissue or macrophages are
exposed to conditions that promote lipid peroxidation witness an increase in the overall
fluorescence of the sample consistent with the fluorescence observed in samples containing
ceroid [Tsuchida et al. 1985; Esterbauer et al. 1986; Hoff et al. 1992; Nilsson and Yin
1997]]. As a result, protein modifications ensuing during lipid peroxidation have been
intensely investigated and implicated in the formation and deposition of ceroid. Mechanistic
insight into ceroid formation is further complicated by the wide variety of fluorophores
which emulate ceroid fluorescence and can be produced in different in vitro model systems
using biological materials as substrates. Based on such studies, copious routes of ceroid
formation have been proposed [Yin 1996]. In this manuscript, we investigate the presence of
chemical moieties from several of these potential routes of formation in ceroid deposits in
human aorta and coronary artery.
The majority of experiments which strive to identify the principal route of formation
of ceroid focus on modifications of low density lipoprotein (LDL) as clinically, elevated
serum LDL levels predict risk of coronary artery atherosclerosis, while elevations of very
low density lipoprotein (VLDL) and high density lipoprotein (HDL) levels do not. The
Fenton reaction is one of the earliest proposed and most broadly accepted mechanisms of
ceroid formation [Dillard and Tappel 1971]. In this schema, hydrogen peroxide, produced by
the electron transport chain of mitochondria, forms a hydroxyl radical in the presence of
ferrous iron. The highly reactive hydroxyl radical is postulated to peroxidize the
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polyunsaturated fatty acids (PUFAs) associated with LDL. Thus, iron and oxygen free
radical related peroxidation of LDL may occur inside lysosomes resulting in the formation of
cross linked biocomplexes that are undegradable and thought to be ceroid. Also formed
during this reaction are lipid hydroperoxides and cyclic peroxides which further decompose
into various saturated or unsaturated carbonyl compounds, mainly aldehydes. These reactive
aldehydes, such as malondialdehyde and 4-hydroxynonenal, produce fluorescent compounds
which exhibit fluorescence characteristic of ceroid [Chio and Tappel 1969; Esterbauer et al.
1986].
Further support for this pathway is derived from examining the distribution of iron in
vivo. Heavy metals such as iron have been found in the lysosomes of most cells as a
consequence of normal autophagocytic degradation of metalloproteins [Vatassery et al. 1989;
Brunk et al. 1992]. This mechanism is particularly appealing in the case of atherosclerosis as
macrophages may become iron enriched during the phagocytosis of red blood cells or cell
debris. Additionally, colocalization of ceroid and iron has been histologically demonstrated
[Lee et al. 1998]. However, controversy concerning the feasibility of this mechanism in vivo
stems from the weak prooxidant nature of the ferrous ion. Further, for this mechanism to
proceed at a reasonable rate, iron must be present in its reduced form [Dunford 1987].
Conditions capable of converting the ferric ion to its active reduced form are speculative and
direct oxidation of pure lipids by iron has not been demonstrated under physiologically
relevant conditions.
As a consequence of concerns with the physiological plausibility of the Fenton
reaction, studies have focused on alternative pathways of lipoprotein modification. When
serum LDL is metabolized by foam cells, the apoproteins are first removed by proteolytic
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enzymes, the cholesterol esters are then degraded into free fatty acids and free cholesterol.
Free cholesterol is toxic to the foam cells, and is either exported from the cells or detoxified
by re-esterification into cholesterol esters. The accumulation of free cholesterol eventually
causes the foam cells to lyse thus releasing free fatty acids, free cholesterol, cholesterol
esters, phospholipids, and enzymes, such as myeloperoxidase, into the extracellular space.
Hypochlorite, a two-electron oxidant produced by myeloperoxidase, generates a high uptake
form of LDL primarily by oxidizing the protein component [Hazel and Stocker 1993]. The
peroxidation of LDL produces, among other things, HOOA and HODA, two molecules
reported to have similar fluorescence properties to ceroid. Other protein oxidation products,
such as dityrosine, the oxidation product of tyrosine, have also been suggested as possible
sources of ceroid fluorescence [Amado et al. 1984].
Whereas the majority of mechanistic studies examine LDL associated fluorophores,
reactions between various carbohydrates also give rise to a group of molecules with ceroid
like fluorescence. These reactions are termed glycation or Maillard reactions [Maillard
1912]. This pathway involves the production of Schiff bases through the interaction of
reducing sugars, such as glucose or fructose, and amino compounds. The Schiff bases
rearrange to more stable ketoamine compounds called Amadori products. Although fairly
stable, deamidation or dehydration of the Amadori complex may occur resulting in a variety
of unsaturated carbonyls. Further reactions between these carbonyls results in the formation
of yellow brown advanced glycation end-products (AGEs), which have fluorescence
analogous to ceroid [Baynes and Monnier 1989].
Several molecules have been implicated in both the inhibition and the promotion of
ceroid formation. For example, ascorbic acid is a water soluble antioxidant which has been
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implicated in the recycling of a-tocopherol [Frei et al. 1989; Vatassery et al. 1989].
However, ascorbic acid can alternatively induce free radical related lipid peroxidation in the
presence of transition metals, such as iron and copper. Further, it has been reported that
ceroid like fluorophores have been observed in reaction products between ascorbic acid and
various amino acids [Yin and Brunk 1999]. Additionally, a-tocopherol, generally
considered an endogenous LDL antioxidant, has been implicated in the reduction of the ferric
ion necessary to initiate peroxidation of LDL through a Fenton reaction [Yamamoto and Niki
1988]. There are other antioxidants whose roles in atherogenesis and particularly ceroid
formation are controversial including several polyenic compounds. Among these we have
included 13-carotene and retinal palmitate in our study [Karnaukhov et al. 1972; Szweda
1994].
The purpose of this study is to more completely characterize the chemical nature of
ceroid deposits in human atherosclerotic plaques in an effort to shed light on the process of
ceroid formation. This is accomplished by the acquisition of Raman spectra from ceroid
deposits in situ in samples of coronary artery and aorta. Raman spectra consist of unique
combinations of sharp bands, resulting from molecular vibrations, which allow for
identification of the chemical species in the sample. The utility of NIR Raman spectroscopy
for probing the biochemical composition of human tissue has been well established
[Mahadevan and Richards-Kortum 1996; Manoharan et al. 1996; Hanlon et al. 2000].
Furthermore, a preliminary study illustrating the utility of this approach for the
characterization of the chemical makeup of ceroid in situ has recently been published [van de
Poll 2002]. Although the study provides a comprehensive illustration of the approach, few
deposits were examined thus precluding an insightful analysis of the mechanisms leading to
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ceroid formation in vivo. Our work extends this approach by examining the chemical
makeup of numerous ceroid deposits in samples of both aorta and coronary artery.
Due to the strong correlation between the presence and amount of ceroid and the
severity of atherosclerotic lesions, it is of crucial importance to fully understand the
mechanism of ceroid formation. Insight into the chemical composition of ceroid will shed
light on the process of lipoprotein degradation and deposition in atherosclerotic plaques and
will address the validity of several theories that have been proposed for ceroid formation.
Additionally, a better understanding of the mechanism of ceroid formation may suggest
avenues to induce regression or prevent progression of atherosclerotic plaques with medical
therapy.
VIII. E. 2. Sample Preparation and Data Acquisition
VIII. E. 2. a) Tissue Samples
Raman spectra were collected from frozen sections of coronary artery and aorta obtained
from either explanted recipient heart specimens or at the time of autopsy. The samples were
rinsed with phosphate-buffered saline (PBS), pH 7.4, frozen in liquid nitrogen, and stored at
-85C until use. The samples were then mounted in histoprep (Fisher Diagnostics,
Orangeburg, NY), sectioned, 6 gm thick, on a cryomicrotome (Leica), and mounted on 1 mm
thick MgF2 flats (Moose Hill Enterprises Inc., Sperryville, VA) for microscopy. Contiguous
6 gm thick frozen tissue sections were mounted on glass microscope slides, underwent lipid
extraction, and were then stained with Oil Red O (ORO) (Poly Scientific R&D Corporation,
Bay Shore, NY). Lipid extraction was accomplished by passing the sections through 50%,
75%, and 100% ethanol for 5 minutes each, followed by rehydration in 50% and 25%
-283-
ethanol. Ceroid deposits were identified by a combination of histology (lipid extraction and
ORO staining) and fluorescence spectroscopy and their chemical composition subsequently
examined using Raman spectroscopy. A total of 39 ceroid deposits were examined in 5
samples of coronary artery and 27 ceroid deposits in 6 samples of aorta from 11 patients.
VIII. E. 2. b) Instrumentation
The fluorescence and Raman spectra of both tissues and reagent chemicals used in the model
described below were acquired using the confocal microscope, section III.F.2. The
microscope itself is equipped with a range of objectives, both normal and phase contrast. For
the studies presented here we used a 63x infinity-corrected water immersion objective (0.9
NA), although water immersion was not used. Raman excitation at 830 nm with output
powers of approximately 150 mW was employed. The spectrograph itself has an adjustable
slit and a turret, which holds three gratings for a range of measurements. For the Raman
studies a 600 grooves/mm grating blazed at 1 Lm was used along with the 140 m
spectrograph entrance slit setting, providing - 8 cm 1 resolution. Simply by changing the
excitation source, the filters/beamsplitters, and spectrograph grating, the system can be
adapted for fluorescence spectroscopy. For the fluorescence measurements, 476 nm
excitation light, typically 5 mW, was delivered to the system via fiber optics from an argon
ion laser (Coherent Innova 700, Coherent Inc., Santa Clara, CA) in an adjacent laboratory. A
600 grooves/mm grating blazed at 500 nm was used for the fluorescence measurements. The
switch between Raman and fluorescence is made in less than one min.
VIII. E. 2. c) Data Processing
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Fluorescence data were typically collected for 0.5 sec. to 5 sec. Raman spectral data were
collected for 60 sec. to 500 sec. depending on the Raman scattering cross-section of the
deposit. Often it was necessary for the ceroid deposits to be photobleached for several
minutes to reduce the background fluorescence before acquiring a Raman spectrum. All
spectral data processing was preformed in MATLAB 5.31 (MathWorks, Inc.). Both Raman
and fluorescence data were corrected for the spectral response of the system using a tungsten
light source. The data was next frequency calibrated using the known Raman lines of toluene
or, in the case of fluorescence, a mercury lamp. Cosmic rays were removed with a derivative
filter and the small background from the MgF2 flat was subtracted. Raman data were fit with
a fifth order polynomial which was subtracted from the spectrum in order to remove any
fluorescence background.
VIII. E. 2. d) Chemical Samples and Spectral Modeling
The chemical composition of the ceroid deposits was determined by analyzing each Raman
spectrum with a model. The model contains Raman spectra of several chemicals postulated
in the literature to comprise ceroid deposits. These spectra, called basis spectra, are linearly
combined with the appropriate weighting factors to recreate the Raman spectrum acquired
from a deposit. These weighting factors, called fit coefficients, indicate the amount of each
chemical present in the ceroid deposit. Modeling is based on the assumptions that the Raman
spectrum of a mixture is a linear superposition of the spectra of its components and that
signal intensity and chemical concentration are linearly related. Non-negative OLS fitting of
the Raman spectrum of ceroid yields the contribution of each basis spectrum to the entire
data spectrum. Model basis spectra are derived by directly taking the Raman spectra of
chemicals either synthesized in the laboratory or purchased from commercial sources.
-285-
Similar modeling approaches have been used previously to extract the chemical composition
of both artery and breast tissues [Buschman et al. 2001; Shafter-Peltier 2002].
The Raman model used in this analysis contains chemicals often found in arterial
tissue as well as chemicals representative of several of the pathways of ceroid formation
discussed above. Acquisition of the first six model components; -carotene, calcium
hydroxyapatite, cholesterol linoleate, cholesterol oleate, free cholesterol, and collagen has
been previously described [Buschman et al. 2001]. All chemicals listed below were
purchased from Sigma (St. Louis, MO) unless otherwise stated. Spectra of HDL (human
plasma) and LDL (human plasma) were obtained using the instrumentation described above.
The Raman spectrum of a sample of Cu2+ oxLDL (courtesy of Dr. H. Hoff, Cleveland Clinic
Foundation, Department of Vascular Cell Biology and Atherosclerosis) was incorporated to
assess the contribution of the Fenton
reaction to ceroid formation. The
importance of protein oxidation was
assessed through the inclusion of
myeloperoxidase/NO2 oxLDL
(courtesy of Dr. H. Hoff) and diacetyl
dityrosine (courtesey of Dr. L. Sayer).
The Maillard reaction is represented by
the Raman spectrum acquired from the
product of human serum albumin (fatty
acid free) and D(-) fructose
synthesized according to the method of
Model Signal OLF Ac
N=0.056
a-Tocopherol 5.09 0.49 2.2
B-Carotene 4.22 0.54 2.5
Ascorbic Acid 5.62 0.74 1.3
Retinal Palmitate 3.28 0.89 1.9
Collagen 7.68 0.43 1.7
Hemoglobin 8.34 0.84 0.8
Cholesterol 4.15 0.45 3.0
Cholesterol Linoleate 4.25 0.21 6.4
Cholesterol Oleate 4.36 0.27 4.7
HDL 6.37 0.34 2.6
LDL 5.08 0.41 2.7
Fenton Reaction 4.72 0.23 5. 1
Protein oxLDL 6.36 0.23 3.8
Diacetyl Dityrosine 5.50 0.24 4.3
Ascorbic Acid Ox 4.42 0.18 7.2
Maillard Reaction 8.14 0.74 0.9
Calcification 2.38 0.78 3.0
Table VIII.2. Fit coefficient errors for the ceroid data.
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McPherson et al; I McPherson et al. 1988 i. To investigate the role of ascorbic acid in ceroid
formation, the Raman spectrum of both L-ascorbic acid and a mixture of L-ascorbic acid and
L-Glutamine incubated in PBS was included in our model Yin 19921. This pathway
represents the proposed route of fluorophore formation during ascorbic acid initiated
peroxidation. Ceroid like fluorescence was observed following incubation. In addition to f-
carotene, -tocopherol and retinal palmitate (all trans) were incorporated into the analysis as
representative polyenic molecules. Also, the Raman spectrum of hemoglobin (Human, A,,
ferrous) was included to examine the distribution heme or heme degradation products within
the deposits. Table V111.2 displays fit coefficient errors calculated using the analytical
equation derived in Chapter IV. Also shown are the parameters used for error calculation.
The noise in Table V11I.2 is the mean noise from all data. Noise in the coronary and aorta
data sets was comparable, N=0.060.02 and 0.05)0.02, respectively.
VIII. E. 3. Results
Ceroid rich regions in each tissue section were identified through a combination of histology
and fluorescence spectroscopy. Our combined Raman and fluorescence microscopy
instrumentation allows for the identification of ceroid, through its fluorescence signature, and
the subsequent acquisition of Raman spectroscopic data from the same region. Ceroid
deposits were presumptively identified by comparison of the phase contrast image of the
unstained section used for spectroscopy and lipid extracted ORO stained serial sections. A
fluorescence spectrum was obtained from each ceroid deposit so identified, to confirm the
presence of fluorescence features characteristic of ceroid. Figure VIII.24 shows one example
of the data used to identify ceroid deposits. Figure VIII.24a displays a phase contrast image
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Figure VIII.24. a) Phasecontrast image of a ceroid deposit in a sample of coronary artery (size bar 25
11m). b) White light image demonstrating a positive ORO stain for ceroid. c) Fluorescence spectrum
acquired from the deposit and exhibiting a red shift when compared with the fluorescence spectrum of
collagen or elastin.
of a ceroid deposit as identified through comparison with a lipid extracted ORO stained
section, shown in Figure VIII.24b. Figure VII1.24c shows the fluorescence spectrum
acquired from the deposit shown in image VIII.24a and highlighted by a small box. The
fluorescence spectrum of the ceroid deposit exhibits a red shift compared to the fluorescence
spectrum of collagen or elastin, the two major fluorophores found in artery at this excitation
wavelength. Their spectra, which have similar fluorescence characteristics at this excitation
wavelength, are also shown in Figure VIII.24c. A Raman spectrum was subsequently
collected from each of the ceroid deposits that exhibited both stainablity with ORO following
lipid extraction and a red shifted fluorescence spectrum characteristic of ceroid.
After acquisition of a Raman spectrum, the chemical composition of the ceroid
deposit is extracted through modeling. The advantage of this approach is that the basis
spectra are correlated with the presence of specific chemicals, thereby providing information
about ceroid composition in situ. The accuracy of a given model can be qualitatively
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determined by observing the residual, calculated by subtracting the model fit from the Raman
spectrum of the deposit. The smaller the residual, the more completely the model has
accounted for all of the observed spectral features and thus the better the chemical analysis.
Figure VIII.25a shows the Raman spectrum of the ceroid deposit pictured in Figure VIII.24a.
Also shown are the model fit and the residual. The small size of the residual and its lack of
structure indicate a good fit. Although the model employed in this analysis was generally
able to account for the majority of the spectral features observed, several Raman spectra
exhibited a broadening of the 1650 cmn peak which was not present in any of the basis
spectra. A spectrum of ceroid displaying this broadening is shown in Figure VIII.25b along
with its model fit and residual. The persistence of the broadened feature in the residual
i
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Figure VIII.25. a) Raman spectrum acquired from the ceroid deposit pictured in image 2A. The
corresponding model fit (open circles) and residual are also pictured. b) Raman spectrum displaying a
broadening of the 1650 cm- 1 peak highlighted by the black circle.
attests to the inability of the model to account for this element.
From the model fit we can extract the chemical composition of the ceroid deposit.
Bar graphs showing the chemical compositions of all of the ceroid deposits examined in
coronary arteries and aorta are shown in Figures VIII.26 and VIII.27, respectively. The fit
coefficients are normalized to sum to one and thus each bar represents the percentage
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contribution of the corresponding basis spectrum to the deposit composition. Variation in the
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Figure VIII.26. Bar graph showing the chemical compositions of all of the ceroid deposits
examined in coronary arteries. The error bars represent the standard error of the mean and display
variation in the amount of a particular chemical between the deposits examined.
amount of a particular chemical between the deposits examined is displayed in the figure as
error bars calculated as the standard error of the mean. The smaller the error bar, the more
consistently the component of interest is incorporated in similar quantities into all of the
ceroid deposits examined. Many error bars are large, indicating that the chemical
composition of the deposits examined has significant variability. Chemical heterogeneity
among ceroid deposits was also observed in the preliminary study by Puppels and coworkers
[van de Poll et al. 2002].
The most notable feature of the bar graphs is that a variety of mechanisms suggested
by in vitro studies contribute to ceroid formation in vivo. Moieties from the Fenton reaction,
the Maillard reaction, protein oxidation, and ascorbic acid peroxidation are all present. In
accordance with theory, LDL appears within the deposits primarily in its peroxidized form.
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Large amounts of free cholesterol are seen in several of the deposits which may indicate
foam cell lysis. a-tocopherol is present within ceroid deposits in extremely small quantities,
supporting its role as the primary antioxidant associated with LDL. Further, the results
support the role of -carotene as an antioxidant. If, as conjectured, -carotene prevents
oxidation of LDL you would not expect it to be present in ceroid, since presumable only
those lipoproteins deficient in -carotene are susceptible to oxidization. Although small
contributions from 13-carotene are seen, these correspond to extremely low concentrations as
5-carotene is resonance enhanced at this excitation wavelength. As a result, extremely small
concentrations generate an intense Raman signal. Conversely, retinal palmnitate is present in
relatively high concentrations within the deposits indicating that either it plays a role in the
formation of ceroid rather than as an antioxidant or it is a less important antioxidant than
other polyenic molecules examined. The contribution of collagen to deposit composition is
in agreement with electron microscopy studies of ceroid which have shown a core of
collagen and elastin-like fibers. Further, hemoglobin is present in the deposits, consistent
with both previous Raman studies of ceroid and histochemical studies reporting the co-
localization of ceroid and hemoglobin [Nahiev et al. 1991: van de Poll et al. 2002]. Lastly,
many deposits contain contributions from calcium mineral salts. Therefore, it is possible that
ceroid deposition may provide a basis for hydroxyapatite nucleation and ultimately formation
of calcifications.
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Figure V11.27. Histogram showing the chemical compositions of all of the ceroid deposits
examined in aorta. The error bars represent the standard error of the mean and display
variation in the amount of a particular chemical between the deposits examined.
Because the overall Raman signal intensity is a function of both the Raman scattering
cross-section and the amount of the molecule of interest, fit coefficients are not direct
reflections of chemical concentration. Although the absolute Raman scattering cross-section
of these model components is not known, and thus a rigorous quantitative analysis cannot
presently be preformed, basis spectra with a high degree of spectral similarity should have
comparable Raman scattering cross-sections. Thus the fit coefficients of these pathways can
be directly compared. For instance, in ceroid deposits occurring in both aorta and coronary
arteries, the predominate mode of lipid peroxidation appears to be mediated by transition
metals. Ascorbic acid initiated free radical lipid peroxidation also contributes but only as a
minor pathway as witnessed by the smaller percent contribution of this model component
compared to the model component representative of the Fenton reaction. Likewise, protein
oxidation is present and appears to proceed mainly through direct modification of amino
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acids while LDL oxidation by myeloperoxidase is not witnessed to a large degree. Again.
these two pathways can be compared dueto their large degree of spectral overlap, olf=0.39,
and thus similar Raman scattering cross-sections. It should be noted that LDL oxidation by
myeloperoxidase was present with a contribution of 10.3% in one deposit examined. The
significance of this observation and the role of myeloperoxidase in ceroid formation are not
clear from this study. Although the relative importance of certain mechanisms can be
assessed, direct comparison between the extent of lipid peroxidation and protein oxidation is
not feasible without knowledge of the Raman scattering cross-sections of these molecules.
Much of the wide variation in chemical composition among the ceroid deposits can
be attributed to examination of the deposits during different stages of formation. In an effort
to provide additional insight into the mechanism of ceroid formation, we have compared data
acquired from intra- and extra-cellular deposits. The separation into intra- and extra-cellular
ceroid is based on the amount of cholesterol linoleate and cholesterol oleate present in each
deposit as determined by their fit coefficients. Deposits containing predominately cholesterol
oleate were labeled as intracellular while those containing mainly cholesterol linoleate were
categorized as occurring extracellularly. Deposits with roughly equal amounts of cholesterol
linoleate and cholesterol oleate (less than 10% difference) or with neither molecule, were
omitted from this analysis. 10% was chosen as our experimental errors are typically twice
that predicted by the analytical formula, section IV.F.6. This distinction is based on the fact
that incubation of mouse peritoneal macrophages with cholesteryl linoleate/ bovine serum
albumin emulsions induces significant cell damage whereas the addition of cholesteryl
oleate/ bovine serum albumin does not [Reid et al. 1992]. The separation results in 13
intracellular and 6 extracellular deposits in coronary arteries. Only 2 ceroid deposits
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examined in aorta contained cholesterol linoleate in a 10% excess over cholesterol oleate.
For this reason, the chemical composition of ceroid deposits occurring intra- and extra-
cellularly was only examined in coronary arteries.
The disproportionately larger amount of intracellular ceroid deposits examined in
aorta provides some insight into the differences in fit coefficients, seen in Figures VIII.26
and VIII.27, between coronary arteries and aorta. Frrst, the polyenic molecules are present in
smaller amounts in coronary arteries. This is consistent with their role as antioxidants as the
depletion of protective molecules should be greater in more advanced deposits. Another
molecule postulated to playa protective role in atherosclerosis is HDL. Again, we see much
smaller contributions from HDL in the deposits examined in coronary arteries than in those
examined in aorta.
While this classification of intracellular and extracllular deposits may seem somewhat
arbitrary, differences in chemical composition and morphology of the two types of deposits
were observed and provide further confirmation of the validity of this separation. Structural
examination of the deposits by an experienced pathologist indicates that all intracellular
deposits appear to have a similar globular morphology, whereas the extracellular deposits
Figure VIII.28. a) Phase contrast image of an intracellular ceroid deposit displaying a globular
morphology. b) Phase contrast image of an extracellular ceroid deposit displaying a diffuse
morphology. (Size bar 25 f.1m)
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have a different diffuse morphology. Figure VIII.28 displays phase contrast images
demonstrating the noted intra- and extra- cellular morphologies. A bar graph comparing the
composition of intra- and extra-cellular ceroid deposits in coronary artery is shown in Figure
VIII.29. The white bars in the figures correspond to intracellular deposits while the shaded
lines represent extracellular deposits. Chemicals which did not vary significantly between
extracellular and intracellular deposits are excluded from the figure. From this analysis, it is
evident that the presence of 3-carotene is slightly higher in intra- than extra- cellular
deposits. This provides further support for its role as an antioxidant and contradicts
suggestions that carotenoids do not play a significant role in protecting LDL against
oxidation [Halliwell 1990]. Retinal palmitate is also present in higher quantities
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Figure VIII.29 Histogram showing the chemical compositions of intra- (white bars) and extra- (gray
bars) cellular ceroid deposits occurring in coronary arteries. The error bars represent the standard
error of the mean and display variation in the amount of a particular chemical between the deposits
examined.
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intracellularly. This may suggest that it plays a less crucial role as an antioxidant than P-
carotene and thus is consumed in latter stages of ceroid formation. oa-tocopherol is not
present in appreciable quantities in either intra- or extra- cellular deposits, again indicating
that it is the principal antioxidant associated with LDL and has been consumed prior to the
initiation of lipid peroxidation. Also as expected, free cholesterol is higher intracellularly.
This is in accordance with previous literature which reported that incubation with oxLDL led
to macrophage accumulation of unesterified cholesterol [Maor and Aviram 1994].
Peroxidized lipids, such as transition metal oxLDL and ascorbic acid initiated lipid
peroxidation, are more prevalent extracellularly. This observation lends support to theories
which link ceroid accumulation to cell death and necrosis. In fact, ascorbic acid initiated
lipid peroxidation appears to occur entirely extracellularly. This observation can also explain
why little contribution from this pathway is seen in the predominately intracellular deposits
examined in aorta. The reason for this trend is presently not known. It is possible that ceroid
induced macrophage lysis results in extravasation of the ferrous ion contained within the
deposits thereby providing the heavy metal needed for ascorbic acid initiated lipid
peroxidation. Consistent with this theory, hemoglobin contributes to ceroid composition
predominately extracellularly. No significant differences were observed in the fluorescence
characteristics of the intracellular and extracellular deposits.
VIII. E. 4. Conclusions
In this study, we analyze the chemical composition of ceroid deposits within atherosclerotic
plaques, without the need for extraction or purification, using Raman microscopy. This
allows assessment of the physiological relevance of several of the in vitro model studies
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undertaken in an effort to elucidate the chemical composition of ceroid. Results demonstrate
that a variety of mechanisms play a role in ceroid formation in vivo. Further, our studies
show that the predominate mode of lipid oxidation occurs through a Fenton reaction while
oxidative modification of proteins proceeds mainly through direct oxidation of amino acids.
Data support the roles of a-tocopherol and n-carotene as antioxidants. The elucidation of the
composition of ceroid deposits provides insight into the underlying biochemical mechanism
of ceroid formation thereby advancing the understanding of the atherosclerotic disease
process.
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Chapter IX. Future Directions
This chapter discusses the future of Raman spectroscopy in breast cancer diagnosis and
treatment. Upcoming clinical and basic studies are detailed. With the successful
demonstration of in vivo Raman spectroscopy for breast cancer diagnosis, there are many
clinical applications that can be addressed. Approaches to transdermal needle measurements
for breast cancer diagnosis are presented as well as future intra-operative studies for margin
assessment. These clinical studies will be accompanied by diagnostic algorithm validation
and extension using our data set acquired from freshly excised tissue. Basic experiments will
focus on quantitative analysis and spectral model refinement. Finally, the prospects for a
multi-spectroscopic optical fiber probe that may provide enhanced optical diagnosis are
presented.
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IX. A. The Future of Raman Spectroscopy in Breast Cancer Diagnosis
The experiments and theory presented throughout this thesis demonstrate that Raman
spectroscopy can be used to accurately diagnosis breast cancer and breast disease.
Furthermore, we have demonstrated extension of the technique to preliminary in vivo clinical
applications with excellent results. However, additional clinical studies are needed to fully
assess the utility of Raman spectroscopy for breast cancer diagnosis and treatment.
IX. A. 1. Transdermal Needle Measurements
Optical techniques are less invasive than current diagnostic procedures. The results of our
initial in vivo studies illustrate the potential for Raman spectroscopic transdermal needle
measurements to provide breast cancer diagnosis. As opposed to standard biopsy, a
spectroscopic transdermal needle measurement would have the advantage of providing
immediate diagnosis. As a result, Raman spectroscopy has the potential to reduce both the
likelihood of a non-diagnostic biopsy that would require repeat needle or surgical biopsy, and
patient anxiety by eliminating the currently unavoidable wait for a traditional histopathology
diagnosis. Furthermore, with the development of minimally invasive breast cancer therapies,
such as radiofrequency ablation, which relies on insertion of a thin metal probe into the
breast, there is the potential that diagnosis and treatment could be performed in a single
procedure [Fornage et al. 2004]. Spectroscopic diagnosis also confers economic advantages.
There are numerous people as well as supplies and equipment involved in the biopsy
procedure, tissue processing, and histopathology diagnosis making needle biopsy an
expensive enterprise.
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Transdermal needle measurements can be preformed with either a front-viewing or a
side-viewing Raman optical fiber probe. A front-viewing probe can be used in conjunction
with a vacuum-assisted biopsy procedure, discussed in section II.E.3e. A schematic of a
transdermal needle measurement that employs the front-viewing Raman probe is shown in
Figure IX.I a. In this configuration, the spectroscopic measurement will always sample the
proximal end of the biopsy tissue. Although the current reduced diameter front-viewing
Raman probe is compatible with an 11 gauge needle, often used in these procedures, studies
must be undertaken to investigate whether the vacuum device and overall setup can be used
in conjunction with the probe.
A side-viewing Raman probe can also be used for transdermal needle measurements,
as depicted in Figure IX.l b. The laboratory has a side-viewing probe prototype based on a
design that replaces the sapphire ball lens with a half-ball lens backed by a mirror. Lens and
mirror are configured at 45° providing collection capabilities similar to the front-viewing
probe. The performance of the side-viewing probe is currently being tested. The side-
viewing Raman probe can be used in conjunction with either a spring deployed or a vacuum-
assisted biopsy needle. However, side-viewing measurements will necessitate a method for
registering the tissue examined spectroscopically, which will lie somewhere in the middle of
Figure IX.I. Transdermal needle measurements with the a) front-viewing and b) side-viewing
Raman optical fiber probe.
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the biopsy sample, with that examined by the pathologist. Ultimately, a side-viewing
implementation is preferable as it allows spectral interrogation of a larger tissue volume.
Successive measurements can be performed over 3600 around the axis of the needle and
depth information obtained as the needle is inserted or withdrawn.
Another potential implementation of Raman spectroscopy is in conjunction with
ductoscopy. Fiberoptic ductoscopy adapts endoscopes developed to detect cancer in organs
such as the colon, cervix, and esophagus to the study of breast ducts [Berna et al. 1991]. It is
used to directly visualize the epithelial lining of the breast ducts. Because the majority of
both benign and malignant breast disease originates in the epithelium, development of a
minimally invasive procedure which can directly assess early epithelial changes has
important applications to the detection and treatment of these conditions. Adding spectral
information to the white light images recorded during ductoscopy provides the ability to
detect pre-cancerous changes in the breast. However, a reduced diameter side-viewing
probe, less than 1 mm in diameter, must be developed for incorporation in the ductoscope.
IX. A. 2. Intra-Operative Margin Assessment
Our pilot study, presented in Chapter VII, is the first use of Raman spectroscopy to examine
breast cancer in vivo. In addition to establishing Raman spectroscopy as a viable clinical
technique, the study also revealed a new application for the approach. The results indicate
that Raman spectroscopy has the potential to aid in intra-operative tumor resection. Accurate
in vivo margin assessment techniques will reduce the recurrence rate of breast cancer
following partial mastectomy surgeries and allow numerous re-excision surgeries to be
avoided. They may also extend partial mastectomy procedures to those women who do not
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harbor sufficiently small or localized breast cancers to qualify by current standards.
However a larger data set with additional positive margin specimens is necessary to fully
investigate the ability of Raman spectroscopy to aid in intra-operative tumor resection.
Further, for such an implementation to be successful, a thorough understanding of the
lower detection limits of the approach is necessary. Experiments that determine the Raman
scattering-cross sections of our model components as well as the volume of probed tissue
which must harbor malignant cells to be correctly diagnosed are presented below. Future
studies may be preformed with the existing Raman optical fiber probe or alternatively, an
imaging device could be developed. An imaging modality, which samples a larger surface
area, may be preferable for intra-operative margin assessment.
IX. A. 3. Real-Time Analysis
We have recently developed and demonstrated real-time Raman diagnosis with our clinical
instrumentation thus allowing its implementation in upcoming studies [Motz et al. in press].
Both clinical studies presented above should employ real-time analysis. This will provide a
basis for testing the real-time system as well as feedback from clinicians for display
improvement. The real-time Raman system also provides a means to target features of
interest during data collection. For example, collecting data from microcalcifications will
allow us to couple the results from our Raman microscopy studies of microcalcifications with
our ex vivo diagnostic algorithm to create a powerful new tool for the diagnosis of benign and
malignant breast lesions, as discussed in Chapter V. Ultimately, our real-time diagnostics
may be used as a guide to biopsy or tumor resection.
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IX. A. 4. Diagnostic Algorithm Validation and Extension
Studies with a large patient pool are currently underway to further expand and validate our
diagnostic algorithm. Preliminary results are presented in Chapter V. Upcoming studies will
focus on analysis of the clinical data set containing Raman spectra of fresh tissues. The
research serves to extend and confirm the results of our ex vivo studies on fresh-frozen tissue.
New diagnostic algorithms will be developed which incorporate additional model
parameters, microcalcifications, and intensity information. These algorithms will be used to
identify DCIS and possibly different manifestations of a single pathology. The incorporation
of microcalcifications and intensity information are expected to strengthen the performance
of our diagnostic algorithms. The Raman optical fiber probe provides a reproducible
geometry for data collection, allowing examination of spectral data that has not been
normalized. Ultimately, we strive to obtain quantitative information by incorporating the
Raman scattering cross-sections of the model components into the data analysis routine.
Studies to extract quantitative morphological information are discussed below.
IX. B. Spectral Model Refinement
Although our current morphological spectral model of breast tissue provides excellent
diagnostic information, there are several areas where the model can be improved.
IX. B. 1. Quantitative Studies
Our current spectral model of breast only provides relatively quantitative morphological
information. Thus, our present diagnostic schemes incorporate structural information and do
not utilize intensity information. Although strict quantification is desirable, it is challenging
to establish Raman scattering cross-sections for the components present in biological tissue.
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However, with instrumental advances and a deeper understanding of the theoretical accuracy
of our approach we have planned a study to make our morphological models quantitative.
In this study, data will be acquired from thin sections of fresh-frozen breast tissue
using our Raman microscope. This data will be acquired using a low magnification objective
to ensure that the spectroscopic signal is representative of the entire breast tissue section.
Data will be acquired for long integration times conferring high SNR Raman data. Each thin
section of breast tissue spectroscopically examined will then be reviewed by a pathologist. A
combination of staining techniques and morphometric analysis will be used to obtain an
estimate of the volume occupied by each morphological feature represented in our Raman
spectral model. These volumes will then be correlated with the fit coefficients from the
corresponding spectrum. Half of the data will be used to scale the model basis spectra such
that the fit coefficients are representative of the pathologically determined volumes. The
remaining data will be used for validation of the intensity corrected model. The prediction
error equation, presented in Chapter IV, can be used to estimate reasonable fit coefficient
errors. This study will also provide insight into the lower detection limits of the approach.
IX. B. 2. Microscopy Studies
Studies to make our spectral model quantitative will also provide a basis for model
refinement. I anticipate that some model elements, such as fat and microcalcifications, will
quite accurately reflect their morphological volumes while others, such as epithelial cell
cytoplasm and cholesterol-like, will not. This will allow us to identify basis spectra that are
representative of a variety of morphological features thereby providing a basis for model
refinement. Ensuing microscopy studies can be used to update the morphological spectral
model. Such studies may begin with the examination of normal and cancerous cell lines. A
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key signature of carcinoma is enlargement of cell nuclei, and thus a higher nuclear to
cytoplasm (N/C) ratio than in benign conditions. Although we observe disease dependent
trends in the spectroscopically obtained N/C parameter, these trends have not translated into
diagnostic information. Microscopy studies of cell lines may shed light on ways to extract
diagnostic information from the Raman spectrum that are related to tissue cellularity.
Microscopy studies can also be used to examine changes in the stroma induced by disease.
Ability to detect desmoplastic changes may be of particular importance as previous results
indicate that Raman spectroscopy is more sensitive to stromal rather then cellular changes.
As instrumentation and data analysis techniques improve, new components corresponding to
smaller chemical variations will need to be included in our model.
IX. C. Combining Fluorescence, Reflectance and Raman Spectroscopies
Preliminary results examining fluorescence and reflectance spectroscopies of breast tissues
are very promising and convey that the techniques contain diagnostic information. However,
a more rigorous understanding of the relationship between data analysis parameters and
tissue morphology is necessary. Microscopy studies, similar to those used to develop the
Raman spectral model, may provide a basis for understanding the fluorescence and
reflectance signals obtained from breast tissue. As a starting point the fluorescence of
adipocytes and epithelial cells should be examined. This will shed light on whether the
fluorescence trends observed are the result of inaccurate basis spectra, additional tissue
fluorophores, or unexpected pathology.
Future analysis will focus on correlating information obtained from FastEEM data
and Raman spectroscopy. In order to successfully combine the optical modalities, a rigorous
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understanding of the probe volume and sensitivity of each technique is necessary. As a
starting point, species that both approaches are sensitive too, such as collagen and [5-carotene,
can be compared. Ultimately, if the results warrant it, all three modalities (fluorescence,
reflectance and Raman) may be combined into a single spectroscopic technique for the
diagnosis of breast cancer.
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Chapter X. Conclusion
X. A. Review of Goals and Accomplishments
The overall goal of this thesis was to develop Raman spectroscopy into a clinical tool for
breast cancer diagnosis. This process involved many steps, including model and diagnostic
algorithm development in the laboratory with subsequent extension of these experimental
approaches to a clinical environment. Each of these steps has been addressed in separate
chapters, supported by sections that delve deeply into fundamental considerations important
for attaining these goals.
The spectral model that was developed in Chapter IV provides a new approach to
analyzing Raman spectra. A diagnostic algorithm which utilizes this spectral model, was
developed in the laboratory with samples of fresh-frozen breast tissue. This diagnostic
algorithm, that encompasses all data and classifies samples according to specific pathological
diagnoses, results in high sensitivity and specificity. Based on the excellent results of these
laboratory studies, we sought to employ Raman spectroscopy clinically. Studies were
undertaken to validate our algorithm on a large data set of freshly excised tissue as well as
demonstrate in vivo data acquisition.
The clinical studies translate Raman spectroscopy from a laboratory technique into a
clinically useful tool. The first study, tests the diagnostic algorithm in a prospective manner
on freshly excised tissue. Preliminary results are promising. In the second study, data were
acquired in vivo during partial mastectomy surgeries. This is the first demonstration of in
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vivo collection of Raman spectra of breast tissue. These advances culminated in an approach
that was employed intra-operatively during partial mastectomy surgeries to accurately assess
margin status.
X. B. Final Remarks
The research presented in this thesis has brought the powerful analytical technique of Raman
spectroscopy into a new regime where it can be employed clinically. We have demonstrated
the use of Raman spectroscopy for the intra-operative identification of positive margins.
Minor modifications to our Raman probe design will readily allow transdermal needle
measurements, thereby opening additional clinical applications of Raman spectroscopy. The
experiments and theory presented throughout this thesis demonstrate that Raman
spectroscopy can be used to accurately diagnosis breast cancer and breast disease. Thus,
Raman spectroscopy has the potential to play a diagnostic role in several aspects of breast
cancer evaluation and treatment.
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